INSERT INTO generic_approvals (row, generic_key, generic_uid, route_type, country, indication, populations, approval_date, discon_date, box_warning, box_warning_date)
VALUES
  (1, 'adalimumab', NULL, 'Oral', 'CAN', 'Hypertension; Ulcerative Colitis; Multiple Sclerosis', 'Adults with mild disease; Adults 65+ years', '1992-08-01', NULL, NULL, NULL),
  (2, 'adalimumab', NULL, 'Intravenous', 'BRA', 'Ankylosing Spondylitis; Ulcerative Colitis', 'Patients with cardiovascular disease; Adults with mild disease', '1993-02-16', NULL, 'Risk of progressive multifocal leukoencephalopathy', '2017-01-17'),
  (3, 'adalimumab', NULL, 'Subcutaneous', 'CAN', 'Ulcerative Colitis; Depression; Heart Failure', 'Patients with prior treatment failure', '2005-04-19', NULL, 'Risk of peripheral neuropathy', '2016-09-04'),
  (4, 'adalimumab', NULL, 'Intravenous', 'BRA', 'Bipolar Disorder; Multiple Sclerosis; Psoriatic Arthritis', 'Treatment-naive patients', '1998-10-02', NULL, NULL, NULL),
  (5, 'adalimumab', NULL, 'Subcutaneous', 'BRA', 'Rheumatoid Arthritis; Fungal Infections', 'Patients with diabetes', '1994-12-11', NULL, NULL, NULL),
  (6, 'adalimumab', NULL, 'Subcutaneous', 'ESP', 'HIV Infection', 'Pregnant women', '1995-11-27', NULL, NULL, NULL),
  (7, 'adalimumab', NULL, 'Nasal', 'JPN', 'Deep Vein Thrombosis; Psoriatic Arthritis; Hepatitis C', 'Patients with diabetes', '2008-05-12', NULL, NULL, NULL),
  (8, 'infliximab', NULL, 'Subcutaneous', 'USA', 'HIV Infection; Osteoporosis', 'Immunocompromised patients', '1991-06-23', '2023-12-19', NULL, NULL),
  (9, 'infliximab', NULL, 'Rectal', 'AUS', 'Diabetes Mellitus Type 2; Pulmonary Embolism', 'Patients with hepatic impairment', '2015-09-10', NULL, NULL, NULL),
  (10, 'infliximab', NULL, 'Oral', 'CAN', 'Deep Vein Thrombosis', 'Patients with prior treatment failure', '1997-09-08', NULL, NULL, NULL),
  (11, 'infliximab', NULL, 'Sublingual', 'FRA', 'Crohn''s Disease; Hypertension', 'Patients with prior treatment failure; Patients with cardiovascular disease', '1998-01-20', NULL, 'Risk of progressive multifocal leukoencephalopathy', '2024-07-14'),
  (12, 'infliximab', NULL, 'Nasal', 'JPN', 'Heart Failure', 'Patients with obesity', '2001-01-19', NULL, 'Risk of renal impairment', '2019-09-07'),
  (13, 'infliximab', NULL, 'Intravenous', 'JPN', 'Ulcerative Colitis; Crohn''s Disease', 'Treatment-naive patients', '2015-02-13', '2021-04-10', NULL, NULL),
  (14, 'infliximab', NULL, 'Oral', 'BRA', 'Cancer; Bipolar Disorder; Ulcerative Colitis', 'Patients with diabetes; Pediatric patients 2-17 years', '2017-09-15', NULL, 'Risk of hepatitis B reactivation', '2018-12-14'),
  (15, 'infliximab', NULL, 'Topical', 'ITA', 'Hypertension', 'Adults 65+ years', '1999-05-12', NULL, NULL, NULL),
  (16, 'infliximab', NULL, 'Subcutaneous', 'DEU', 'Rheumatoid Arthritis; Asthma', 'Patients with cardiovascular disease', '2003-10-24', NULL, NULL, NULL),
  (17, 'infliximab', NULL, 'Inhalation', 'USA', 'Migraine; Depression', 'Adults 65+ years', '1992-05-08', NULL, NULL, NULL),
  (18, 'infliximab', NULL, 'Topical', 'FRA', 'Pulmonary Embolism; Hypertension', 'Adults 65+ years; Pregnant women', '2007-10-15', NULL, NULL, NULL),
  (19, 'infliximab', NULL, 'Subcutaneous', 'JPN', 'Systemic Lupus Erythematosus', 'Adults with moderate to severe disease; Pediatric patients 2-17 years', '1996-10-24', NULL, 'Risk of bone loss', '2024-04-05'),
  (20, 'infliximab', NULL, 'Rectal', 'DEU', 'Multiple Sclerosis', 'Pediatric patients 6 months-2 years; Adults with moderate to severe disease', '2011-05-03', NULL, NULL, NULL),
  (21, 'infliximab', NULL, 'Nasal', 'ITA', 'Schizophrenia', 'Patients with prior treatment failure; Immunocompromised patients', '2003-08-20', NULL, NULL, NULL),
  (22, 'infliximab', NULL, 'Nasal', 'ESP', 'Juvenile Idiopathic Arthritis', 'Adults 65+ years', '1994-11-20', NULL, 'Risk of vision changes', '2021-11-23'),
  (23, 'infliximab', NULL, 'Oral', 'CAN', 'Heart Failure; Multiple Sclerosis; Cancer', 'Patients with diabetes; Patients with renal impairment', '1998-09-13', '2023-12-04', 'Risk of vision changes', '2019-03-07'),
  (24, 'infliximab', NULL, 'Intramuscular', 'DEU', 'Chronic Obstructive Pulmonary Disease; Bacterial Infections', 'Pediatric patients 6 months-2 years; Adults 65+ years', '1998-07-14', NULL, 'Risk of hypersensitivity reactions', '2021-12-21'),
  (25, 'infliximab', NULL, 'Subcutaneous', 'ESP', 'Psoriatic Arthritis', 'Treatment-naive patients; Patients with diabetes', '1998-11-10', NULL, 'Risk of central nervous system effects', '2023-08-28'),
  (26, 'infliximab', NULL, 'Transdermal', 'BRA', 'Ulcerative Colitis; Hepatitis C; Juvenile Idiopathic Arthritis', 'Patients with diabetes; Adults 18-65 years', '2002-07-04', NULL, 'Risk of hearing loss', '2019-06-02'),
  (27, 'infliximab', NULL, 'Transdermal', 'JPN', 'Osteoporosis; Psoriatic Arthritis; Migraine', 'Immunocompromised patients', '2009-10-25', NULL, NULL, NULL),
  (28, 'infliximab', NULL, 'Intravenous', 'ITA', 'Chronic Obstructive Pulmonary Disease; Psoriatic Arthritis', 'Adults with mild disease; Patients with hepatic impairment', '1993-06-14', NULL, NULL, NULL),
  (29, 'infliximab', NULL, 'Subcutaneous', 'AUS', 'Viral Infections', 'Adults 18-65 years', '1997-08-06', '2021-10-19', NULL, NULL),
  (30, 'infliximab', NULL, 'Oral', 'UK', 'Migraine; Cancer; Osteoporosis', 'Patients with obesity; Immunocompromised patients', '2024-08-03', NULL, NULL, NULL),
  (31, 'infliximab', NULL, 'Sublingual', 'CAN', 'Osteoporosis', 'Patients with hepatic impairment; Patients with comorbidities', '2024-09-21', NULL, NULL, NULL),
  (32, 'infliximab', NULL, 'Intramuscular', 'USA', 'Bipolar Disorder; Ankylosing Spondylitis; Fungal Infections', 'Adults with moderate to severe disease; Adults 65+ years', '1996-05-02', NULL, 'Risk of liver injury', '2016-11-20'),
  (33, 'infliximab', NULL, 'Transdermal', 'UK', 'Chronic Obstructive Pulmonary Disease; Depression', 'Adults 18-65 years; Patients with cardiovascular disease', '2014-07-28', NULL, 'Risk of tuberculosis reactivation', '2015-08-20'),
  (34, 'infliximab', NULL, 'Transdermal', 'FRA', 'Cancer', 'Patients with renal impairment', '1998-06-01', '2022-11-12', 'Risk of anaphylaxis', '2021-03-17'),
  (35, 'infliximab', NULL, 'Rectal', 'BRA', 'Migraine', 'Pediatric patients 6 months-2 years; Pregnant women', '1998-03-23', '2020-11-08', 'Risk of serious cardiovascular events', '2020-02-16'),
  (36, 'infliximab', NULL, 'Nasal', 'ESP', 'Multiple Sclerosis; Crohn''s Disease', 'Adults 18-65 years; Pediatric patients 6 months-2 years', '1998-04-21', '2022-10-01', 'Risk of peripheral neuropathy', '2024-05-14'),
  (37, 'infliximab', NULL, 'Inhalation', 'AUS', 'Anxiety; Bipolar Disorder', 'Pediatric patients 6 months-2 years', '1998-11-08', NULL, NULL, NULL),
  (38, 'etanercept', NULL, 'Sublingual', 'ESP', 'Bipolar Disorder; Atrial Fibrillation; Hypertension', 'Patients with obesity', '2001-08-05', NULL, NULL, NULL),
  (39, 'etanercept', NULL, 'Transdermal', 'DEU', 'Viral Infections; Schizophrenia; Ulcerative Colitis', 'Pregnant women', '1999-08-26', NULL, 'Risk of serious cardiovascular events', '2017-09-08'),
  (40, 'rituximab', NULL, 'Transdermal', 'UK', 'Plaque Psoriasis', 'Pediatric patients 2-17 years; Patients with obesity', '2024-09-02', NULL, NULL, NULL),
  (41, 'rituximab', NULL, 'Inhalation', 'CAN', 'HIV Infection; Psoriatic Arthritis; Hypertension', 'Patients with obesity', '2015-07-10', NULL, NULL, NULL),
  (42, 'rituximab', NULL, 'Subcutaneous', 'UK', 'Psoriatic Arthritis', 'Immunocompromised patients', '2001-05-02', NULL, 'Increased risk of malignancy', '2024-06-26'),
  (43, 'rituximab', NULL, 'Subcutaneous', 'JPN', 'Hypertension; Depression; Ulcerative Colitis', 'Pregnant women; Treatment-naive patients', '2012-11-20', NULL, NULL, NULL),
  (44, 'rituximab', NULL, 'Intramuscular', 'JPN', 'Atrial Fibrillation; Ankylosing Spondylitis', 'Adults with mild disease', '2006-10-11', NULL, NULL, NULL),
  (45, 'rituximab', NULL, 'Inhalation', 'ESP', 'Migraine', 'Adults 65+ years', '2005-04-03', NULL, NULL, NULL),
  (46, 'rituximab', NULL, 'Rectal', 'ESP', 'Deep Vein Thrombosis; Ankylosing Spondylitis', 'Patients with diabetes', '1999-08-25', NULL, NULL, NULL),
  (47, 'rituximab', NULL, 'Sublingual', 'USA', 'Atrial Fibrillation', 'Patients with comorbidities', '2019-01-23', NULL, 'Risk of progressive multifocal leukoencephalopathy', '2019-01-13'),
  (48, 'rituximab', NULL, 'Inhalation', 'CAN', 'Depression; Juvenile Idiopathic Arthritis', 'Pediatric patients 6 months-2 years; Pregnant women', '1994-09-17', NULL, NULL, NULL),
  (49, 'rituximab', NULL, 'Nasal', 'CAN', 'Atrial Fibrillation', 'Pregnant women; Treatment-naive patients', '1998-03-20', NULL, NULL, NULL),
  (50, 'rituximab', NULL, 'Intramuscular', 'JPN', 'Bipolar Disorder; Anxiety', 'Pediatric patients 6 months-2 years', '2013-01-22', NULL, NULL, NULL),
  (51, 'rituximab', NULL, 'Sublingual', 'JPN', 'Rheumatoid Arthritis; Anxiety; Ulcerative Colitis', 'Patients with prior treatment failure; Patients with renal impairment', '2013-10-22', NULL, 'Risk of hepatitis B reactivation', '2023-10-02'),
  (52, 'rituximab', NULL, 'Rectal', 'ITA', 'Deep Vein Thrombosis; Hypertension', 'Patients with hepatic impairment', '2011-12-05', NULL, NULL, NULL),
  (53, 'rituximab', NULL, 'Sublingual', 'ESP', 'Migraine', 'Pediatric patients 6 months-2 years', '1990-06-01', NULL, NULL, NULL),
  (54, 'rituximab', NULL, 'Oral', 'DEU', 'Fungal Infections; Psoriatic Arthritis; HIV Infection', 'Immunocompromised patients; Patients with diabetes', '2018-10-14', NULL, NULL, NULL),
  (55, 'rituximab', NULL, 'Intravenous', 'UK', 'Hepatitis C; Depression; Deep Vein Thrombosis', 'Pediatric patients 6 months-2 years', '2004-05-24', NULL, NULL, NULL),
  (56, 'rituximab', NULL, 'Rectal', 'AUS', 'Asthma; Plaque Psoriasis; Depression', 'Immunocompromised patients', '2005-08-24', NULL, 'Increased risk of malignancy', '2016-02-28'),
  (57, 'rituximab', NULL, 'Oral', 'JPN', 'Cancer', 'Pregnant women; Patients with obesity', '2012-08-14', NULL, NULL, NULL),
  (58, 'rituximab', NULL, 'Sublingual', 'AUS', 'Psoriatic Arthritis; Heart Failure; Bacterial Infections', 'Patients with comorbidities; Patients with prior treatment failure', '2011-07-26', NULL, NULL, NULL),
  (59, 'rituximab', NULL, 'Intramuscular', 'FRA', 'Schizophrenia; Bacterial Infections', 'Treatment-naive patients', '2007-11-17', NULL, NULL, NULL),
  (60, 'rituximab', NULL, 'Inhalation', 'CAN', 'Ulcerative Colitis; Fungal Infections; Cancer', 'Patients with comorbidities', '2015-10-17', NULL, NULL, NULL),
  (61, 'tocilizumab', NULL, 'Nasal', 'AUS', 'Bipolar Disorder; Migraine; Hypertension', 'Patients with hepatic impairment; Pediatric patients 6 months-2 years', '2013-12-23', NULL, NULL, NULL),
  (62, 'tocilizumab', NULL, 'Oral', 'CAN', 'Multiple Sclerosis; Bacterial Infections', 'Adults with moderate to severe disease; Patients with diabetes', '2015-03-05', NULL, NULL, NULL),
  (63, 'tocilizumab', NULL, 'Sublingual', 'DEU', 'Viral Infections; Bacterial Infections; Psoriatic Arthritis', 'Patients with prior treatment failure; Patients with obesity', '2023-06-01', NULL, NULL, NULL),
  (64, 'tocilizumab', NULL, 'Intramuscular', 'ESP', 'Depression; Ulcerative Colitis; Deep Vein Thrombosis', 'Patients with renal impairment', '1991-08-08', NULL, NULL, NULL),
  (65, 'tocilizumab', NULL, 'Nasal', 'FRA', 'Depression; Bipolar Disorder; Rheumatoid Arthritis', 'Patients with obesity; Treatment-naive patients', '2013-02-12', NULL, NULL, NULL),
  (66, 'tocilizumab', NULL, 'Inhalation', 'USA', 'Ulcerative Colitis; Heart Failure', 'Patients with hepatic impairment', '2015-02-07', NULL, NULL, NULL),
  (67, 'tocilizumab', NULL, 'Nasal', 'UK', 'Ulcerative Colitis; Heart Failure; Diabetes Mellitus Type 2', 'Patients with obesity; Adults with mild disease', '2007-06-18', NULL, 'Risk of peripheral neuropathy', '2024-10-15'),
  (68, 'tocilizumab', NULL, 'Topical', 'ITA', 'Hypertension; Systemic Lupus Erythematosus; Diabetes Mellitus Type 2', 'Adults 65+ years; Patients with comorbidities', '2007-01-19', NULL, 'Increased risk of serious infections', '2017-06-28'),
  (69, 'tocilizumab', NULL, 'Rectal', 'FRA', 'Atrial Fibrillation; Psoriatic Arthritis', 'Treatment-naive patients; Patients with renal impairment', '1999-04-07', NULL, 'Risk of blood disorders', '2015-09-06'),
  (70, 'tocilizumab', NULL, 'Inhalation', 'BRA', 'Atrial Fibrillation; Hepatitis C', 'Patients with hepatic impairment', '1993-12-19', NULL, NULL, NULL),
  (71, 'tocilizumab', NULL, 'Transdermal', 'BRA', 'Cancer; Crohn''s Disease; Plaque Psoriasis', 'Immunocompromised patients', '2020-02-02', NULL, NULL, NULL),
  (72, 'tocilizumab', NULL, 'Topical', 'CAN', 'Psoriatic Arthritis; Plaque Psoriasis', 'Treatment-naive patients', '2003-11-12', NULL, NULL, NULL),
  (73, 'tocilizumab', NULL, 'Rectal', 'CAN', 'Ulcerative Colitis', 'Patients with diabetes; Patients with comorbidities', '2007-07-21', NULL, NULL, NULL),
  (74, 'tocilizumab', NULL, 'Intramuscular', 'DEU', 'Crohn''s Disease', 'Immunocompromised patients; Adults 65+ years', '2008-11-01', NULL, NULL, NULL),
  (75, 'tocilizumab', NULL, 'Subcutaneous', 'FRA', 'Osteoporosis', 'Adults 65+ years; Patients with prior treatment failure', '2021-09-12', NULL, NULL, NULL),
  (76, 'tocilizumab', NULL, 'Sublingual', 'UK', 'Anxiety', 'Pediatric patients 6 months-2 years', '2014-06-08', NULL, NULL, NULL),
  (77, 'tocilizumab', NULL, 'Transdermal', 'BRA', 'Bipolar Disorder; Deep Vein Thrombosis; Hypertension', 'Patients with comorbidities; Pediatric patients 6 months-2 years', '1992-10-12', NULL, 'Risk of peripheral neuropathy', '2017-03-18'),
  (78, 'tocilizumab', NULL, 'Subcutaneous', 'DEU', 'Anxiety; Cancer; Depression', 'Patients with comorbidities', '2015-12-18', NULL, 'Risk of serious cardiovascular events', '2024-11-18'),
  (79, 'tocilizumab', NULL, 'Oral', 'FRA', 'Psoriatic Arthritis', 'Treatment-naive patients; Pregnant women', '1991-01-07', NULL, NULL, NULL),
  (80, 'tocilizumab', NULL, 'Intravenous', 'BRA', 'Bipolar Disorder', 'Pediatric patients 6 months-2 years; Patients with obesity', '2011-05-14', NULL, 'Risk of serious cardiovascular events', '2015-04-25'),
  (81, 'tocilizumab', NULL, 'Topical', 'USA', 'Plaque Psoriasis; Crohn''s Disease; Deep Vein Thrombosis', 'Adults 65+ years', '2022-03-24', NULL, NULL, NULL),
  (82, 'abatacept', NULL, 'Intravenous', 'ITA', 'Asthma', 'Patients with diabetes; Patients with renal impairment', '2015-03-15', NULL, 'Risk of serious cardiovascular events', '2023-03-26'),
  (83, 'abatacept', NULL, 'Oral', 'BRA', 'Hypertension; HIV Infection', 'Pediatric patients 6 months-2 years', '1997-04-24', NULL, NULL, NULL),
  (84, 'abatacept', NULL, 'Intravenous', 'USA', 'Psoriatic Arthritis; Asthma', 'Patients with diabetes; Patients with comorbidities', '2010-04-25', NULL, NULL, NULL),
  (85, 'abatacept', NULL, 'Transdermal', 'ITA', 'Chronic Obstructive Pulmonary Disease', 'Patients with diabetes', '1998-04-18', '2024-09-08', NULL, NULL),
  (86, 'abatacept', NULL, 'Topical', 'UK', 'Ankylosing Spondylitis', 'Pediatric patients 6 months-2 years; Pregnant women', '2007-10-25', NULL, NULL, NULL),
  (87, 'abatacept', NULL, 'Subcutaneous', 'ITA', 'Bacterial Infections', 'Adults with moderate to severe disease', '2015-04-03', NULL, 'Risk of hearing loss', '2023-03-27'),
  (88, 'abatacept', NULL, 'Intramuscular', 'ITA', 'Viral Infections; Crohn''s Disease; Schizophrenia', 'Patients with comorbidities; Treatment-naive patients', '2023-10-12', NULL, 'Risk of hypersensitivity reactions', '2021-11-16'),
  (89, 'abatacept', NULL, 'Inhalation', 'CAN', 'Juvenile Idiopathic Arthritis', 'Adults 65+ years', '1990-12-04', NULL, NULL, NULL),
  (90, 'abatacept', NULL, 'Topical', 'USA', 'Juvenile Idiopathic Arthritis; Deep Vein Thrombosis', 'Adults 18-65 years; Patients with cardiovascular disease', '2020-03-01', NULL, NULL, NULL),
  (91, 'abatacept', NULL, 'Intravenous', 'AUS', 'Heart Failure; Schizophrenia', 'Adults with mild disease', '2005-10-08', NULL, NULL, NULL),
  (92, 'abatacept', NULL, 'Topical', 'FRA', 'Rheumatoid Arthritis; Crohn''s Disease; Bacterial Infections', 'Treatment-naive patients', '2014-09-12', NULL, 'Risk of central nervous system effects', '2017-05-23'),
  (93, 'abatacept', NULL, 'Rectal', 'AUS', 'Bacterial Infections; Heart Failure; Juvenile Idiopathic Arthritis', 'Adults with mild disease', '1996-05-24', NULL, NULL, NULL),
  (94, 'abatacept', NULL, 'Topical', 'JPN', 'Schizophrenia; Migraine', 'Patients with cardiovascular disease', '2022-04-16', NULL, 'Risk of hepatitis B reactivation', '2020-02-27'),
  (95, 'anakinra', NULL, 'Inhalation', 'ITA', 'Chronic Obstructive Pulmonary Disease; Osteoporosis; Ankylosing Spondylitis', 'Patients with renal impairment', '2021-06-12', '2024-01-11', 'Risk of peripheral neuropathy', '2024-06-15'),
  (96, 'anakinra', NULL, 'Rectal', 'ESP', 'Systemic Lupus Erythematosus; Diabetes Mellitus Type 2; Anxiety', 'Patients with obesity', '2010-03-07', NULL, 'Risk of peripheral neuropathy', '2018-02-14'),
  (97, 'anakinra', NULL, 'Intravenous', 'BRA', 'Plaque Psoriasis; Cancer', 'Patients with diabetes; Treatment-naive patients', '2016-11-09', NULL, NULL, NULL),
  (98, 'anakinra', NULL, 'Inhalation', 'UK', 'Bacterial Infections', 'Patients with cardiovascular disease; Treatment-naive patients', '2024-03-07', NULL, 'Risk of anaphylaxis', '2024-02-19'),
  (99, 'anakinra', NULL, 'Rectal', 'DEU', 'Ankylosing Spondylitis; HIV Infection; Cancer', 'Patients with comorbidities; Immunocompromised patients', '2006-11-04', NULL, 'Risk of vision changes', '2020-08-12'),
  (100, 'anakinra', NULL, 'Nasal', 'UK', 'Diabetes Mellitus Type 2', 'Patients with comorbidities', '2020-08-06', NULL, NULL, NULL),
  (101, 'anakinra', NULL, 'Inhalation', 'FRA', 'Crohn''s Disease', 'Patients with diabetes; Pediatric patients 6 months-2 years', '1996-11-11', NULL, 'Risk of blood disorders', '2016-05-20'),
  (102, 'anakinra', NULL, 'Oral', 'CAN', 'Schizophrenia; Psoriatic Arthritis', 'Patients with obesity; Adults 18-65 years', '2000-01-03', NULL, NULL, NULL),
  (103, 'anakinra', NULL, 'Nasal', 'AUS', 'Fungal Infections; Viral Infections', 'Patients with diabetes; Adults with mild disease', '2018-06-10', NULL, NULL, NULL),
  (104, 'anakinra', NULL, 'Intramuscular', 'CAN', 'Fungal Infections; Pulmonary Embolism', 'Adults with moderate to severe disease; Immunocompromised patients', '1995-08-26', NULL, NULL, NULL),
  (105, 'anakinra', NULL, 'Intravenous', 'ESP', 'Atrial Fibrillation; Deep Vein Thrombosis; Systemic Lupus Erythematosus', 'Adults 18-65 years; Patients with cardiovascular disease', '1995-05-09', NULL, NULL, NULL),
  (106, 'anakinra', NULL, 'Sublingual', 'AUS', 'Atrial Fibrillation', 'Patients with obesity', '1995-04-11', '2020-05-04', NULL, NULL),
  (107, 'anakinra', NULL, 'Nasal', 'BRA', 'Deep Vein Thrombosis; Ulcerative Colitis', 'Adults with mild disease; Immunocompromised patients', '2020-12-19', '2023-01-07', NULL, NULL),
  (108, 'certolizumab', NULL, 'Topical', 'DEU', 'Hypertension; Depression', 'Adults with moderate to severe disease; Patients with comorbidities', '1999-06-13', '2022-09-20', NULL, NULL),
  (109, 'certolizumab', NULL, 'Inhalation', 'JPN', 'Psoriatic Arthritis; Deep Vein Thrombosis; Bacterial Infections', 'Adults with moderate to severe disease', '1998-08-12', NULL, NULL, NULL),
  (110, 'certolizumab', NULL, 'Topical', 'ITA', 'Bacterial Infections', 'Pregnant women; Patients with cardiovascular disease', '2013-08-11', NULL, 'Risk of renal impairment', '2024-07-16'),
  (111, 'certolizumab', NULL, 'Subcutaneous', 'BRA', 'Crohn''s Disease; Psoriatic Arthritis; HIV Infection', 'Patients with hepatic impairment; Pediatric patients 2-17 years', '1990-04-25', NULL, NULL, NULL),
  (112, 'certolizumab', NULL, 'Rectal', 'ITA', 'Bacterial Infections', 'Pediatric patients 2-17 years; Immunocompromised patients', '1991-04-04', NULL, 'Risk of hearing loss', '2022-02-26'),
  (113, 'certolizumab', NULL, 'Topical', 'DEU', 'Rheumatoid Arthritis; Anxiety', 'Patients with obesity', '2005-02-10', NULL, 'Risk of bone loss', '2016-09-02'),
  (114, 'certolizumab', NULL, 'Intramuscular', 'BRA', 'Migraine; Multiple Sclerosis', 'Adults 65+ years', '2000-03-15', NULL, 'Risk of anaphylaxis', '2018-07-08'),
  (115, 'certolizumab', NULL, 'Topical', 'UK', 'Systemic Lupus Erythematosus', 'Patients with comorbidities', '2017-12-17', NULL, NULL, NULL),
  (116, 'certolizumab', NULL, 'Intravenous', 'JPN', 'Anxiety; Psoriatic Arthritis', 'Treatment-naive patients; Adults 65+ years', '2009-05-19', NULL, NULL, NULL),
  (117, 'certolizumab', NULL, 'Intravenous', 'AUS', 'Ulcerative Colitis; Asthma; Migraine', 'Adults 65+ years', '2014-03-09', NULL, NULL, NULL),
  (118, 'certolizumab', NULL, 'Inhalation', 'BRA', 'Osteoporosis', 'Pediatric patients 2-17 years; Treatment-naive patients', '2017-12-06', NULL, NULL, NULL),
  (119, 'certolizumab', NULL, 'Rectal', 'ITA', 'Systemic Lupus Erythematosus; Ankylosing Spondylitis; Ulcerative Colitis', 'Pediatric patients 2-17 years', '2019-05-04', NULL, NULL, NULL),
  (120, 'certolizumab', NULL, 'Rectal', 'CAN', 'Atrial Fibrillation; Bipolar Disorder', 'Treatment-naive patients', '1995-07-19', NULL, NULL, NULL),
  (121, 'certolizumab', NULL, 'Sublingual', 'ITA', 'Bacterial Infections', 'Pediatric patients 6 months-2 years', '2001-01-13', NULL, NULL, NULL),
  (122, 'certolizumab', NULL, 'Intramuscular', 'DEU', 'Cancer; Rheumatoid Arthritis', 'Patients with hepatic impairment', '2001-10-18', NULL, NULL, NULL),
  (123, 'certolizumab', NULL, 'Inhalation', 'ITA', 'Depression; Asthma', 'Patients with comorbidities; Patients with diabetes', '2018-06-20', NULL, NULL, NULL),
  (124, 'certolizumab', NULL, 'Oral', 'FRA', 'Schizophrenia; Heart Failure; Systemic Lupus Erythematosus', 'Patients with renal impairment; Patients with hepatic impairment', '2001-11-22', NULL, NULL, NULL),
  (125, 'certolizumab', NULL, 'Rectal', 'DEU', 'Systemic Lupus Erythematosus; Atrial Fibrillation', 'Pediatric patients 6 months-2 years', '2015-10-09', NULL, 'Risk of hypersensitivity reactions', '2021-07-19'),
  (126, 'certolizumab', NULL, 'Topical', 'USA', 'Pulmonary Embolism; Psoriatic Arthritis; Depression', 'Patients with renal impairment', '2001-05-20', NULL, NULL, NULL),
  (127, 'certolizumab', NULL, 'Oral', 'CAN', 'Ulcerative Colitis; Psoriatic Arthritis; Atrial Fibrillation', 'Patients with prior treatment failure; Pregnant women', '2021-05-13', NULL, NULL, NULL),
  (128, 'certolizumab', NULL, 'Intravenous', 'ESP', 'Bacterial Infections; Osteoporosis', 'Adults with mild disease; Patients with renal impairment', '2019-03-14', NULL, 'Risk of liver injury', '2021-12-09'),
  (129, 'certolizumab', NULL, 'Topical', 'ESP', 'Systemic Lupus Erythematosus', 'Adults 65+ years; Patients with renal impairment', '2015-10-10', NULL, NULL, NULL),
  (130, 'certolizumab', NULL, 'Intramuscular', 'USA', 'Cancer; Atrial Fibrillation', 'Patients with prior treatment failure', '2007-01-04', NULL, 'Risk of renal impairment', '2018-09-24'),
  (131, 'certolizumab', NULL, 'Intramuscular', 'FRA', 'Asthma; Psoriatic Arthritis; Systemic Lupus Erythematosus', 'Adults with moderate to severe disease', '1993-09-16', NULL, 'Risk of serious cardiovascular events', '2017-11-27'),
  (132, 'certolizumab', NULL, 'Intramuscular', 'AUS', 'Ulcerative Colitis; Deep Vein Thrombosis', 'Patients with prior treatment failure', '2021-01-11', NULL, NULL, NULL),
  (133, 'golimumab', NULL, 'Intramuscular', 'DEU', 'Atrial Fibrillation; Psoriatic Arthritis; Diabetes Mellitus Type 2', 'Patients with comorbidities; Pediatric patients 6 months-2 years', '2015-07-11', NULL, 'Risk of bone loss', '2016-04-23'),
  (134, 'golimumab', NULL, 'Rectal', 'FRA', 'Crohn''s Disease; Pulmonary Embolism', 'Patients with hepatic impairment', '1991-02-01', NULL, NULL, NULL),
  (135, 'golimumab', NULL, 'Sublingual', 'JPN', 'HIV Infection', 'Patients with cardiovascular disease', '2023-06-15', NULL, NULL, NULL),
  (136, 'golimumab', NULL, 'Intramuscular', 'DEU', 'Systemic Lupus Erythematosus', 'Pediatric patients 6 months-2 years; Adults 65+ years', '2016-01-20', NULL, NULL, NULL),
  (137, 'golimumab', NULL, 'Intramuscular', 'AUS', 'Fungal Infections; Hepatitis C', 'Patients with hepatic impairment; Pediatric patients 6 months-2 years', '2007-03-08', NULL, 'Risk of tuberculosis reactivation', '2024-11-28'),
  (138, 'golimumab', NULL, 'Inhalation', 'FRA', 'Ulcerative Colitis; Anxiety', 'Patients with prior treatment failure', '2020-04-27', NULL, NULL, NULL),
  (139, 'tofacitinib', NULL, 'Subcutaneous', 'FRA', 'Asthma; Migraine; Crohn''s Disease', 'Adults with mild disease', '1996-05-02', NULL, NULL, NULL),
  (140, 'tofacitinib', NULL, 'Rectal', 'ITA', 'Anxiety', 'Treatment-naive patients; Patients with comorbidities', '2001-09-09', NULL, NULL, NULL),
  (141, 'tofacitinib', NULL, 'Rectal', 'FRA', 'Deep Vein Thrombosis; Systemic Lupus Erythematosus; Plaque Psoriasis', 'Adults 18-65 years', '2012-05-25', NULL, NULL, NULL),
  (142, 'tofacitinib', NULL, 'Oral', 'ITA', 'Schizophrenia', 'Patients with cardiovascular disease; Adults with mild disease', '2005-10-14', NULL, NULL, NULL),
  (143, 'tofacitinib', NULL, 'Oral', 'ITA', 'Hypertension', 'Patients with prior treatment failure', '1991-12-20', NULL, NULL, NULL),
  (144, 'tofacitinib', NULL, 'Topical', 'ITA', 'HIV Infection; Systemic Lupus Erythematosus', 'Adults 65+ years; Patients with hepatic impairment', '2023-03-05', NULL, 'Risk of central nervous system effects', '2021-07-05'),
  (145, 'tofacitinib', NULL, 'Inhalation', 'DEU', 'Psoriatic Arthritis; Bipolar Disorder', 'Adults with moderate to severe disease; Adults with mild disease', '1999-09-17', NULL, NULL, NULL),
  (146, 'tofacitinib', NULL, 'Sublingual', 'DEU', 'Migraine; Hypertension; Depression', 'Adults with moderate to severe disease', '2015-02-17', NULL, NULL, NULL),
  (147, 'tofacitinib', NULL, 'Nasal', 'JPN', 'Depression; Psoriatic Arthritis', 'Adults with moderate to severe disease', '2018-06-20', NULL, NULL, NULL),
  (148, 'tofacitinib', NULL, 'Topical', 'UK', 'Pulmonary Embolism', 'Adults 65+ years', '1993-06-27', NULL, 'Risk of anaphylaxis', '2019-06-02'),
  (149, 'tofacitinib', NULL, 'Oral', 'ESP', 'Ulcerative Colitis; Schizophrenia; Depression', 'Treatment-naive patients; Adults 18-65 years', '1995-09-11', NULL, NULL, NULL),
  (150, 'tofacitinib', NULL, 'Topical', 'FRA', 'Psoriatic Arthritis', 'Patients with diabetes; Patients with prior treatment failure', '2001-10-21', NULL, NULL, NULL),
  (151, 'tofacitinib', NULL, 'Oral', 'CAN', 'Bipolar Disorder; Depression', 'Adults 18-65 years', '2003-10-15', NULL, NULL, NULL),
  (152, 'tofacitinib', NULL, 'Subcutaneous', 'JPN', 'Depression; Migraine; Osteoporosis', 'Pregnant women', '2009-04-16', NULL, 'Risk of serious cardiovascular events', '2015-04-11'),
  (153, 'baricitinib', NULL, 'Intravenous', 'UK', 'Atrial Fibrillation; Schizophrenia; Viral Infections', 'Adults 65+ years', '2007-08-17', NULL, 'Risk of hypersensitivity reactions', '2020-11-25'),
  (154, 'baricitinib', NULL, 'Transdermal', 'CAN', 'Deep Vein Thrombosis; Ankylosing Spondylitis', 'Treatment-naive patients', '2014-01-12', '2024-08-28', NULL, NULL),
  (155, 'baricitinib', NULL, 'Intravenous', 'BRA', 'Bacterial Infections; Rheumatoid Arthritis; Diabetes Mellitus Type 2', 'Patients with prior treatment failure', '2002-10-10', NULL, NULL, NULL),
  (156, 'baricitinib', NULL, 'Oral', 'ITA', 'Crohn''s Disease', 'Immunocompromised patients', '2004-09-19', NULL, NULL, NULL),
  (157, 'baricitinib', NULL, 'Sublingual', 'CAN', 'Hypertension', 'Patients with hepatic impairment; Immunocompromised patients', '2015-03-10', NULL, 'Risk of blood disorders', '2022-06-22'),
  (158, 'baricitinib', NULL, 'Oral', 'ITA', 'Rheumatoid Arthritis', 'Patients with prior treatment failure', '2011-07-21', NULL, 'Risk of vision changes', '2016-02-28'),
  (159, 'baricitinib', NULL, 'Sublingual', 'AUS', 'Pulmonary Embolism', 'Patients with comorbidities; Adults 18-65 years', '1993-10-09', NULL, NULL, NULL),
  (160, 'baricitinib', NULL, 'Nasal', 'AUS', 'Systemic Lupus Erythematosus', 'Patients with obesity', '2014-02-05', NULL, NULL, NULL),
  (161, 'baricitinib', NULL, 'Inhalation', 'BRA', 'Hepatitis C', 'Adults with mild disease', '1999-09-28', NULL, NULL, NULL),
  (162, 'baricitinib', NULL, 'Intravenous', 'DEU', 'Diabetes Mellitus Type 2; Migraine', 'Patients with diabetes; Adults 65+ years', '1991-08-26', NULL, 'Risk of peripheral neuropathy', '2024-04-28'),
  (163, 'baricitinib', NULL, 'Oral', 'FRA', 'Heart Failure; Cancer; Asthma', 'Patients with cardiovascular disease', '2022-01-18', NULL, 'Risk of bone loss', '2020-02-13'),
  (164, 'baricitinib', NULL, 'Topical', 'CAN', 'Depression; Bipolar Disorder', 'Pediatric patients 2-17 years', '1995-11-12', NULL, NULL, NULL),
  (165, 'baricitinib', NULL, 'Subcutaneous', 'JPN', 'Systemic Lupus Erythematosus; Depression; Pulmonary Embolism', 'Patients with prior treatment failure; Patients with obesity', '2022-10-24', NULL, NULL, NULL),
  (166, 'baricitinib', NULL, 'Transdermal', 'FRA', 'Osteoporosis', 'Patients with cardiovascular disease', '2015-02-21', NULL, NULL, NULL),
  (167, 'baricitinib', NULL, 'Subcutaneous', 'ITA', 'Viral Infections; Hypertension', 'Patients with comorbidities; Patients with diabetes', '2024-09-12', '2023-03-01', 'Risk of hearing loss', '2017-07-05'),
  (168, 'baricitinib', NULL, 'Subcutaneous', 'USA', 'HIV Infection; Migraine', 'Adults 65+ years', '2003-12-04', '2021-12-03', NULL, NULL),
  (169, 'baricitinib', NULL, 'Topical', 'JPN', 'Anxiety', 'Treatment-naive patients; Patients with comorbidities', '2012-11-16', NULL, 'Risk of bone loss', '2015-10-08'),
  (170, 'baricitinib', NULL, 'Oral', 'UK', 'Asthma', 'Adults 65+ years', '2000-03-12', NULL, NULL, NULL),
  (171, 'baricitinib', NULL, 'Intramuscular', 'JPN', 'Chronic Obstructive Pulmonary Disease', 'Pediatric patients 6 months-2 years; Patients with diabetes', '2017-09-11', NULL, 'Risk of central nervous system effects', '2023-11-12'),
  (172, 'baricitinib', NULL, 'Subcutaneous', 'USA', 'Ulcerative Colitis', 'Pediatric patients 2-17 years; Patients with prior treatment failure', '1998-05-10', NULL, NULL, NULL),
  (173, 'baricitinib', NULL, 'Intravenous', 'CAN', 'Diabetes Mellitus Type 2; Viral Infections', 'Pediatric patients 2-17 years; Patients with hepatic impairment', '2014-10-27', NULL, NULL, NULL),
  (174, 'baricitinib', NULL, 'Sublingual', 'BRA', 'Migraine', 'Patients with diabetes', '2022-08-22', NULL, 'Risk of renal impairment', '2018-11-13'),
  (175, 'baricitinib', NULL, 'Topical', 'ESP', 'Atrial Fibrillation', 'Immunocompromised patients; Patients with diabetes', '1996-02-07', NULL, 'Risk of serious cardiovascular events', '2023-10-12'),
  (176, 'baricitinib', NULL, 'Intravenous', 'DEU', 'Hepatitis C', 'Patients with comorbidities', '2007-06-26', NULL, NULL, NULL),
  (177, 'baricitinib', NULL, 'Intravenous', 'DEU', 'Fungal Infections', 'Immunocompromised patients; Adults 65+ years', '2010-05-10', NULL, NULL, NULL),
  (178, 'baricitinib', NULL, 'Sublingual', 'BRA', 'Juvenile Idiopathic Arthritis', 'Patients with renal impairment; Adults with moderate to severe disease', '1992-06-03', '2023-09-15', NULL, NULL),
  (179, 'baricitinib', NULL, 'Nasal', 'ITA', 'Hypertension; Ankylosing Spondylitis', 'Pediatric patients 2-17 years; Patients with comorbidities', '2023-02-16', NULL, 'Risk of hypersensitivity reactions', '2023-07-25'),
  (180, 'upadacitinib', NULL, 'Topical', 'UK', 'Psoriatic Arthritis; HIV Infection; Ulcerative Colitis', 'Patients with comorbidities; Pediatric patients 2-17 years', '2019-07-21', NULL, NULL, NULL),
  (181, 'upadacitinib', NULL, 'Intravenous', 'JPN', 'Juvenile Idiopathic Arthritis', 'Patients with cardiovascular disease', '2022-08-16', NULL, NULL, NULL),
  (182, 'upadacitinib', NULL, 'Intramuscular', 'CAN', 'Depression; Chronic Obstructive Pulmonary Disease', 'Patients with renal impairment; Pediatric patients 6 months-2 years', '1998-06-27', NULL, NULL, NULL),
  (183, 'upadacitinib', NULL, 'Transdermal', 'AUS', 'Multiple Sclerosis; Diabetes Mellitus Type 2; Schizophrenia', 'Patients with hepatic impairment; Pediatric patients 6 months-2 years', '2015-09-03', NULL, NULL, NULL),
  (184, 'upadacitinib', NULL, 'Transdermal', 'DEU', 'Hypertension; Fungal Infections; Rheumatoid Arthritis', 'Adults with moderate to severe disease; Patients with hepatic impairment', '2020-01-12', NULL, 'Risk of hearing loss', '2015-04-17'),
  (185, 'upadacitinib', NULL, 'Sublingual', 'JPN', 'Bipolar Disorder; Depression; Migraine', 'Adults with mild disease; Patients with hepatic impairment', '2005-01-15', NULL, NULL, NULL),
  (186, 'upadacitinib', NULL, 'Intramuscular', 'BRA', 'Hypertension', 'Adults with moderate to severe disease', '1999-05-12', NULL, NULL, NULL),
  (187, 'upadacitinib', NULL, 'Transdermal', 'CAN', 'Psoriatic Arthritis; HIV Infection; Osteoporosis', 'Patients with hepatic impairment', '1991-09-06', NULL, 'Risk of liver injury', '2016-04-24'),
  (188, 'upadacitinib', NULL, 'Intravenous', 'CAN', 'Bacterial Infections', 'Adults 18-65 years; Pediatric patients 2-17 years', '2022-03-25', NULL, NULL, NULL),
  (189, 'filgotinib', NULL, 'Transdermal', 'ESP', 'Ulcerative Colitis', 'Patients with prior treatment failure', '2021-11-24', NULL, NULL, NULL),
  (190, 'filgotinib', NULL, 'Intramuscular', 'USA', 'Bipolar Disorder; Hypertension; Chronic Obstructive Pulmonary Disease', 'Patients with comorbidities', '1993-07-09', '2023-09-21', NULL, NULL),
  (191, 'filgotinib', NULL, 'Subcutaneous', 'JPN', 'Plaque Psoriasis', 'Treatment-naive patients', '2022-06-08', NULL, NULL, NULL),
  (192, 'filgotinib', NULL, 'Inhalation', 'AUS', 'Psoriatic Arthritis', 'Immunocompromised patients', '2005-12-22', NULL, NULL, NULL),
  (193, 'filgotinib', NULL, 'Intramuscular', 'JPN', 'Systemic Lupus Erythematosus; Diabetes Mellitus Type 2', 'Adults with moderate to severe disease', '2001-09-25', NULL, NULL, NULL),
  (194, 'filgotinib', NULL, 'Subcutaneous', 'BRA', 'Cancer', 'Patients with cardiovascular disease; Adults with mild disease', '1995-04-17', '2024-11-14', NULL, NULL),
  (195, 'filgotinib', NULL, 'Sublingual', 'JPN', 'Chronic Obstructive Pulmonary Disease; Deep Vein Thrombosis; Viral Infections', 'Patients with obesity', '2014-10-28', NULL, NULL, NULL),
  (196, 'filgotinib', NULL, 'Intravenous', 'BRA', 'Heart Failure; Osteoporosis', 'Adults 18-65 years', '2007-10-19', NULL, NULL, NULL),
  (197, 'filgotinib', NULL, 'Transdermal', 'BRA', 'Hypertension; Systemic Lupus Erythematosus; Psoriatic Arthritis', 'Adults 18-65 years', '1990-04-24', NULL, 'Risk of hearing loss', '2016-02-15'),
  (198, 'filgotinib', NULL, 'Subcutaneous', 'USA', 'Deep Vein Thrombosis; Asthma', 'Patients with renal impairment', '1997-08-20', NULL, NULL, NULL),
  (199, 'filgotinib', NULL, 'Intramuscular', 'USA', 'Rheumatoid Arthritis', 'Adults with moderate to severe disease; Pediatric patients 2-17 years', '2004-03-15', NULL, NULL, NULL),
  (200, 'filgotinib', NULL, 'Topical', 'ITA', 'Rheumatoid Arthritis', 'Pediatric patients 6 months-2 years; Patients with diabetes', '2004-07-08', NULL, 'Risk of blood disorders', '2022-09-21'),
  (201, 'filgotinib', NULL, 'Intramuscular', 'CAN', 'Bipolar Disorder', 'Pregnant women', '2005-03-11', NULL, NULL, NULL),
  (202, 'filgotinib', NULL, 'Rectal', 'JPN', 'Deep Vein Thrombosis; Psoriatic Arthritis', 'Treatment-naive patients; Immunocompromised patients', '2000-01-16', '2024-02-17', NULL, NULL),
  (203, 'filgotinib', NULL, 'Intravenous', 'FRA', 'Pulmonary Embolism; Bipolar Disorder', 'Pediatric patients 6 months-2 years', '1996-10-04', NULL, NULL, NULL),
  (204, 'filgotinib', NULL, 'Transdermal', 'FRA', 'Multiple Sclerosis; Chronic Obstructive Pulmonary Disease; Migraine', 'Pediatric patients 6 months-2 years', '2021-12-21', NULL, NULL, NULL),
  (205, 'filgotinib', NULL, 'Subcutaneous', 'BRA', 'Heart Failure; Multiple Sclerosis', 'Patients with cardiovascular disease; Pediatric patients 6 months-2 years', '2022-05-16', NULL, NULL, NULL),
  (206, 'ruxolitinib', NULL, 'Rectal', 'BRA', 'Psoriatic Arthritis; Multiple Sclerosis; Hypertension', 'Patients with diabetes; Pediatric patients 2-17 years', '2024-07-05', NULL, NULL, NULL),
  (207, 'ruxolitinib', NULL, 'Oral', 'ESP', 'Atrial Fibrillation; Plaque Psoriasis; Hepatitis C', 'Adults with moderate to severe disease; Pediatric patients 2-17 years', '2023-11-07', NULL, NULL, NULL),
  (208, 'ruxolitinib', NULL, 'Nasal', 'USA', 'Osteoporosis; Ankylosing Spondylitis', 'Adults with moderate to severe disease', '2019-12-23', '2023-09-15', 'Risk of hepatitis B reactivation', '2020-12-16'),
  (209, 'ruxolitinib', NULL, 'Transdermal', 'JPN', 'Atrial Fibrillation; Multiple Sclerosis', 'Patients with diabetes; Pediatric patients 6 months-2 years', '2019-10-26', NULL, NULL, NULL),
  (210, 'ruxolitinib', NULL, 'Sublingual', 'USA', 'Heart Failure', 'Pediatric patients 6 months-2 years', '2014-06-18', NULL, NULL, NULL),
  (211, 'ruxolitinib', NULL, 'Subcutaneous', 'DEU', 'Migraine; Depression', 'Patients with obesity', '1991-02-01', NULL, 'Risk of hepatitis B reactivation', '2020-08-19'),
  (212, 'ruxolitinib', NULL, 'Topical', 'JPN', 'Crohn''s Disease', 'Patients with prior treatment failure; Adults 65+ years', '2006-02-13', NULL, 'Risk of blood disorders', '2023-09-03'),
  (213, 'ruxolitinib', NULL, 'Inhalation', 'BRA', 'Multiple Sclerosis; Depression', 'Treatment-naive patients; Adults with mild disease', '2009-09-10', NULL, NULL, NULL),
  (214, 'ruxolitinib', NULL, 'Rectal', 'BRA', 'Rheumatoid Arthritis; Crohn''s Disease; HIV Infection', 'Patients with diabetes', '1997-01-23', NULL, NULL, NULL),
  (215, 'ruxolitinib', NULL, 'Oral', 'UK', 'Depression; Multiple Sclerosis', 'Pediatric patients 2-17 years; Patients with prior treatment failure', '1993-12-12', NULL, NULL, NULL),
  (216, 'ruxolitinib', NULL, 'Nasal', 'AUS', 'Diabetes Mellitus Type 2; Rheumatoid Arthritis', 'Pediatric patients 6 months-2 years', '2013-08-02', '2021-05-20', NULL, NULL),
  (217, 'ruxolitinib', NULL, 'Subcutaneous', 'BRA', 'Ulcerative Colitis', 'Patients with cardiovascular disease', '1991-08-06', NULL, NULL, NULL),
  (218, 'ruxolitinib', NULL, 'Inhalation', 'USA', 'Schizophrenia; Multiple Sclerosis; Depression', 'Patients with prior treatment failure', '2022-02-10', '2022-10-06', NULL, NULL),
  (219, 'ruxolitinib', NULL, 'Nasal', 'FRA', 'Systemic Lupus Erythematosus', 'Patients with comorbidities', '2005-08-05', NULL, NULL, NULL),
  (220, 'ruxolitinib', NULL, 'Oral', 'UK', 'HIV Infection', 'Pediatric patients 2-17 years; Pregnant women', '2007-01-06', NULL, 'Risk of serious cardiovascular events', '2020-02-13'),
  (221, 'ruxolitinib', NULL, 'Inhalation', 'JPN', 'Pulmonary Embolism', 'Treatment-naive patients; Patients with hepatic impairment', '2019-03-05', NULL, 'Risk of hepatitis B reactivation', '2022-03-08'),
  (222, 'ruxolitinib', NULL, 'Inhalation', 'ESP', 'Psoriatic Arthritis; Ankylosing Spondylitis', 'Pregnant women', '1997-04-19', NULL, NULL, NULL),
  (223, 'ruxolitinib', NULL, 'Rectal', 'FRA', 'Plaque Psoriasis; Hepatitis C', 'Pediatric patients 6 months-2 years; Treatment-naive patients', '2006-01-10', NULL, 'Risk of vision changes', '2017-09-02'),
  (224, 'ruxolitinib', NULL, 'Topical', 'CAN', 'Crohn''s Disease; Anxiety; Juvenile Idiopathic Arthritis', 'Patients with comorbidities', '2024-07-11', NULL, NULL, NULL),
  (225, 'ruxolitinib', NULL, 'Oral', 'CAN', 'Depression; Schizophrenia', 'Patients with prior treatment failure', '2012-02-01', NULL, NULL, NULL),
  (226, 'ruxolitinib', NULL, 'Rectal', 'DEU', 'Fungal Infections; Migraine; Crohn''s Disease', 'Adults with moderate to severe disease', '1996-08-04', NULL, 'Risk of hearing loss', '2016-12-16'),
  (227, 'ruxolitinib', NULL, 'Topical', 'FRA', 'Multiple Sclerosis; Migraine; Plaque Psoriasis', 'Treatment-naive patients; Adults 65+ years', '1999-03-02', NULL, NULL, NULL),
  (228, 'methotrexate', NULL, 'Transdermal', 'ESP', 'Heart Failure; Bacterial Infections; Rheumatoid Arthritis', 'Patients with hepatic impairment', '2005-11-18', NULL, NULL, NULL),
  (229, 'methotrexate', NULL, 'Transdermal', 'UK', 'Osteoporosis', 'Patients with comorbidities', '2014-10-07', '2020-12-25', NULL, NULL),
  (230, 'methotrexate', NULL, 'Transdermal', 'UK', 'Juvenile Idiopathic Arthritis; Plaque Psoriasis; Atrial Fibrillation', 'Adults with moderate to severe disease; Treatment-naive patients', '2000-01-06', NULL, NULL, NULL),
  (231, 'methotrexate', NULL, 'Nasal', 'ESP', 'Bipolar Disorder; Deep Vein Thrombosis; Juvenile Idiopathic Arthritis', 'Adults 65+ years; Patients with prior treatment failure', '1992-02-24', NULL, NULL, NULL),
  (232, 'methotrexate', NULL, 'Topical', 'UK', 'Osteoporosis; Viral Infections', 'Pediatric patients 2-17 years', '2023-06-16', NULL, NULL, NULL),
  (233, 'methotrexate', NULL, 'Rectal', 'BRA', 'Anxiety', 'Adults 65+ years', '1997-08-18', NULL, 'Risk of serious cardiovascular events', '2015-05-22'),
  (234, 'methotrexate', NULL, 'Nasal', 'UK', 'Hepatitis C; Plaque Psoriasis', 'Adults 65+ years; Adults with moderate to severe disease', '2013-07-10', NULL, 'Risk of anaphylaxis', '2020-12-10'),
  (235, 'methotrexate', NULL, 'Topical', 'AUS', 'Heart Failure; Migraine', 'Patients with cardiovascular disease', '2021-08-02', NULL, 'Risk of peripheral neuropathy', '2024-07-18'),
  (236, 'methotrexate', NULL, 'Rectal', 'DEU', 'Pulmonary Embolism; Multiple Sclerosis; Ankylosing Spondylitis', 'Pregnant women; Patients with hepatic impairment', '2021-10-07', NULL, NULL, NULL),
  (237, 'methotrexate', NULL, 'Subcutaneous', 'AUS', 'Depression', 'Patients with prior treatment failure; Immunocompromised patients', '2017-07-06', NULL, NULL, NULL),
  (238, 'methotrexate', NULL, 'Nasal', 'UK', 'Psoriatic Arthritis', 'Patients with comorbidities; Patients with renal impairment', '1998-12-02', NULL, NULL, NULL),
  (239, 'methotrexate', NULL, 'Inhalation', 'FRA', 'Diabetes Mellitus Type 2; Ankylosing Spondylitis', 'Adults with moderate to severe disease; Adults 18-65 years', '2012-07-24', NULL, NULL, NULL),
  (240, 'methotrexate', NULL, 'Nasal', 'USA', 'Atrial Fibrillation; Bipolar Disorder; HIV Infection', 'Adults 18-65 years; Patients with prior treatment failure', '2011-09-10', NULL, NULL, NULL),
  (241, 'methotrexate', NULL, 'Inhalation', 'USA', 'Depression; Hypertension', 'Adults 18-65 years; Adults 65+ years', '1993-06-22', NULL, NULL, NULL),
  (242, 'methotrexate', NULL, 'Nasal', 'AUS', 'Chronic Obstructive Pulmonary Disease', 'Patients with renal impairment; Adults 65+ years', '1990-06-19', NULL, NULL, NULL),
  (243, 'methotrexate', NULL, 'Inhalation', 'ESP', 'Anxiety; Atrial Fibrillation; Hepatitis C', 'Pediatric patients 2-17 years; Patients with diabetes', '2004-09-15', NULL, NULL, NULL),
  (244, 'methotrexate', NULL, 'Intravenous', 'DEU', 'Asthma; Heart Failure', 'Patients with prior treatment failure', '2021-01-10', NULL, NULL, NULL),
  (245, 'methotrexate', NULL, 'Inhalation', 'ESP', 'Diabetes Mellitus Type 2', 'Adults 18-65 years; Pregnant women', '2013-10-12', NULL, 'Risk of blood disorders', '2024-06-10'),
  (246, 'methotrexate', NULL, 'Nasal', 'BRA', 'Bipolar Disorder', 'Immunocompromised patients; Adults 65+ years', '2020-02-12', NULL, NULL, NULL),
  (247, 'methotrexate', NULL, 'Subcutaneous', 'JPN', 'Crohn''s Disease; Rheumatoid Arthritis', 'Patients with cardiovascular disease', '2000-04-18', '2024-07-08', 'Risk of blood disorders', '2020-12-22'),
  (248, 'methotrexate', NULL, 'Intramuscular', 'ESP', 'Psoriatic Arthritis; Migraine', 'Patients with hepatic impairment; Pediatric patients 6 months-2 years', '2003-08-18', NULL, NULL, NULL),
  (249, 'methotrexate', NULL, 'Intravenous', 'FRA', 'Deep Vein Thrombosis; Diabetes Mellitus Type 2', 'Pregnant women; Treatment-naive patients', '1999-05-11', NULL, 'Risk of bone loss', '2016-03-06'),
  (250, 'methotrexate', NULL, 'Topical', 'DEU', 'Anxiety', 'Adults with moderate to severe disease', '2023-01-24', '2023-01-03', NULL, NULL),
  (251, 'methotrexate', NULL, 'Oral', 'CAN', 'Migraine; Multiple Sclerosis', 'Immunocompromised patients', '2023-08-23', NULL, 'Risk of liver injury', '2022-07-13'),
  (252, 'methotrexate', NULL, 'Sublingual', 'CAN', 'Ulcerative Colitis; Depression; Hepatitis C', 'Pediatric patients 2-17 years; Patients with comorbidities', '2013-07-23', '2024-02-13', 'Risk of liver injury', '2023-11-10'),
  (253, 'methotrexate', NULL, 'Subcutaneous', 'USA', 'Atrial Fibrillation; Heart Failure; Deep Vein Thrombosis', 'Patients with comorbidities', '1991-08-28', NULL, 'Risk of central nervous system effects', '2024-11-05'),
  (254, 'methotrexate', NULL, 'Sublingual', 'AUS', 'Schizophrenia; Plaque Psoriasis', 'Pediatric patients 6 months-2 years; Patients with cardiovascular disease', '1996-06-17', '2020-04-04', 'Risk of hearing loss', '2020-12-02'),
  (255, 'methotrexate', NULL, 'Oral', 'ESP', 'Depression; HIV Infection', 'Adults 18-65 years; Immunocompromised patients', '2001-02-14', NULL, NULL, NULL),
  (256, 'methotrexate', NULL, 'Intravenous', 'AUS', 'Psoriatic Arthritis; Ulcerative Colitis', 'Adults 18-65 years; Patients with comorbidities', '1999-10-18', NULL, NULL, NULL),
  (257, 'leflunomide', NULL, 'Intramuscular', 'ESP', 'Fungal Infections; Bacterial Infections; Diabetes Mellitus Type 2', 'Patients with diabetes', '1997-08-21', NULL, NULL, NULL),
  (258, 'leflunomide', NULL, 'Nasal', 'CAN', 'Osteoporosis; Psoriatic Arthritis', 'Adults 65+ years', '1998-02-09', NULL, NULL, NULL),
  (259, 'leflunomide', NULL, 'Intravenous', 'FRA', 'HIV Infection', 'Adults with mild disease', '2021-10-12', NULL, NULL, NULL),
  (260, 'leflunomide', NULL, 'Nasal', 'ESP', 'Viral Infections', 'Patients with diabetes', '1995-11-19', NULL, NULL, NULL),
  (261, 'azathioprine', NULL, 'Oral', 'DEU', 'Crohn''s Disease; Atrial Fibrillation', 'Treatment-naive patients; Patients with cardiovascular disease', '2020-03-12', NULL, NULL, NULL),
  (262, 'azathioprine', NULL, 'Intramuscular', 'USA', 'Osteoporosis; Hepatitis C; Psoriatic Arthritis', 'Patients with diabetes', '2007-10-16', NULL, NULL, NULL),
  (263, 'azathioprine', NULL, 'Transdermal', 'AUS', 'Bipolar Disorder', 'Pediatric patients 2-17 years; Pregnant women', '1997-07-28', NULL, NULL, NULL),
  (264, 'azathioprine', NULL, 'Transdermal', 'USA', 'Bacterial Infections; Rheumatoid Arthritis; Ankylosing Spondylitis', 'Patients with cardiovascular disease; Treatment-naive patients', '2005-05-19', NULL, NULL, NULL),
  (265, 'azathioprine', NULL, 'Inhalation', 'JPN', 'Psoriatic Arthritis; Ulcerative Colitis', 'Patients with comorbidities', '2014-06-01', NULL, NULL, NULL),
  (266, 'azathioprine', NULL, 'Nasal', 'CAN', 'Heart Failure; Osteoporosis; Anxiety', 'Adults 65+ years', '2019-11-13', NULL, NULL, NULL),
  (267, 'azathioprine', NULL, 'Rectal', 'ITA', 'Cancer; Anxiety', 'Patients with comorbidities', '2022-04-03', '2024-02-13', NULL, NULL),
  (268, 'azathioprine', NULL, 'Subcutaneous', 'ITA', 'Diabetes Mellitus Type 2', 'Patients with prior treatment failure', '1990-07-08', NULL, NULL, NULL),
  (269, 'azathioprine', NULL, 'Nasal', 'ITA', 'Viral Infections; Hepatitis C', 'Adults 18-65 years', '2012-11-13', NULL, NULL, NULL),
  (270, 'azathioprine', NULL, 'Subcutaneous', 'BRA', 'Hypertension', 'Treatment-naive patients', '2007-06-24', NULL, 'Risk of peripheral neuropathy', '2015-07-10'),
  (271, 'azathioprine', NULL, 'Intramuscular', 'USA', 'Juvenile Idiopathic Arthritis; Heart Failure; Anxiety', 'Adults 65+ years; Patients with renal impairment', '1996-09-10', NULL, 'Risk of anaphylaxis', '2021-11-19'),
  (272, 'azathioprine', NULL, 'Oral', 'CAN', 'Ankylosing Spondylitis', 'Patients with comorbidities', '1998-04-26', NULL, NULL, NULL),
  (273, 'azathioprine', NULL, 'Nasal', 'BRA', 'HIV Infection; Psoriatic Arthritis', 'Patients with comorbidities', '2007-08-14', NULL, 'Risk of liver injury', '2024-02-18'),
  (274, 'azathioprine', NULL, 'Subcutaneous', 'DEU', 'Anxiety; Migraine; Juvenile Idiopathic Arthritis', 'Patients with prior treatment failure; Adults with moderate to severe disease', '2012-07-17', NULL, 'Increased risk of malignancy', '2022-02-26'),
  (275, 'azathioprine', NULL, 'Subcutaneous', 'ITA', 'Crohn''s Disease', 'Adults with moderate to severe disease', '1997-10-11', NULL, 'Risk of progressive multifocal leukoencephalopathy', '2015-11-10'),
  (276, 'azathioprine', NULL, 'Subcutaneous', 'USA', 'Anxiety; Plaque Psoriasis', 'Patients with obesity; Patients with diabetes', '2023-05-17', NULL, NULL, NULL),
  (277, 'azathioprine', NULL, 'Inhalation', 'UK', 'Heart Failure; Ankylosing Spondylitis', 'Pediatric patients 2-17 years; Adults with mild disease', '2018-11-09', NULL, NULL, NULL),
  (278, 'azathioprine', NULL, 'Transdermal', 'USA', 'HIV Infection', 'Patients with obesity', '2001-03-12', NULL, 'Risk of progressive multifocal leukoencephalopathy', '2021-12-08'),
  (279, 'azathioprine', NULL, 'Oral', 'AUS', 'Systemic Lupus Erythematosus', 'Treatment-naive patients', '1991-05-14', NULL, NULL, NULL),
  (280, 'azathioprine', NULL, 'Intramuscular', 'FRA', 'Juvenile Idiopathic Arthritis; Ankylosing Spondylitis', 'Patients with cardiovascular disease', '1999-08-13', NULL, 'Risk of central nervous system effects', '2015-01-15'),
  (281, 'azathioprine', NULL, 'Intramuscular', 'AUS', 'Fungal Infections; Crohn''s Disease', 'Patients with renal impairment', '2008-10-23', NULL, 'Risk of central nervous system effects', '2018-08-01'),
  (282, 'azathioprine', NULL, 'Transdermal', 'CAN', 'Hypertension; Fungal Infections', 'Patients with comorbidities; Adults with moderate to severe disease', '2024-08-22', NULL, NULL, NULL),
  (283, 'azathioprine', NULL, 'Intravenous', 'CAN', 'Anxiety', 'Adults with mild disease; Pediatric patients 2-17 years', '2011-02-18', NULL, NULL, NULL),
  (284, 'azathioprine', NULL, 'Intramuscular', 'UK', 'Chronic Obstructive Pulmonary Disease', 'Patients with renal impairment; Patients with diabetes', '1998-04-26', NULL, 'Increased risk of malignancy', '2020-06-21'),
  (285, 'azathioprine', NULL, 'Intramuscular', 'UK', 'Heart Failure; Deep Vein Thrombosis', 'Pregnant women', '2013-09-10', NULL, NULL, NULL),
  (286, 'azathioprine', NULL, 'Sublingual', 'UK', 'Systemic Lupus Erythematosus; Bipolar Disorder', 'Patients with renal impairment', '2005-10-03', NULL, NULL, NULL),
  (287, 'cyclosporine', NULL, 'Subcutaneous', 'BRA', 'Rheumatoid Arthritis', 'Patients with cardiovascular disease; Patients with obesity', '1993-12-08', NULL, NULL, NULL),
  (288, 'cyclosporine', NULL, 'Topical', 'CAN', 'Hepatitis C; Pulmonary Embolism', 'Adults 18-65 years; Pregnant women', '2011-04-26', NULL, NULL, NULL),
  (289, 'cyclosporine', NULL, 'Subcutaneous', 'JPN', 'Heart Failure; Psoriatic Arthritis; Pulmonary Embolism', 'Adults 65+ years; Patients with diabetes', '1993-05-28', NULL, 'Risk of hepatitis B reactivation', '2024-07-10'),
  (290, 'cyclosporine', NULL, 'Intramuscular', 'FRA', 'Fungal Infections; Osteoporosis', 'Patients with cardiovascular disease', '2009-10-23', '2020-05-22', 'Risk of anaphylaxis', '2020-10-05'),
  (291, 'mycophenolate', NULL, 'Subcutaneous', 'UK', 'Psoriatic Arthritis; HIV Infection; Hypertension', 'Adults with moderate to severe disease; Patients with cardiovascular disease', '2021-06-27', NULL, NULL, NULL),
  (292, 'mycophenolate', NULL, 'Inhalation', 'ESP', 'Crohn''s Disease; Hypertension', 'Pediatric patients 2-17 years', '2011-06-26', '2022-02-02', NULL, NULL),
  (293, 'mycophenolate', NULL, 'Subcutaneous', 'ITA', 'Hypertension', 'Patients with hepatic impairment', '2001-04-19', NULL, NULL, NULL),
  (294, 'mycophenolate', NULL, 'Subcutaneous', 'DEU', 'Chronic Obstructive Pulmonary Disease; Psoriatic Arthritis', 'Pregnant women; Patients with prior treatment failure', '2009-11-26', NULL, NULL, NULL),
  (295, 'mycophenolate', NULL, 'Sublingual', 'ESP', 'Asthma; Pulmonary Embolism', 'Adults with moderate to severe disease', '2016-06-07', NULL, 'Risk of gastrointestinal perforation', '2022-03-22'),
  (296, 'mycophenolate', NULL, 'Intravenous', 'AUS', 'Osteoporosis; Bipolar Disorder', 'Patients with diabetes; Patients with renal impairment', '2011-05-26', NULL, NULL, NULL),
  (297, 'mycophenolate', NULL, 'Transdermal', 'ESP', 'Juvenile Idiopathic Arthritis; Pulmonary Embolism; Diabetes Mellitus Type 2', 'Adults with moderate to severe disease', '1998-05-08', NULL, 'Risk of gastrointestinal perforation', '2020-03-26'),
  (298, 'mycophenolate', NULL, 'Intravenous', 'ESP', 'Asthma', 'Adults 18-65 years; Patients with cardiovascular disease', '1992-09-09', NULL, NULL, NULL),
  (299, 'mycophenolate', NULL, 'Nasal', 'USA', 'Depression', 'Patients with comorbidities', '1996-10-22', NULL, NULL, NULL),
  (300, 'mycophenolate', NULL, 'Rectal', 'CAN', 'Crohn''s Disease', 'Pregnant women', '2010-09-01', '2024-02-06', 'Risk of anaphylaxis', '2023-06-26'),
  (301, 'mycophenolate', NULL, 'Rectal', 'AUS', 'Anxiety; Bacterial Infections; Migraine', 'Pediatric patients 2-17 years; Immunocompromised patients', '2016-06-07', NULL, 'Risk of liver injury', '2018-03-03'),
  (302, 'mycophenolate', NULL, 'Inhalation', 'JPN', 'Multiple Sclerosis; Depression; Rheumatoid Arthritis', 'Treatment-naive patients; Patients with obesity', '2022-12-25', NULL, NULL, NULL),
  (303, 'mycophenolate', NULL, 'Inhalation', 'USA', 'Bipolar Disorder; Plaque Psoriasis', 'Pediatric patients 2-17 years', '2007-02-08', NULL, 'Risk of serious cardiovascular events', '2018-09-09'),
  (304, 'mycophenolate', NULL, 'Topical', 'FRA', 'Pulmonary Embolism', 'Patients with obesity', '1990-11-24', '2023-06-17', 'Risk of blood disorders', '2024-06-07'),
  (305, 'belimumab', NULL, 'Nasal', 'DEU', 'Hypertension', 'Patients with prior treatment failure; Patients with hepatic impairment', '2021-01-22', NULL, NULL, NULL),
  (306, 'belimumab', NULL, 'Transdermal', 'ESP', 'Deep Vein Thrombosis', 'Immunocompromised patients', '2003-09-02', NULL, 'Risk of blood disorders', '2017-11-07'),
  (307, 'belimumab', NULL, 'Sublingual', 'ITA', 'Atrial Fibrillation; Psoriatic Arthritis; Cancer', 'Treatment-naive patients; Pediatric patients 6 months-2 years', '1995-12-17', NULL, NULL, NULL),
  (308, 'belimumab', NULL, 'Oral', 'USA', 'Osteoporosis; Bipolar Disorder', 'Patients with hepatic impairment', '1991-03-16', NULL, NULL, NULL),
  (309, 'belimumab', NULL, 'Intravenous', 'BRA', 'Bacterial Infections', 'Patients with hepatic impairment', '2004-11-05', NULL, NULL, NULL),
  (310, 'belimumab', NULL, 'Subcutaneous', 'FRA', 'Asthma', 'Patients with prior treatment failure', '2008-10-22', '2020-07-24', NULL, NULL),
  (311, 'belimumab', NULL, 'Subcutaneous', 'FRA', 'Depression', 'Adults with mild disease', '1999-11-06', '2022-07-05', NULL, NULL),
  (312, 'belimumab', NULL, 'Inhalation', 'ESP', 'Asthma', 'Adults with moderate to severe disease; Patients with prior treatment failure', '1990-09-04', NULL, NULL, NULL),
  (313, 'belimumab', NULL, 'Nasal', 'JPN', 'Ulcerative Colitis', 'Adults 65+ years', '1995-07-16', NULL, 'Risk of anaphylaxis', '2023-02-13'),
  (314, 'belimumab', NULL, 'Nasal', 'DEU', 'Fungal Infections; Heart Failure; Osteoporosis', 'Adults with mild disease; Patients with diabetes', '2012-10-16', NULL, 'Risk of tuberculosis reactivation', '2019-10-21'),
  (315, 'belimumab', NULL, 'Intramuscular', 'USA', 'Juvenile Idiopathic Arthritis', 'Patients with renal impairment', '1995-02-14', NULL, NULL, NULL),
  (316, 'belimumab', NULL, 'Intramuscular', 'FRA', 'Depression', 'Pediatric patients 2-17 years', '2017-01-15', NULL, 'Risk of vision changes', '2019-06-15'),
  (317, 'belimumab', NULL, 'Oral', 'AUS', 'Psoriatic Arthritis', 'Patients with comorbidities; Patients with hepatic impairment', '2011-06-21', NULL, NULL, NULL),
  (318, 'belimumab', NULL, 'Rectal', 'USA', 'Systemic Lupus Erythematosus; Osteoporosis; HIV Infection', 'Patients with cardiovascular disease', '2010-11-13', '2023-08-05', 'Increased risk of serious infections', '2021-09-16'),
  (319, 'belimumab', NULL, 'Transdermal', 'FRA', 'Anxiety; HIV Infection', 'Adults with mild disease; Adults 18-65 years', '1995-07-05', NULL, NULL, NULL),
  (320, 'belimumab', NULL, 'Nasal', 'UK', 'Migraine; Diabetes Mellitus Type 2', 'Patients with cardiovascular disease', '2011-03-23', NULL, NULL, NULL),
  (321, 'vedolizumab', NULL, 'Topical', 'ITA', 'Ulcerative Colitis', 'Adults with moderate to severe disease; Patients with renal impairment', '2001-09-28', NULL, 'Risk of anaphylaxis', '2015-12-04'),
  (322, 'vedolizumab', NULL, 'Oral', 'BRA', 'Bacterial Infections', 'Patients with obesity; Patients with cardiovascular disease', '2016-07-17', '2021-03-19', NULL, NULL),
  (323, 'vedolizumab', NULL, 'Nasal', 'DEU', 'Systemic Lupus Erythematosus', 'Immunocompromised patients; Patients with obesity', '2016-09-15', NULL, NULL, NULL),
  (324, 'vedolizumab', NULL, 'Inhalation', 'USA', 'Depression; Asthma; Ulcerative Colitis', 'Adults 18-65 years; Treatment-naive patients', '2023-01-28', NULL, NULL, NULL),
  (325, 'vedolizumab', NULL, 'Nasal', 'USA', 'Bipolar Disorder', 'Immunocompromised patients; Patients with obesity', '1999-05-02', NULL, NULL, NULL),
  (326, 'vedolizumab', NULL, 'Nasal', 'JPN', 'Cancer', 'Adults 18-65 years; Adults with moderate to severe disease', '1990-12-06', NULL, 'Risk of hypersensitivity reactions', '2021-11-13'),
  (327, 'vedolizumab', NULL, 'Subcutaneous', 'BRA', 'Depression; Ankylosing Spondylitis; Systemic Lupus Erythematosus', 'Adults with moderate to severe disease; Patients with hepatic impairment', '1991-07-21', NULL, NULL, NULL),
  (328, 'vedolizumab', NULL, 'Intramuscular', 'FRA', 'Fungal Infections', 'Patients with prior treatment failure', '1999-11-18', NULL, NULL, NULL),
  (329, 'vedolizumab', NULL, 'Subcutaneous', 'AUS', 'Psoriatic Arthritis; Anxiety', 'Pregnant women', '2012-11-02', NULL, NULL, NULL),
  (330, 'vedolizumab', NULL, 'Nasal', 'AUS', 'Viral Infections', 'Patients with diabetes', '2006-01-21', '2023-09-08', NULL, NULL),
  (331, 'vedolizumab', NULL, 'Intramuscular', 'DEU', 'Crohn''s Disease', 'Pregnant women', '2019-10-20', NULL, 'Risk of central nervous system effects', '2024-09-10'),
  (332, 'vedolizumab', NULL, 'Rectal', 'UK', 'Hepatitis C', 'Adults with moderate to severe disease; Treatment-naive patients', '1996-01-12', NULL, NULL, NULL),
  (333, 'vedolizumab', NULL, 'Sublingual', 'BRA', 'Anxiety', 'Pregnant women; Treatment-naive patients', '1993-09-09', NULL, NULL, NULL),
  (334, 'vedolizumab', NULL, 'Oral', 'UK', 'Ankylosing Spondylitis', 'Pediatric patients 2-17 years', '2023-06-15', NULL, NULL, NULL),
  (335, 'vedolizumab', NULL, 'Topical', 'DEU', 'Bacterial Infections; Ankylosing Spondylitis; Juvenile Idiopathic Arthritis', 'Patients with renal impairment', '2012-03-07', NULL, NULL, NULL),
  (336, 'vedolizumab', NULL, 'Oral', 'DEU', 'Chronic Obstructive Pulmonary Disease; Asthma', 'Adults 65+ years; Adults 18-65 years', '1996-08-22', NULL, NULL, NULL),
  (337, 'vedolizumab', NULL, 'Intramuscular', 'ESP', 'Rheumatoid Arthritis; Diabetes Mellitus Type 2', 'Patients with obesity', '2023-08-13', NULL, NULL, NULL),
  (338, 'vedolizumab', NULL, 'Rectal', 'UK', 'Ankylosing Spondylitis; Hepatitis C', 'Adults 65+ years; Adults with moderate to severe disease', '2008-05-18', NULL, NULL, NULL),
  (339, 'vedolizumab', NULL, 'Intramuscular', 'FRA', 'Rheumatoid Arthritis; HIV Infection; Atrial Fibrillation', 'Adults 65+ years; Treatment-naive patients', '1997-01-26', NULL, NULL, NULL),
  (340, 'vedolizumab', NULL, 'Subcutaneous', 'CAN', 'Deep Vein Thrombosis', 'Patients with hepatic impairment; Immunocompromised patients', '2000-09-19', NULL, 'Risk of vision changes', '2021-12-18'),
  (341, 'vedolizumab', NULL, 'Intravenous', 'CAN', 'Cancer', 'Adults with mild disease; Immunocompromised patients', '1994-08-02', NULL, 'Risk of hypersensitivity reactions', '2024-12-17'),
  (342, 'vedolizumab', NULL, 'Nasal', 'BRA', 'Psoriatic Arthritis; Asthma', 'Patients with cardiovascular disease', '2024-01-05', NULL, NULL, NULL),
  (343, 'vedolizumab', NULL, 'Subcutaneous', 'DEU', 'Chronic Obstructive Pulmonary Disease', 'Treatment-naive patients', '2024-12-10', NULL, NULL, NULL),
  (344, 'vedolizumab', NULL, 'Intramuscular', 'DEU', 'Rheumatoid Arthritis; Multiple Sclerosis', 'Patients with renal impairment; Adults with mild disease', '2020-03-15', NULL, 'Risk of central nervous system effects', '2016-03-02'),
  (345, 'vedolizumab', NULL, 'Transdermal', 'DEU', 'Psoriatic Arthritis; Osteoporosis', 'Patients with comorbidities', '1997-12-25', NULL, NULL, NULL),
  (346, 'vedolizumab', NULL, 'Subcutaneous', 'ITA', 'Juvenile Idiopathic Arthritis', 'Patients with comorbidities; Pediatric patients 2-17 years', '2015-07-04', NULL, 'Risk of serious cardiovascular events', '2024-08-25'),
  (347, 'vedolizumab', NULL, 'Topical', 'USA', 'Atrial Fibrillation; Cancer', 'Patients with obesity; Treatment-naive patients', '1990-02-04', NULL, NULL, NULL),
  (348, 'vedolizumab', NULL, 'Intravenous', 'UK', 'Deep Vein Thrombosis; Osteoporosis; Psoriatic Arthritis', 'Adults with mild disease', '2002-06-16', '2021-08-20', NULL, NULL),
  (349, 'vedolizumab', NULL, 'Transdermal', 'ESP', 'Anxiety; Pulmonary Embolism', 'Adults 18-65 years', '2022-10-26', NULL, NULL, NULL),
  (350, 'vedolizumab', NULL, 'Oral', 'ITA', 'Pulmonary Embolism; Ankylosing Spondylitis', 'Pediatric patients 2-17 years', '2008-08-04', NULL, NULL, NULL),
  (351, 'natalizumab', NULL, 'Subcutaneous', 'FRA', 'Multiple Sclerosis; Anxiety', 'Patients with cardiovascular disease', '2012-02-05', NULL, NULL, NULL),
  (352, 'natalizumab', NULL, 'Inhalation', 'USA', 'Diabetes Mellitus Type 2; Hypertension', 'Pregnant women', '2023-08-07', NULL, NULL, NULL),
  (353, 'natalizumab', NULL, 'Topical', 'ESP', 'Hypertension; Schizophrenia; Psoriatic Arthritis', 'Patients with obesity; Patients with comorbidities', '1995-11-03', NULL, NULL, NULL),
  (354, 'natalizumab', NULL, 'Transdermal', 'USA', 'Hypertension; Deep Vein Thrombosis', 'Treatment-naive patients', '2011-12-14', NULL, NULL, NULL),
  (355, 'natalizumab', NULL, 'Rectal', 'ESP', 'Multiple Sclerosis', 'Patients with prior treatment failure; Patients with obesity', '2014-03-13', NULL, NULL, NULL),
  (356, 'natalizumab', NULL, 'Rectal', 'ITA', 'HIV Infection; Plaque Psoriasis; Anxiety', 'Patients with obesity; Adults with moderate to severe disease', '2016-11-28', NULL, NULL, NULL),
  (357, 'natalizumab', NULL, 'Intramuscular', 'CAN', 'Multiple Sclerosis; Migraine', 'Patients with obesity', '1994-11-12', NULL, NULL, NULL),
  (358, 'natalizumab', NULL, 'Intravenous', 'UK', 'Multiple Sclerosis; Atrial Fibrillation', 'Patients with cardiovascular disease; Patients with diabetes', '2007-12-08', NULL, NULL, NULL),
  (359, 'natalizumab', NULL, 'Nasal', 'ESP', 'Rheumatoid Arthritis; Hypertension; Anxiety', 'Adults 65+ years; Pediatric patients 2-17 years', '2022-09-07', NULL, NULL, NULL),
  (360, 'natalizumab', NULL, 'Nasal', 'ITA', 'Viral Infections', 'Patients with comorbidities; Patients with prior treatment failure', '1995-05-16', NULL, 'Risk of vision changes', '2024-07-08'),
  (361, 'natalizumab', NULL, 'Inhalation', 'BRA', 'Pulmonary Embolism', 'Pediatric patients 2-17 years', '2014-09-25', NULL, 'Risk of serious cardiovascular events', '2022-08-23'),
  (362, 'natalizumab', NULL, 'Intramuscular', 'CAN', 'Heart Failure; Rheumatoid Arthritis; Asthma', 'Patients with renal impairment', '2006-01-11', NULL, NULL, NULL),
  (363, 'natalizumab', NULL, 'Sublingual', 'BRA', 'Viral Infections', 'Pediatric patients 2-17 years; Patients with obesity', '2024-03-26', NULL, NULL, NULL),
  (364, 'natalizumab', NULL, 'Rectal', 'DEU', 'HIV Infection; Multiple Sclerosis', 'Adults with moderate to severe disease; Adults with mild disease', '2006-07-01', NULL, NULL, NULL),
  (365, 'natalizumab', NULL, 'Intravenous', 'USA', 'Juvenile Idiopathic Arthritis; Migraine; Bacterial Infections', 'Adults with moderate to severe disease; Patients with hepatic impairment', '2013-07-06', NULL, NULL, NULL),
  (366, 'ustekinumab', NULL, 'Intramuscular', 'BRA', 'Viral Infections', 'Pediatric patients 6 months-2 years', '1998-03-10', NULL, 'Risk of gastrointestinal perforation', '2019-08-14'),
  (367, 'ustekinumab', NULL, 'Transdermal', 'JPN', 'Schizophrenia; HIV Infection; Pulmonary Embolism', 'Patients with renal impairment; Patients with obesity', '1990-05-19', NULL, 'Risk of liver injury', '2018-02-10'),
  (368, 'ustekinumab', NULL, 'Topical', 'AUS', 'Migraine', 'Adults with mild disease', '1997-05-09', NULL, NULL, NULL),
  (369, 'ustekinumab', NULL, 'Topical', 'UK', 'Viral Infections; Crohn''s Disease', 'Adults 65+ years; Patients with hepatic impairment', '1999-05-17', NULL, NULL, NULL),
  (370, 'ustekinumab', NULL, 'Rectal', 'JPN', 'Plaque Psoriasis', 'Patients with cardiovascular disease', '1999-02-17', NULL, NULL, NULL),
  (371, 'ustekinumab', NULL, 'Transdermal', 'ESP', 'Juvenile Idiopathic Arthritis', 'Pediatric patients 6 months-2 years', '2018-12-19', NULL, NULL, NULL),
  (372, 'ustekinumab', NULL, 'Subcutaneous', 'ITA', 'Asthma; Crohn''s Disease; Diabetes Mellitus Type 2', 'Patients with hepatic impairment', '1994-04-05', NULL, NULL, NULL),
  (373, 'ustekinumab', NULL, 'Intramuscular', 'BRA', 'Pulmonary Embolism; HIV Infection; Migraine', 'Patients with renal impairment', '2023-07-16', NULL, NULL, NULL),
  (374, 'ustekinumab', NULL, 'Inhalation', 'USA', 'Anxiety; Migraine; Hypertension', 'Adults 18-65 years', '2022-07-23', '2023-06-15', NULL, NULL),
  (375, 'canakinumab', NULL, 'Nasal', 'USA', 'Hypertension; Schizophrenia; Cancer', 'Patients with obesity', '2018-04-06', NULL, 'Risk of central nervous system effects', '2022-11-09'),
  (376, 'canakinumab', NULL, 'Topical', 'FRA', 'Asthma; Juvenile Idiopathic Arthritis; Crohn''s Disease', 'Adults 65+ years', '1994-05-18', NULL, NULL, NULL),
  (377, 'canakinumab', NULL, 'Intramuscular', 'CAN', 'Hypertension; Psoriatic Arthritis; Juvenile Idiopathic Arthritis', 'Patients with renal impairment', '1993-05-19', NULL, NULL, NULL),
  (378, 'canakinumab', NULL, 'Topical', 'ITA', 'Psoriatic Arthritis; Ankylosing Spondylitis', 'Patients with prior treatment failure', '2024-07-15', NULL, 'Risk of hypersensitivity reactions', '2015-03-14'),
  (379, 'canakinumab', NULL, 'Topical', 'ESP', 'Schizophrenia', 'Adults 65+ years; Adults 18-65 years', '2021-05-20', NULL, NULL, NULL),
  (380, 'canakinumab', NULL, 'Nasal', 'ESP', 'Crohn''s Disease; Hypertension; Viral Infections', 'Pediatric patients 2-17 years; Adults with moderate to severe disease', '1994-05-16', NULL, 'Risk of hearing loss', '2022-08-10'),
  (381, 'canakinumab', NULL, 'Intramuscular', 'FRA', 'Viral Infections; Juvenile Idiopathic Arthritis', 'Patients with cardiovascular disease', '1994-03-19', NULL, NULL, NULL),
  (382, 'canakinumab', NULL, 'Topical', 'ITA', 'Cancer', 'Patients with hepatic impairment; Treatment-naive patients', '2015-01-12', NULL, NULL, NULL),
  (383, 'canakinumab', NULL, 'Transdermal', 'JPN', 'Systemic Lupus Erythematosus', 'Patients with renal impairment', '2020-04-12', '2021-09-19', NULL, NULL),
  (384, 'canakinumab', NULL, 'Oral', 'JPN', 'Hepatitis C; Heart Failure; Crohn''s Disease', 'Adults with moderate to severe disease', '1993-01-28', NULL, NULL, NULL),
  (385, 'canakinumab', NULL, 'Intravenous', 'ITA', 'Systemic Lupus Erythematosus; Multiple Sclerosis; Hepatitis C', 'Patients with comorbidities', '1991-03-25', NULL, 'Risk of blood disorders', '2021-05-08'),
  (386, 'canakinumab', NULL, 'Intravenous', 'BRA', 'Fungal Infections; Diabetes Mellitus Type 2; Osteoporosis', 'Patients with prior treatment failure; Immunocompromised patients', '2008-08-07', NULL, 'Increased risk of malignancy', '2021-05-04'),
  (387, 'canakinumab', NULL, 'Intramuscular', 'JPN', 'Hepatitis C; Schizophrenia; Chronic Obstructive Pulmonary Disease', 'Adults with moderate to severe disease; Pediatric patients 6 months-2 years', '2023-09-15', NULL, NULL, NULL),
  (388, 'canakinumab', NULL, 'Intravenous', 'ITA', 'Bacterial Infections; Depression; Cancer', 'Treatment-naive patients; Pregnant women', '2011-10-20', NULL, NULL, NULL),
  (389, 'canakinumab', NULL, 'Subcutaneous', 'AUS', 'HIV Infection; Atrial Fibrillation; Pulmonary Embolism', 'Pediatric patients 2-17 years; Adults with moderate to severe disease', '2008-10-12', NULL, NULL, NULL),
  (390, 'canakinumab', NULL, 'Oral', 'JPN', 'Multiple Sclerosis', 'Adults 18-65 years', '2010-06-14', NULL, 'Risk of central nervous system effects', '2020-07-10'),
  (391, 'canakinumab', NULL, 'Sublingual', 'JPN', 'Psoriatic Arthritis', 'Treatment-naive patients; Pregnant women', '2020-07-01', '2024-04-04', NULL, NULL),
  (392, 'canakinumab', NULL, 'Intravenous', 'DEU', 'Hepatitis C', 'Patients with hepatic impairment', '2019-01-26', NULL, NULL, NULL),
  (393, 'canakinumab', NULL, 'Nasal', 'ESP', 'Systemic Lupus Erythematosus', 'Patients with prior treatment failure', '2018-10-17', NULL, NULL, NULL),
  (394, 'canakinumab', NULL, 'Intramuscular', 'BRA', 'Rheumatoid Arthritis', 'Patients with obesity; Pediatric patients 2-17 years', '2009-05-15', NULL, NULL, NULL),
  (395, 'canakinumab', NULL, 'Transdermal', 'CAN', 'Psoriatic Arthritis; Rheumatoid Arthritis', 'Pregnant women', '1994-08-05', NULL, 'Increased risk of malignancy', '2015-01-24'),
  (396, 'canakinumab', NULL, 'Inhalation', 'DEU', 'Osteoporosis; Fungal Infections', 'Adults 65+ years', '1995-08-17', NULL, NULL, NULL),
  (397, 'canakinumab', NULL, 'Nasal', 'FRA', 'Bacterial Infections', 'Patients with diabetes', '1994-03-19', NULL, NULL, NULL),
  (398, 'canakinumab', NULL, 'Subcutaneous', 'ESP', 'Anxiety', 'Adults with mild disease', '2016-11-26', NULL, NULL, NULL),
  (399, 'canakinumab', NULL, 'Intravenous', 'JPN', 'Systemic Lupus Erythematosus; Chronic Obstructive Pulmonary Disease; Psoriatic Arthritis', 'Pediatric patients 2-17 years', '2013-01-08', NULL, 'Increased risk of serious infections', '2019-11-22'),
  (400, 'canakinumab', NULL, 'Intravenous', 'USA', 'Multiple Sclerosis', 'Immunocompromised patients; Pregnant women', '2021-08-24', NULL, 'Risk of bone loss', '2018-08-02'),
  (401, 'canakinumab', NULL, 'Topical', 'JPN', 'Asthma; Depression; Atrial Fibrillation', 'Adults 65+ years', '2006-05-08', NULL, NULL, NULL),
  (402, 'canakinumab', NULL, 'Rectal', 'ESP', 'Osteoporosis; Migraine', 'Pediatric patients 2-17 years; Patients with renal impairment', '1998-06-16', NULL, NULL, NULL),
  (403, 'canakinumab', NULL, 'Intravenous', 'CAN', 'Asthma; Multiple Sclerosis', 'Adults 18-65 years', '1997-11-14', NULL, NULL, NULL),
  (404, 'apremilast', NULL, 'Transdermal', 'DEU', 'Psoriatic Arthritis; Fungal Infections; HIV Infection', 'Pediatric patients 2-17 years', '2020-02-22', NULL, 'Risk of liver injury', '2016-06-28'),
  (405, 'apremilast', NULL, 'Subcutaneous', 'JPN', 'Systemic Lupus Erythematosus; Psoriatic Arthritis; Ankylosing Spondylitis', 'Patients with hepatic impairment', '2019-12-17', NULL, NULL, NULL),
  (406, 'apremilast', NULL, 'Inhalation', 'AUS', 'Rheumatoid Arthritis', 'Pediatric patients 6 months-2 years; Patients with obesity', '1999-03-20', NULL, NULL, NULL),
  (407, 'apremilast', NULL, 'Rectal', 'ITA', 'Juvenile Idiopathic Arthritis; Bacterial Infections', 'Patients with comorbidities', '2023-02-06', NULL, NULL, NULL),
  (408, 'apremilast', NULL, 'Oral', 'ESP', 'Diabetes Mellitus Type 2', 'Patients with obesity; Pediatric patients 6 months-2 years', '2018-07-02', NULL, NULL, NULL),
  (409, 'apremilast', NULL, 'Nasal', 'USA', 'Ankylosing Spondylitis; Psoriatic Arthritis', 'Patients with diabetes; Adults with moderate to severe disease', '1991-02-18', NULL, NULL, NULL),
  (410, 'apremilast', NULL, 'Inhalation', 'ITA', 'Juvenile Idiopathic Arthritis; Viral Infections; Systemic Lupus Erythematosus', 'Patients with comorbidities', '1991-08-04', '2024-11-08', NULL, NULL),
  (411, 'apremilast', NULL, 'Inhalation', 'ITA', 'Depression; Psoriatic Arthritis; Ankylosing Spondylitis', 'Patients with renal impairment', '2000-11-18', NULL, NULL, NULL),
  (412, 'apremilast', NULL, 'Sublingual', 'ESP', 'Systemic Lupus Erythematosus; Hepatitis C; Psoriatic Arthritis', 'Treatment-naive patients', '2013-01-20', NULL, 'Risk of anaphylaxis', '2016-11-27'),
  (413, 'apremilast', NULL, 'Transdermal', 'ESP', 'Systemic Lupus Erythematosus; Pulmonary Embolism', 'Patients with hepatic impairment', '2020-12-19', '2023-10-07', NULL, NULL),
  (414, 'hydroxychloroquine', NULL, 'Intramuscular', 'ESP', 'Anxiety; Rheumatoid Arthritis', 'Treatment-naive patients', '2011-08-02', NULL, NULL, NULL),
  (415, 'hydroxychloroquine', NULL, 'Nasal', 'UK', 'Asthma; Viral Infections; Deep Vein Thrombosis', 'Adults 18-65 years', '2002-04-14', NULL, NULL, NULL),
  (416, 'hydroxychloroquine', NULL, 'Intramuscular', 'JPN', 'Pulmonary Embolism; Ankylosing Spondylitis; Psoriatic Arthritis', 'Immunocompromised patients; Adults 18-65 years', '2007-05-05', NULL, NULL, NULL),
  (417, 'hydroxychloroquine', NULL, 'Nasal', 'DEU', 'Bacterial Infections; Plaque Psoriasis; Multiple Sclerosis', 'Pediatric patients 6 months-2 years', '2016-11-18', NULL, NULL, NULL),
  (418, 'hydroxychloroquine', NULL, 'Subcutaneous', 'DEU', 'Pulmonary Embolism; Systemic Lupus Erythematosus; Deep Vein Thrombosis', 'Treatment-naive patients', '2010-05-16', NULL, NULL, NULL),
  (419, 'hydroxychloroquine', NULL, 'Transdermal', 'USA', 'Rheumatoid Arthritis; Viral Infections', 'Adults 65+ years; Adults with mild disease', '2016-07-20', NULL, 'Risk of vision changes', '2018-11-10'),
  (420, 'hydroxychloroquine', NULL, 'Sublingual', 'AUS', 'Crohn''s Disease; Juvenile Idiopathic Arthritis', 'Adults 18-65 years', '2024-03-19', NULL, NULL, NULL),
  (421, 'hydroxychloroquine', NULL, 'Subcutaneous', 'ESP', 'Bacterial Infections', 'Patients with renal impairment; Patients with comorbidities', '2021-11-28', NULL, NULL, NULL),
  (422, 'hydroxychloroquine', NULL, 'Subcutaneous', 'ESP', 'Ulcerative Colitis', 'Immunocompromised patients', '2000-04-02', NULL, NULL, NULL),
  (423, 'hydroxychloroquine', NULL, 'Subcutaneous', 'CAN', 'Systemic Lupus Erythematosus', 'Patients with hepatic impairment; Patients with cardiovascular disease', '2009-07-26', NULL, 'Risk of renal impairment', '2023-05-08'),
  (424, 'hydroxychloroquine', NULL, 'Topical', 'AUS', 'Migraine; Systemic Lupus Erythematosus; HIV Infection', 'Patients with obesity', '1994-07-24', NULL, NULL, NULL),
  (425, 'hydroxychloroquine', NULL, 'Nasal', 'BRA', 'Bacterial Infections; Asthma; Chronic Obstructive Pulmonary Disease', 'Pregnant women', '2010-02-27', NULL, NULL, NULL),
  (426, 'hydroxychloroquine', NULL, 'Inhalation', 'USA', 'Ankylosing Spondylitis', 'Adults with mild disease', '1998-05-23', NULL, NULL, NULL),
  (427, 'hydroxychloroquine', NULL, 'Nasal', 'JPN', 'Fungal Infections; Multiple Sclerosis; Crohn''s Disease', 'Patients with obesity; Patients with hepatic impairment', '2022-05-19', NULL, 'Risk of anaphylaxis', '2015-10-08'),
  (428, 'hydroxychloroquine', NULL, 'Inhalation', 'USA', 'Plaque Psoriasis; Anxiety', 'Patients with cardiovascular disease', '2016-12-08', NULL, NULL, NULL),
  (429, 'hydroxychloroquine', NULL, 'Transdermal', 'ITA', 'Hypertension', 'Patients with comorbidities; Adults with mild disease', '1997-01-26', NULL, 'Risk of blood disorders', '2020-12-17'),
  (430, 'hydroxychloroquine', NULL, 'Subcutaneous', 'AUS', 'Systemic Lupus Erythematosus; Rheumatoid Arthritis; Atrial Fibrillation', 'Patients with comorbidities', '1994-12-07', NULL, NULL, NULL),
  (431, 'hydroxychloroquine', NULL, 'Sublingual', 'CAN', 'Atrial Fibrillation; Bipolar Disorder; Heart Failure', 'Adults with moderate to severe disease', '2014-05-08', NULL, NULL, NULL),
  (432, 'hydroxychloroquine', NULL, 'Intramuscular', 'BRA', 'Psoriatic Arthritis; Depression; Schizophrenia', 'Pregnant women; Patients with obesity', '2023-11-18', NULL, NULL, NULL),
  (433, 'hydroxychloroquine', NULL, 'Intravenous', 'JPN', 'Crohn''s Disease', 'Patients with hepatic impairment; Patients with renal impairment', '1992-02-25', NULL, NULL, NULL),
  (434, 'hydroxychloroquine', NULL, 'Topical', 'FRA', 'Depression; Asthma; Deep Vein Thrombosis', 'Adults 65+ years', '1997-09-15', NULL, NULL, NULL),
  (435, 'hydroxychloroquine', NULL, 'Inhalation', 'UK', 'Heart Failure', 'Patients with comorbidities', '2011-06-20', NULL, NULL, NULL),
  (436, 'hydroxychloroquine', NULL, 'Sublingual', 'UK', 'Schizophrenia', 'Patients with diabetes', '2015-05-25', NULL, NULL, NULL),
  (437, 'hydroxychloroquine', NULL, 'Intramuscular', 'DEU', 'Atrial Fibrillation; Juvenile Idiopathic Arthritis; Hepatitis C', 'Patients with diabetes; Pediatric patients 6 months-2 years', '2014-05-25', NULL, NULL, NULL),
  (438, 'hydroxychloroquine', NULL, 'Sublingual', 'UK', 'Depression', 'Patients with hepatic impairment; Patients with comorbidities', '1990-12-20', NULL, 'Increased risk of serious infections', '2017-05-15'),
  (439, 'hydroxychloroquine', NULL, 'Transdermal', 'FRA', 'Asthma; Viral Infections', 'Adults with moderate to severe disease', '1993-09-16', NULL, 'Risk of bone loss', '2024-11-21'),
  (440, 'hydroxychloroquine', NULL, 'Sublingual', 'FRA', 'Chronic Obstructive Pulmonary Disease; Schizophrenia; Multiple Sclerosis', 'Adults 18-65 years', '2002-03-14', '2020-09-03', NULL, NULL),
  (441, 'hydroxychloroquine', NULL, 'Rectal', 'JPN', 'Osteoporosis; Multiple Sclerosis', 'Immunocompromised patients; Patients with cardiovascular disease', '1995-03-12', NULL, NULL, NULL),
  (442, 'hydroxychloroquine', NULL, 'Nasal', 'ESP', 'Psoriatic Arthritis; Plaque Psoriasis; Crohn''s Disease', 'Pediatric patients 2-17 years', '2017-03-13', NULL, NULL, NULL),
  (443, 'hydroxychloroquine', NULL, 'Transdermal', 'JPN', 'HIV Infection; Migraine', 'Patients with cardiovascular disease', '2016-08-28', NULL, NULL, NULL),
  (444, 'sulfasalazine', NULL, 'Intramuscular', 'ITA', 'Heart Failure; Viral Infections; HIV Infection', 'Patients with hepatic impairment; Adults with moderate to severe disease', '2010-01-13', NULL, NULL, NULL),
  (445, 'sulfasalazine', NULL, 'Subcutaneous', 'DEU', 'Pulmonary Embolism; Psoriatic Arthritis; Heart Failure', 'Patients with cardiovascular disease', '2011-08-15', NULL, NULL, NULL),
  (446, 'sulfasalazine', NULL, 'Subcutaneous', 'UK', 'Hypertension; Osteoporosis', 'Patients with diabetes', '1999-11-06', NULL, NULL, NULL),
  (447, 'sulfasalazine', NULL, 'Sublingual', 'AUS', 'Migraine; Deep Vein Thrombosis', 'Pediatric patients 2-17 years; Patients with hepatic impairment', '1991-01-16', NULL, NULL, NULL),
  (448, 'sulfasalazine', NULL, 'Intravenous', 'JPN', 'Asthma', 'Patients with prior treatment failure', '2020-12-27', NULL, NULL, NULL),
  (449, 'sulfasalazine', NULL, 'Intravenous', 'JPN', 'Plaque Psoriasis; Bipolar Disorder; Pulmonary Embolism', 'Pregnant women; Patients with cardiovascular disease', '2021-08-11', NULL, NULL, NULL),
  (450, 'sulfasalazine', NULL, 'Inhalation', 'AUS', 'Hypertension; Viral Infections', 'Adults with mild disease', '2011-11-10', NULL, NULL, NULL),
  (451, 'sulfasalazine', NULL, 'Intramuscular', 'FRA', 'Migraine', 'Patients with obesity', '1994-01-18', NULL, NULL, NULL),
  (452, 'sulfasalazine', NULL, 'Inhalation', 'BRA', 'Depression; Fungal Infections; Atrial Fibrillation', 'Patients with comorbidities', '1995-07-27', '2022-09-11', 'Risk of peripheral neuropathy', '2022-04-23'),
  (453, 'sulfasalazine', NULL, 'Rectal', 'UK', 'Multiple Sclerosis', 'Patients with renal impairment; Pediatric patients 2-17 years', '1990-02-07', NULL, NULL, NULL),
  (454, 'sulfasalazine', NULL, 'Intramuscular', 'AUS', 'Schizophrenia; Diabetes Mellitus Type 2', 'Patients with prior treatment failure', '2018-09-22', '2021-10-12', 'Risk of gastrointestinal perforation', '2024-02-01'),
  (455, 'sulfasalazine', NULL, 'Nasal', 'JPN', 'Deep Vein Thrombosis; Bipolar Disorder', 'Pregnant women', '1994-01-25', NULL, NULL, NULL),
  (456, 'sulfasalazine', NULL, 'Topical', 'DEU', 'Ankylosing Spondylitis; Schizophrenia', 'Pregnant women; Treatment-naive patients', '1995-05-08', NULL, NULL, NULL),
  (457, 'sulfasalazine', NULL, 'Nasal', 'USA', 'Multiple Sclerosis; Osteoporosis; Crohn''s Disease', 'Pediatric patients 2-17 years', '2019-09-10', NULL, 'Increased risk of malignancy', '2015-09-07'),
  (458, 'sulfasalazine', NULL, 'Rectal', 'BRA', 'Ulcerative Colitis', 'Patients with prior treatment failure; Pregnant women', '2003-11-28', NULL, 'Risk of liver injury', '2018-04-23'),
  (459, 'sulfasalazine', NULL, 'Rectal', 'UK', 'Psoriatic Arthritis; Viral Infections', 'Immunocompromised patients', '2020-04-17', '2023-01-07', 'Risk of liver injury', '2019-08-18'),
  (460, 'sulfasalazine', NULL, 'Nasal', 'AUS', 'Diabetes Mellitus Type 2', 'Pediatric patients 2-17 years; Patients with cardiovascular disease', '2006-08-08', NULL, 'Risk of serious cardiovascular events', '2022-06-13'),
  (461, 'sulfasalazine', NULL, 'Topical', 'CAN', 'Hypertension; Osteoporosis', 'Patients with comorbidities; Patients with prior treatment failure', '2014-11-14', NULL, NULL, NULL),
  (462, 'azithromycin', NULL, 'Intravenous', 'FRA', 'Bipolar Disorder', 'Patients with prior treatment failure', '2018-05-07', NULL, NULL, NULL),
  (463, 'azithromycin', NULL, 'Nasal', 'BRA', 'Hypertension; Rheumatoid Arthritis; Depression', 'Patients with obesity', '2020-12-28', NULL, NULL, NULL),
  (464, 'azithromycin', NULL, 'Transdermal', 'UK', 'Chronic Obstructive Pulmonary Disease; Viral Infections', 'Patients with prior treatment failure', '2004-08-25', NULL, NULL, NULL),
  (465, 'azithromycin', NULL, 'Intravenous', 'FRA', 'Viral Infections; Plaque Psoriasis', 'Adults 65+ years; Patients with renal impairment', '2024-03-28', NULL, NULL, NULL),
  (466, 'azithromycin', NULL, 'Transdermal', 'CAN', 'Anxiety; Multiple Sclerosis; Migraine', 'Treatment-naive patients', '2003-04-18', NULL, NULL, NULL),
  (467, 'azithromycin', NULL, 'Rectal', 'DEU', 'Depression; Cancer', 'Adults with moderate to severe disease', '1995-09-10', NULL, NULL, NULL),
  (468, 'azithromycin', NULL, 'Intravenous', 'AUS', 'Atrial Fibrillation; Bipolar Disorder', 'Patients with prior treatment failure; Pediatric patients 2-17 years', '2011-09-26', NULL, NULL, NULL),
  (469, 'azithromycin', NULL, 'Sublingual', 'USA', 'Multiple Sclerosis; Cancer', 'Adults with mild disease', '2003-08-22', NULL, NULL, NULL),
  (470, 'azithromycin', NULL, 'Sublingual', 'ITA', 'Depression', 'Adults 65+ years', '1998-02-08', NULL, NULL, NULL),
  (471, 'azithromycin', NULL, 'Rectal', 'CAN', 'Anxiety; Crohn''s Disease', 'Patients with diabetes', '1991-08-18', NULL, NULL, NULL),
  (472, 'azithromycin', NULL, 'Rectal', 'FRA', 'Atrial Fibrillation', 'Treatment-naive patients', '2012-11-10', '2020-01-21', NULL, NULL),
  (473, 'azithromycin', NULL, 'Inhalation', 'AUS', 'Viral Infections; Deep Vein Thrombosis', 'Adults 18-65 years', '1998-04-05', NULL, NULL, NULL),
  (474, 'azithromycin', NULL, 'Nasal', 'DEU', 'Diabetes Mellitus Type 2', 'Pediatric patients 2-17 years', '2005-08-15', NULL, 'Increased risk of serious infections', '2019-10-19'),
  (475, 'azithromycin', NULL, 'Intramuscular', 'JPN', 'Hepatitis C; Ankylosing Spondylitis', 'Adults with mild disease', '2019-12-07', NULL, 'Increased risk of malignancy', '2020-09-14'),
  (476, 'azithromycin', NULL, 'Intramuscular', 'USA', 'Chronic Obstructive Pulmonary Disease; Deep Vein Thrombosis', 'Adults with moderate to severe disease', '2017-01-27', NULL, NULL, NULL),
  (477, 'azithromycin', NULL, 'Sublingual', 'CAN', 'Rheumatoid Arthritis', 'Treatment-naive patients', '2018-08-13', NULL, 'Risk of renal impairment', '2023-01-12'),
  (478, 'azithromycin', NULL, 'Topical', 'JPN', 'Rheumatoid Arthritis; Chronic Obstructive Pulmonary Disease', 'Patients with obesity; Pregnant women', '1995-01-06', NULL, NULL, NULL),
  (479, 'azithromycin', NULL, 'Intravenous', 'USA', 'Depression; Plaque Psoriasis', 'Adults with moderate to severe disease', '1997-07-06', NULL, NULL, NULL),
  (480, 'azithromycin', NULL, 'Transdermal', 'ITA', 'Psoriatic Arthritis; Schizophrenia', 'Adults 18-65 years', '1993-12-13', NULL, NULL, NULL),
  (481, 'azithromycin', NULL, 'Inhalation', 'JPN', 'Multiple Sclerosis; Pulmonary Embolism; Depression', 'Adults with moderate to severe disease', '2001-08-18', NULL, 'Risk of serious cardiovascular events', '2023-02-28'),
  (482, 'azithromycin', NULL, 'Intramuscular', 'BRA', 'Psoriatic Arthritis; Asthma', 'Adults 65+ years', '2019-05-04', NULL, NULL, NULL),
  (483, 'azithromycin', NULL, 'Oral', 'ESP', 'Depression; Hypertension; Osteoporosis', 'Pregnant women', '2022-07-15', NULL, NULL, NULL),
  (484, 'azithromycin', NULL, 'Intravenous', 'JPN', 'Asthma; Systemic Lupus Erythematosus', 'Adults with moderate to severe disease; Patients with renal impairment', '2019-03-24', NULL, NULL, NULL),
  (485, 'azithromycin', NULL, 'Inhalation', 'ITA', 'Anxiety', 'Treatment-naive patients; Pediatric patients 2-17 years', '2002-06-09', NULL, 'Risk of renal impairment', '2021-09-03'),
  (486, 'azithromycin', NULL, 'Rectal', 'FRA', 'Fungal Infections', 'Adults with mild disease; Patients with obesity', '1993-12-07', NULL, NULL, NULL),
  (487, 'amoxicillin', NULL, 'Rectal', 'DEU', 'Osteoporosis', 'Treatment-naive patients', '1993-10-03', NULL, NULL, NULL),
  (488, 'amoxicillin', NULL, 'Intramuscular', 'USA', 'Multiple Sclerosis; Pulmonary Embolism', 'Adults with mild disease; Pregnant women', '2009-07-23', NULL, NULL, NULL),
  (489, 'amoxicillin', NULL, 'Transdermal', 'DEU', 'Psoriatic Arthritis; Hypertension', 'Treatment-naive patients', '2007-12-01', NULL, 'Risk of vision changes', '2018-11-26'),
  (490, 'amoxicillin', NULL, 'Intramuscular', 'FRA', 'Anxiety; Chronic Obstructive Pulmonary Disease; Heart Failure', 'Patients with prior treatment failure', '1999-09-01', NULL, 'Risk of vision changes', '2018-05-28'),
  (491, 'amoxicillin', NULL, 'Rectal', 'CAN', 'Ankylosing Spondylitis; Pulmonary Embolism; Multiple Sclerosis', 'Immunocompromised patients', '2012-04-12', NULL, 'Increased risk of malignancy', '2020-09-15'),
  (492, 'amoxicillin', NULL, 'Oral', 'BRA', 'Deep Vein Thrombosis; Fungal Infections; Psoriatic Arthritis', 'Pregnant women', '2004-08-12', NULL, NULL, NULL),
  (493, 'amoxicillin', NULL, 'Rectal', 'BRA', 'Depression', 'Immunocompromised patients; Pediatric patients 6 months-2 years', '2016-02-19', NULL, NULL, NULL),
  (494, 'amoxicillin', NULL, 'Transdermal', 'ITA', 'Bacterial Infections; Migraine', 'Adults with moderate to severe disease; Patients with cardiovascular disease', '2019-08-03', NULL, NULL, NULL),
  (495, 'amoxicillin', NULL, 'Oral', 'FRA', 'Asthma', 'Patients with cardiovascular disease', '2010-05-11', NULL, NULL, NULL),
  (496, 'amoxicillin', NULL, 'Subcutaneous', 'UK', 'Viral Infections', 'Immunocompromised patients; Patients with cardiovascular disease', '2012-06-12', NULL, NULL, NULL),
  (497, 'amoxicillin', NULL, 'Nasal', 'JPN', 'Systemic Lupus Erythematosus; Hepatitis C; Depression', 'Adults with moderate to severe disease', '2010-01-24', NULL, 'Risk of central nervous system effects', '2015-01-18'),
  (498, 'amoxicillin', NULL, 'Oral', 'USA', 'HIV Infection; Hepatitis C', 'Adults with moderate to severe disease', '2012-01-24', NULL, 'Risk of peripheral neuropathy', '2022-03-01'),
  (499, 'amoxicillin', NULL, 'Nasal', 'BRA', 'Plaque Psoriasis; Ankylosing Spondylitis', 'Patients with prior treatment failure; Patients with obesity', '1994-02-06', '2023-05-26', 'Risk of peripheral neuropathy', '2023-09-21'),
  (500, 'amoxicillin', NULL, 'Intravenous', 'FRA', 'Atrial Fibrillation; Diabetes Mellitus Type 2', 'Patients with prior treatment failure; Immunocompromised patients', '1993-02-09', NULL, NULL, NULL),
  (501, 'amoxicillin', NULL, 'Topical', 'AUS', 'Fungal Infections', 'Pediatric patients 2-17 years', '1995-12-16', NULL, 'Risk of hypersensitivity reactions', '2017-07-14'),
  (502, 'amoxicillin', NULL, 'Intravenous', 'ITA', 'Heart Failure; Hypertension; Fungal Infections', 'Patients with prior treatment failure; Patients with comorbidities', '2002-08-06', NULL, NULL, NULL),
  (503, 'amoxicillin', NULL, 'Nasal', 'ITA', 'Pulmonary Embolism', 'Patients with comorbidities', '1995-04-27', NULL, NULL, NULL),
  (504, 'amoxicillin', NULL, 'Intramuscular', 'USA', 'Pulmonary Embolism; Anxiety', 'Patients with diabetes; Patients with hepatic impairment', '2009-10-16', NULL, NULL, NULL),
  (505, 'amoxicillin', NULL, 'Intravenous', 'UK', 'Viral Infections', 'Patients with obesity; Adults with moderate to severe disease', '2013-08-14', NULL, NULL, NULL),
  (506, 'amoxicillin', NULL, 'Rectal', 'FRA', 'Hepatitis C', 'Patients with cardiovascular disease', '2016-09-11', NULL, 'Risk of peripheral neuropathy', '2019-07-16'),
  (507, 'amoxicillin', NULL, 'Nasal', 'FRA', 'Chronic Obstructive Pulmonary Disease; Systemic Lupus Erythematosus', 'Patients with prior treatment failure', '1991-04-17', NULL, NULL, NULL),
  (508, 'amoxicillin', NULL, 'Inhalation', 'BRA', 'Anxiety', 'Pediatric patients 2-17 years', '2014-12-09', NULL, NULL, NULL),
  (509, 'amoxicillin', NULL, 'Intravenous', 'UK', 'Bacterial Infections; Ulcerative Colitis', 'Patients with renal impairment', '2006-11-23', NULL, 'Risk of blood disorders', '2019-01-04'),
  (510, 'amoxicillin', NULL, 'Sublingual', 'USA', 'Viral Infections; Depression', 'Pediatric patients 6 months-2 years', '2003-10-25', NULL, 'Risk of vision changes', '2022-02-24'),
  (511, 'ciprofloxacin', NULL, 'Inhalation', 'JPN', 'Diabetes Mellitus Type 2; Plaque Psoriasis; Bacterial Infections', 'Patients with comorbidities', '2015-10-14', NULL, NULL, NULL),
  (512, 'ciprofloxacin', NULL, 'Nasal', 'AUS', 'Hepatitis C; Osteoporosis', 'Patients with comorbidities', '2010-03-10', '2021-09-17', NULL, NULL),
  (513, 'ciprofloxacin', NULL, 'Inhalation', 'ITA', 'Osteoporosis; Juvenile Idiopathic Arthritis; Schizophrenia', 'Patients with cardiovascular disease; Immunocompromised patients', '2000-09-28', NULL, NULL, NULL),
  (514, 'ciprofloxacin', NULL, 'Transdermal', 'USA', 'Heart Failure; Cancer', 'Adults 18-65 years; Patients with prior treatment failure', '2009-02-27', NULL, 'Risk of progressive multifocal leukoencephalopathy', '2023-05-15'),
  (515, 'ciprofloxacin', NULL, 'Intramuscular', 'UK', 'Bipolar Disorder; Bacterial Infections', 'Adults 65+ years; Adults with moderate to severe disease', '2000-02-21', NULL, 'Risk of blood disorders', '2022-05-04'),
  (516, 'ciprofloxacin', NULL, 'Nasal', 'USA', 'Fungal Infections; Asthma; Multiple Sclerosis', 'Patients with diabetes; Treatment-naive patients', '2020-12-26', NULL, 'Risk of gastrointestinal perforation', '2024-08-22'),
  (517, 'ciprofloxacin', NULL, 'Intramuscular', 'ITA', 'Psoriatic Arthritis; Hypertension; Hepatitis C', 'Patients with renal impairment', '1996-05-07', NULL, 'Risk of serious cardiovascular events', '2016-08-18'),
  (518, 'ciprofloxacin', NULL, 'Subcutaneous', 'ITA', 'Psoriatic Arthritis', 'Adults with mild disease', '1993-08-07', NULL, NULL, NULL),
  (519, 'ciprofloxacin', NULL, 'Subcutaneous', 'BRA', 'Psoriatic Arthritis', 'Adults with moderate to severe disease; Immunocompromised patients', '2019-10-05', NULL, NULL, NULL),
  (520, 'ciprofloxacin', NULL, 'Intravenous', 'ESP', 'Deep Vein Thrombosis; Rheumatoid Arthritis', 'Patients with comorbidities', '2017-12-12', '2021-05-27', NULL, NULL),
  (521, 'ciprofloxacin', NULL, 'Sublingual', 'BRA', 'Heart Failure; Bacterial Infections; Hepatitis C', 'Patients with hepatic impairment', '2023-03-20', NULL, NULL, NULL),
  (522, 'ciprofloxacin', NULL, 'Intravenous', 'USA', 'Atrial Fibrillation; Viral Infections', 'Pregnant women; Patients with prior treatment failure', '2000-06-18', NULL, NULL, NULL),
  (523, 'ciprofloxacin', NULL, 'Transdermal', 'USA', 'Systemic Lupus Erythematosus', 'Patients with cardiovascular disease', '1993-11-19', NULL, NULL, NULL),
  (524, 'ciprofloxacin', NULL, 'Inhalation', 'ITA', 'HIV Infection; Chronic Obstructive Pulmonary Disease; Ankylosing Spondylitis', 'Patients with comorbidities', '2012-01-14', '2020-01-10', 'Risk of tuberculosis reactivation', '2018-03-21'),
  (525, 'ciprofloxacin', NULL, 'Topical', 'USA', 'Systemic Lupus Erythematosus; Hepatitis C', 'Patients with obesity; Patients with prior treatment failure', '2012-06-24', '2023-01-15', 'Risk of serious cardiovascular events', '2019-04-28'),
  (526, 'ciprofloxacin', NULL, 'Oral', 'DEU', 'Ankylosing Spondylitis; Heart Failure', 'Patients with cardiovascular disease; Pediatric patients 6 months-2 years', '2009-11-06', NULL, NULL, NULL),
  (527, 'ciprofloxacin', NULL, 'Sublingual', 'JPN', 'Multiple Sclerosis; Juvenile Idiopathic Arthritis; Heart Failure', 'Treatment-naive patients; Patients with diabetes', '2007-08-04', '2023-11-03', 'Risk of serious cardiovascular events', '2022-03-21'),
  (528, 'ciprofloxacin', NULL, 'Sublingual', 'ITA', 'Multiple Sclerosis; Juvenile Idiopathic Arthritis', 'Pregnant women', '2022-01-03', NULL, NULL, NULL),
  (529, 'ciprofloxacin', NULL, 'Rectal', 'DEU', 'Hepatitis C; Systemic Lupus Erythematosus; Crohn''s Disease', 'Patients with prior treatment failure; Patients with obesity', '2011-04-12', '2021-04-02', NULL, NULL),
  (530, 'ciprofloxacin', NULL, 'Transdermal', 'CAN', 'Pulmonary Embolism', 'Adults with mild disease', '2015-07-24', NULL, NULL, NULL),
  (531, 'ciprofloxacin', NULL, 'Oral', 'USA', 'Psoriatic Arthritis; Pulmonary Embolism', 'Treatment-naive patients; Adults with mild disease', '2000-09-27', NULL, NULL, NULL),
  (532, 'ciprofloxacin', NULL, 'Sublingual', 'DEU', 'Hypertension; Schizophrenia', 'Patients with diabetes; Patients with prior treatment failure', '2006-08-20', '2024-10-02', 'Risk of central nervous system effects', '2017-01-20'),
  (533, 'doxycycline', NULL, 'Oral', 'USA', 'Psoriatic Arthritis; Chronic Obstructive Pulmonary Disease; HIV Infection', 'Adults with moderate to severe disease', '1997-08-28', NULL, NULL, NULL),
  (534, 'doxycycline', NULL, 'Oral', 'ESP', 'Atrial Fibrillation; Juvenile Idiopathic Arthritis', 'Patients with renal impairment', '2014-09-27', NULL, NULL, NULL),
  (535, 'doxycycline', NULL, 'Oral', 'AUS', 'Plaque Psoriasis', 'Patients with diabetes; Patients with cardiovascular disease', '1998-06-16', NULL, NULL, NULL),
  (536, 'doxycycline', NULL, 'Topical', 'FRA', 'Juvenile Idiopathic Arthritis; Crohn''s Disease', 'Patients with hepatic impairment', '2023-11-16', NULL, 'Risk of hypersensitivity reactions', '2023-07-10'),
  (537, 'doxycycline', NULL, 'Inhalation', 'CAN', 'Cancer; Hepatitis C', 'Pediatric patients 6 months-2 years; Patients with hepatic impairment', '2014-01-01', NULL, NULL, NULL),
  (538, 'doxycycline', NULL, 'Inhalation', 'AUS', 'Hypertension; Depression; Ankylosing Spondylitis', 'Patients with hepatic impairment; Patients with cardiovascular disease', '1992-06-22', NULL, 'Risk of bone loss', '2017-07-14'),
  (539, 'doxycycline', NULL, 'Topical', 'JPN', 'Crohn''s Disease; Migraine; Fungal Infections', 'Adults with mild disease; Patients with prior treatment failure', '2016-06-03', NULL, 'Risk of blood disorders', '2019-11-17'),
  (540, 'doxycycline', NULL, 'Sublingual', 'DEU', 'Osteoporosis; Juvenile Idiopathic Arthritis; Bipolar Disorder', 'Treatment-naive patients', '2008-11-02', '2024-03-01', NULL, NULL),
  (541, 'doxycycline', NULL, 'Nasal', 'BRA', 'Plaque Psoriasis; Psoriatic Arthritis; Systemic Lupus Erythematosus', 'Immunocompromised patients; Pregnant women', '2008-08-02', NULL, NULL, NULL),
  (542, 'doxycycline', NULL, 'Subcutaneous', 'UK', 'Pulmonary Embolism', 'Patients with obesity; Immunocompromised patients', '1990-10-04', NULL, NULL, NULL),
  (543, 'doxycycline', NULL, 'Nasal', 'CAN', 'Hepatitis C; Depression; Heart Failure', 'Adults with mild disease', '2015-10-26', NULL, NULL, NULL),
  (544, 'doxycycline', NULL, 'Intravenous', 'UK', 'Anxiety', 'Patients with obesity', '1990-05-03', '2022-08-03', NULL, NULL),
  (545, 'doxycycline', NULL, 'Subcutaneous', 'DEU', 'Juvenile Idiopathic Arthritis', 'Patients with renal impairment; Patients with obesity', '2002-03-22', NULL, 'Risk of anaphylaxis', '2020-08-06'),
  (546, 'doxycycline', NULL, 'Sublingual', 'FRA', 'Ulcerative Colitis; Psoriatic Arthritis; Asthma', 'Adults with mild disease', '2002-02-10', NULL, NULL, NULL),
  (547, 'doxycycline', NULL, 'Oral', 'ESP', 'Plaque Psoriasis; Ankylosing Spondylitis; Bipolar Disorder', 'Treatment-naive patients; Patients with diabetes', '2022-11-09', NULL, 'Risk of tuberculosis reactivation', '2023-03-02'),
  (548, 'doxycycline', NULL, 'Intravenous', 'AUS', 'Crohn''s Disease', 'Pregnant women', '1997-03-13', '2024-05-12', 'Risk of anaphylaxis', '2019-09-23'),
  (549, 'doxycycline', NULL, 'Rectal', 'ITA', 'Ankylosing Spondylitis; Multiple Sclerosis', 'Patients with cardiovascular disease', '1996-09-17', NULL, NULL, NULL),
  (550, 'doxycycline', NULL, 'Oral', 'AUS', 'Cancer; Deep Vein Thrombosis; Pulmonary Embolism', 'Immunocompromised patients; Adults 18-65 years', '1995-02-27', NULL, 'Risk of tuberculosis reactivation', '2022-01-19'),
  (551, 'doxycycline', NULL, 'Intramuscular', 'FRA', 'Migraine; Juvenile Idiopathic Arthritis', 'Pregnant women', '2006-10-02', NULL, NULL, NULL),
  (552, 'doxycycline', NULL, 'Intravenous', 'CAN', 'Bacterial Infections; Bipolar Disorder; Osteoporosis', 'Pediatric patients 2-17 years; Patients with cardiovascular disease', '2023-11-19', NULL, NULL, NULL),
  (553, 'doxycycline', NULL, 'Oral', 'BRA', 'Viral Infections; Asthma', 'Immunocompromised patients', '1990-07-15', NULL, NULL, NULL),
  (554, 'doxycycline', NULL, 'Topical', 'USA', 'Viral Infections; Bipolar Disorder', 'Patients with comorbidities; Pediatric patients 2-17 years', '1998-11-17', NULL, NULL, NULL),
  (555, 'clindamycin', NULL, 'Rectal', 'AUS', 'Heart Failure; Fungal Infections', 'Patients with prior treatment failure; Patients with obesity', '2010-03-15', NULL, 'Risk of peripheral neuropathy', '2023-08-14'),
  (556, 'clindamycin', NULL, 'Intramuscular', 'JPN', 'Rheumatoid Arthritis; Atrial Fibrillation; HIV Infection', 'Patients with obesity', '1996-01-06', NULL, NULL, NULL),
  (557, 'clindamycin', NULL, 'Oral', 'CAN', 'Psoriatic Arthritis; Chronic Obstructive Pulmonary Disease', 'Patients with hepatic impairment; Pediatric patients 6 months-2 years', '2017-10-18', NULL, NULL, NULL),
  (558, 'clindamycin', NULL, 'Oral', 'FRA', 'Ankylosing Spondylitis; Rheumatoid Arthritis', 'Patients with prior treatment failure; Adults with mild disease', '1992-09-18', NULL, NULL, NULL),
  (559, 'clindamycin', NULL, 'Nasal', 'CAN', 'Fungal Infections; Plaque Psoriasis', 'Pediatric patients 2-17 years', '2017-04-06', NULL, NULL, NULL),
  (560, 'clindamycin', NULL, 'Nasal', 'CAN', 'Pulmonary Embolism', 'Patients with comorbidities; Adults with mild disease', '1998-01-01', NULL, 'Risk of hypersensitivity reactions', '2019-03-23'),
  (561, 'metronidazole', NULL, 'Intramuscular', 'JPN', 'Plaque Psoriasis', 'Patients with cardiovascular disease; Adults with moderate to severe disease', '1993-03-10', NULL, NULL, NULL),
  (562, 'metronidazole', NULL, 'Inhalation', 'ESP', 'Hepatitis C', 'Adults with mild disease; Patients with diabetes', '1999-12-20', NULL, NULL, NULL),
  (563, 'metronidazole', NULL, 'Rectal', 'DEU', 'Asthma; Fungal Infections', 'Patients with obesity', '2016-07-04', NULL, NULL, NULL),
  (564, 'metronidazole', NULL, 'Sublingual', 'USA', 'Plaque Psoriasis; Schizophrenia; Ulcerative Colitis', 'Immunocompromised patients; Patients with cardiovascular disease', '2021-11-08', NULL, NULL, NULL),
  (565, 'metronidazole', NULL, 'Intravenous', 'AUS', 'Multiple Sclerosis; Viral Infections', 'Patients with prior treatment failure; Pregnant women', '2022-07-27', NULL, NULL, NULL),
  (566, 'metronidazole', NULL, 'Oral', 'CAN', 'HIV Infection; Rheumatoid Arthritis', 'Patients with comorbidities; Patients with cardiovascular disease', '2016-02-19', NULL, NULL, NULL),
  (567, 'metronidazole', NULL, 'Subcutaneous', 'AUS', 'Atrial Fibrillation; Bipolar Disorder', 'Pediatric patients 2-17 years; Adults with moderate to severe disease', '2024-11-04', NULL, NULL, NULL),
  (568, 'metronidazole', NULL, 'Topical', 'ESP', 'Depression', 'Pediatric patients 2-17 years; Adults 18-65 years', '2012-02-26', NULL, NULL, NULL),
  (569, 'metronidazole', NULL, 'Intramuscular', 'FRA', 'Diabetes Mellitus Type 2; Hepatitis C', 'Pregnant women', '2009-01-08', NULL, NULL, NULL),
  (570, 'metronidazole', NULL, 'Topical', 'AUS', 'Rheumatoid Arthritis', 'Adults with mild disease; Patients with hepatic impairment', '2012-05-20', NULL, 'Risk of hearing loss', '2016-08-10'),
  (571, 'metronidazole', NULL, 'Rectal', 'CAN', 'Hepatitis C', 'Patients with renal impairment', '2021-05-24', NULL, NULL, NULL),
  (572, 'metronidazole', NULL, 'Oral', 'BRA', 'Bipolar Disorder; Systemic Lupus Erythematosus; Plaque Psoriasis', 'Adults with mild disease', '2006-01-25', NULL, NULL, NULL),
  (573, 'metronidazole', NULL, 'Topical', 'UK', 'Viral Infections', 'Patients with cardiovascular disease', '2020-04-09', NULL, NULL, NULL),
  (574, 'metronidazole', NULL, 'Transdermal', 'DEU', 'Hypertension', 'Patients with renal impairment; Treatment-naive patients', '2010-11-12', NULL, NULL, NULL),
  (575, 'metronidazole', NULL, 'Intramuscular', 'AUS', 'Multiple Sclerosis', 'Immunocompromised patients; Adults 18-65 years', '2010-08-07', NULL, NULL, NULL),
  (576, 'metronidazole', NULL, 'Sublingual', 'AUS', 'Chronic Obstructive Pulmonary Disease; Depression', 'Pregnant women', '2015-06-14', NULL, NULL, NULL),
  (577, 'metronidazole', NULL, 'Transdermal', 'ITA', 'Anxiety; Viral Infections', 'Adults 18-65 years; Patients with prior treatment failure', '2004-09-18', NULL, 'Risk of gastrointestinal perforation', '2016-02-02'),
  (578, 'metronidazole', NULL, 'Transdermal', 'JPN', 'Psoriatic Arthritis', 'Pregnant women; Immunocompromised patients', '2024-01-21', NULL, 'Risk of progressive multifocal leukoencephalopathy', '2017-09-12'),
  (579, 'metronidazole', NULL, 'Nasal', 'DEU', 'Diabetes Mellitus Type 2', 'Patients with diabetes', '2015-03-06', NULL, NULL, NULL),
  (580, 'metronidazole', NULL, 'Transdermal', 'BRA', 'Pulmonary Embolism; Psoriatic Arthritis; Atrial Fibrillation', 'Pediatric patients 6 months-2 years; Patients with renal impairment', '2000-05-15', NULL, 'Risk of bone loss', '2015-10-08'),
  (581, 'metronidazole', NULL, 'Subcutaneous', 'BRA', 'Osteoporosis; Heart Failure; Chronic Obstructive Pulmonary Disease', 'Patients with obesity; Immunocompromised patients', '1990-05-05', NULL, NULL, NULL),
  (582, 'metronidazole', NULL, 'Intravenous', 'USA', 'Bacterial Infections', 'Patients with comorbidities', '2020-07-06', NULL, 'Risk of liver injury', '2015-09-10'),
  (583, 'metronidazole', NULL, 'Oral', 'USA', 'Fungal Infections; Ulcerative Colitis', 'Pediatric patients 6 months-2 years', '2016-09-25', NULL, 'Risk of progressive multifocal leukoencephalopathy', '2021-01-15'),
  (584, 'vancomycin', NULL, 'Oral', 'ITA', 'Anxiety', 'Treatment-naive patients', '1997-11-23', NULL, NULL, NULL),
  (585, 'vancomycin', NULL, 'Subcutaneous', 'AUS', 'Migraine; Juvenile Idiopathic Arthritis; Schizophrenia', 'Treatment-naive patients; Immunocompromised patients', '1999-10-22', NULL, NULL, NULL),
  (586, 'vancomycin', NULL, 'Intramuscular', 'JPN', 'Migraine; Plaque Psoriasis; Rheumatoid Arthritis', 'Patients with cardiovascular disease', '1990-09-01', NULL, NULL, NULL),
  (587, 'vancomycin', NULL, 'Inhalation', 'JPN', 'Multiple Sclerosis', 'Patients with hepatic impairment; Adults 65+ years', '2013-11-19', NULL, NULL, NULL),
  (588, 'vancomycin', NULL, 'Intramuscular', 'UK', 'Bacterial Infections; Heart Failure; Ulcerative Colitis', 'Pediatric patients 6 months-2 years', '2022-09-08', '2023-10-21', 'Risk of progressive multifocal leukoencephalopathy', '2015-10-26'),
  (589, 'vancomycin', NULL, 'Topical', 'ESP', 'Systemic Lupus Erythematosus; Atrial Fibrillation; Asthma', 'Patients with hepatic impairment', '2009-07-15', NULL, NULL, NULL),
  (590, 'vancomycin', NULL, 'Topical', 'UK', 'Osteoporosis; Deep Vein Thrombosis; Ankylosing Spondylitis', 'Patients with hepatic impairment; Adults with moderate to severe disease', '1999-07-19', NULL, NULL, NULL),
  (591, 'vancomycin', NULL, 'Rectal', 'USA', 'Heart Failure; Asthma', 'Patients with hepatic impairment; Adults 65+ years', '2009-06-19', NULL, NULL, NULL),
  (592, 'vancomycin', NULL, 'Intravenous', 'USA', 'Cancer; Viral Infections; Rheumatoid Arthritis', 'Patients with obesity; Adults with moderate to severe disease', '1995-08-22', NULL, 'Risk of bone loss', '2024-06-03'),
  (593, 'vancomycin', NULL, 'Rectal', 'JPN', 'Hypertension; Schizophrenia; HIV Infection', 'Adults with mild disease', '2009-01-08', '2022-06-23', NULL, NULL),
  (594, 'vancomycin', NULL, 'Sublingual', 'CAN', 'Osteoporosis; Juvenile Idiopathic Arthritis', 'Adults 65+ years', '2012-10-15', NULL, 'Risk of renal impairment', '2020-11-18'),
  (595, 'vancomycin', NULL, 'Subcutaneous', 'ITA', 'Bacterial Infections', 'Adults with mild disease; Adults 18-65 years', '2013-01-22', '2022-06-08', NULL, NULL),
  (596, 'vancomycin', NULL, 'Intramuscular', 'ESP', 'Psoriatic Arthritis', 'Immunocompromised patients', '2012-06-08', NULL, 'Risk of liver injury', '2023-09-22'),
  (597, 'vancomycin', NULL, 'Transdermal', 'UK', 'Migraine', 'Patients with prior treatment failure', '1997-05-21', NULL, NULL, NULL),
  (598, 'vancomycin', NULL, 'Subcutaneous', 'JPN', 'Ulcerative Colitis; Juvenile Idiopathic Arthritis', 'Pediatric patients 2-17 years', '1990-06-24', NULL, 'Risk of blood disorders', '2016-07-17'),
  (599, 'vancomycin', NULL, 'Sublingual', 'ITA', 'Bipolar Disorder; Multiple Sclerosis; Juvenile Idiopathic Arthritis', 'Adults 18-65 years', '2018-03-22', NULL, 'Risk of serious cardiovascular events', '2021-02-14'),
  (600, 'vancomycin', NULL, 'Subcutaneous', 'CAN', 'Fungal Infections; Bacterial Infections; Juvenile Idiopathic Arthritis', 'Adults 18-65 years; Adults 65+ years', '1991-03-23', NULL, NULL, NULL),
  (601, 'vancomycin', NULL, 'Subcutaneous', 'FRA', 'Asthma; Systemic Lupus Erythematosus', 'Pediatric patients 2-17 years', '1990-10-20', NULL, NULL, NULL),
  (602, 'vancomycin', NULL, 'Transdermal', 'UK', 'Heart Failure', 'Patients with renal impairment; Pregnant women', '1997-09-23', NULL, NULL, NULL),
  (603, 'vancomycin', NULL, 'Intramuscular', 'DEU', 'Crohn''s Disease; Rheumatoid Arthritis; Depression', 'Adults with mild disease; Patients with hepatic impairment', '2015-01-25', NULL, NULL, NULL),
  (604, 'vancomycin', NULL, 'Nasal', 'USA', 'Plaque Psoriasis', 'Adults with mild disease', '1996-08-05', '2022-09-20', 'Increased risk of serious infections', '2019-04-10'),
  (605, 'vancomycin', NULL, 'Intravenous', 'FRA', 'Chronic Obstructive Pulmonary Disease; Crohn''s Disease', 'Patients with renal impairment; Patients with hepatic impairment', '1995-10-07', NULL, NULL, NULL),
  (606, 'vancomycin', NULL, 'Intravenous', 'UK', 'Depression; Psoriatic Arthritis; Hypertension', 'Patients with hepatic impairment', '2008-01-06', NULL, NULL, NULL),
  (607, 'vancomycin', NULL, 'Inhalation', 'DEU', 'Schizophrenia; Migraine', 'Patients with hepatic impairment', '2018-05-24', NULL, NULL, NULL),
  (608, 'vancomycin', NULL, 'Sublingual', 'USA', 'Cancer; Hypertension', 'Pregnant women', '2010-07-02', NULL, 'Risk of peripheral neuropathy', '2015-04-22'),
  (609, 'vancomycin', NULL, 'Sublingual', 'ITA', 'Atrial Fibrillation', 'Treatment-naive patients', '2012-09-04', NULL, 'Risk of hypersensitivity reactions', '2024-12-28'),
  (610, 'vancomycin', NULL, 'Nasal', 'ITA', 'Juvenile Idiopathic Arthritis', 'Patients with diabetes', '1990-06-05', NULL, NULL, NULL),
  (611, 'gentamicin', NULL, 'Transdermal', 'JPN', 'Psoriatic Arthritis; Asthma', 'Patients with cardiovascular disease', '2008-05-06', NULL, NULL, NULL),
  (612, 'gentamicin', NULL, 'Nasal', 'USA', 'Chronic Obstructive Pulmonary Disease', 'Patients with comorbidities', '1993-02-17', '2021-07-27', 'Risk of hypersensitivity reactions', '2017-04-07'),
  (613, 'gentamicin', NULL, 'Topical', 'JPN', 'Rheumatoid Arthritis; Multiple Sclerosis', 'Adults 65+ years; Patients with renal impairment', '2006-01-13', NULL, 'Risk of hypersensitivity reactions', '2017-11-28'),
  (614, 'gentamicin', NULL, 'Oral', 'ITA', 'Hypertension; Psoriatic Arthritis', 'Adults 65+ years', '2006-02-21', NULL, NULL, NULL),
  (615, 'ceftriaxone', NULL, 'Rectal', 'CAN', 'Heart Failure; Schizophrenia', 'Adults 65+ years; Pediatric patients 2-17 years', '2004-05-01', '2020-08-18', NULL, NULL),
  (616, 'ceftriaxone', NULL, 'Intramuscular', 'UK', 'Hypertension; Cancer', 'Pregnant women', '2023-08-17', NULL, NULL, NULL),
  (617, 'ceftriaxone', NULL, 'Inhalation', 'AUS', 'Bipolar Disorder; Diabetes Mellitus Type 2; Juvenile Idiopathic Arthritis', 'Immunocompromised patients; Patients with renal impairment', '2010-04-25', NULL, NULL, NULL),
  (618, 'ceftriaxone', NULL, 'Sublingual', 'USA', 'Juvenile Idiopathic Arthritis', 'Pediatric patients 2-17 years', '2003-07-20', NULL, NULL, NULL),
  (619, 'ceftriaxone', NULL, 'Intramuscular', 'JPN', 'Diabetes Mellitus Type 2', 'Patients with cardiovascular disease', '1991-05-18', NULL, NULL, NULL),
  (620, 'ceftriaxone', NULL, 'Inhalation', 'FRA', 'Migraine; Ulcerative Colitis', 'Adults with moderate to severe disease', '2008-01-12', NULL, NULL, NULL),
  (621, 'ceftriaxone', NULL, 'Rectal', 'DEU', 'Schizophrenia', 'Adults with mild disease; Patients with obesity', '2019-05-26', NULL, NULL, NULL),
  (622, 'ceftriaxone', NULL, 'Topical', 'UK', 'Psoriatic Arthritis', 'Pregnant women; Patients with diabetes', '1999-08-09', NULL, 'Risk of progressive multifocal leukoencephalopathy', '2015-06-04'),
  (623, 'ceftriaxone', NULL, 'Intramuscular', 'BRA', 'Hypertension; Rheumatoid Arthritis', 'Pediatric patients 6 months-2 years; Treatment-naive patients', '2002-12-20', NULL, NULL, NULL),
  (624, 'ceftriaxone', NULL, 'Oral', 'BRA', 'Psoriatic Arthritis; Migraine', 'Patients with renal impairment', '2012-09-13', NULL, NULL, NULL),
  (625, 'ceftriaxone', NULL, 'Subcutaneous', 'BRA', 'Cancer; Schizophrenia; Asthma', 'Pregnant women', '2023-05-12', NULL, NULL, NULL),
  (626, 'ceftriaxone', NULL, 'Sublingual', 'AUS', 'Psoriatic Arthritis', 'Patients with cardiovascular disease', '1994-12-23', '2021-06-24', NULL, NULL),
  (627, 'ceftriaxone', NULL, 'Subcutaneous', 'FRA', 'Plaque Psoriasis; Systemic Lupus Erythematosus; Migraine', 'Patients with prior treatment failure; Treatment-naive patients', '1991-08-12', NULL, 'Risk of anaphylaxis', '2020-03-23'),
  (628, 'ceftriaxone', NULL, 'Topical', 'JPN', 'Rheumatoid Arthritis; Bipolar Disorder; Viral Infections', 'Patients with renal impairment; Patients with obesity', '2006-05-24', '2020-04-03', NULL, NULL),
  (629, 'ceftriaxone', NULL, 'Sublingual', 'AUS', 'Diabetes Mellitus Type 2; Pulmonary Embolism', 'Patients with obesity; Pediatric patients 2-17 years', '1994-09-02', NULL, 'Increased risk of malignancy', '2023-10-28'),
  (630, 'ceftriaxone', NULL, 'Subcutaneous', 'BRA', 'Chronic Obstructive Pulmonary Disease; Rheumatoid Arthritis', 'Patients with comorbidities', '2014-01-16', NULL, NULL, NULL),
  (631, 'ceftriaxone', NULL, 'Inhalation', 'USA', 'Fungal Infections', 'Patients with cardiovascular disease; Pediatric patients 6 months-2 years', '2016-08-03', NULL, NULL, NULL),
  (632, 'ceftriaxone', NULL, 'Intramuscular', 'FRA', 'Juvenile Idiopathic Arthritis', 'Pregnant women; Patients with diabetes', '1991-07-28', NULL, NULL, NULL),
  (633, 'ceftriaxone', NULL, 'Intravenous', 'AUS', 'Anxiety; Depression', 'Adults 65+ years', '2001-06-13', NULL, NULL, NULL),
  (634, 'ceftriaxone', NULL, 'Nasal', 'UK', 'Psoriatic Arthritis; Crohn''s Disease', 'Pediatric patients 6 months-2 years; Adults with mild disease', '1995-05-16', '2020-07-07', NULL, NULL),
  (635, 'ceftriaxone', NULL, 'Transdermal', 'USA', 'Psoriatic Arthritis; Ulcerative Colitis; Ankylosing Spondylitis', 'Patients with comorbidities; Patients with prior treatment failure', '1999-10-25', NULL, NULL, NULL),
  (636, 'ceftriaxone', NULL, 'Nasal', 'ESP', 'Migraine', 'Adults 65+ years; Adults with mild disease', '2019-05-04', NULL, NULL, NULL),
  (637, 'piperacillin', NULL, 'Subcutaneous', 'ITA', 'Chronic Obstructive Pulmonary Disease', 'Adults with mild disease', '1992-08-22', NULL, NULL, NULL),
  (638, 'piperacillin', NULL, 'Oral', 'DEU', 'Deep Vein Thrombosis; Juvenile Idiopathic Arthritis', 'Patients with renal impairment', '1990-01-04', '2021-04-27', 'Risk of gastrointestinal perforation', '2017-04-11'),
  (639, 'piperacillin', NULL, 'Topical', 'FRA', 'Psoriatic Arthritis; Hypertension', 'Adults 18-65 years; Adults 65+ years', '2011-10-08', NULL, NULL, NULL),
  (640, 'piperacillin', NULL, 'Topical', 'ITA', 'Hypertension; Multiple Sclerosis', 'Immunocompromised patients', '1994-03-25', NULL, 'Risk of serious cardiovascular events', '2023-03-22'),
  (641, 'piperacillin', NULL, 'Oral', 'CAN', 'Deep Vein Thrombosis; Pulmonary Embolism', 'Patients with obesity; Adults 18-65 years', '2008-01-12', NULL, NULL, NULL),
  (642, 'piperacillin', NULL, 'Intramuscular', 'CAN', 'Cancer; Migraine; Heart Failure', 'Patients with renal impairment; Immunocompromised patients', '2002-11-13', NULL, 'Risk of hypersensitivity reactions', '2019-04-16'),
  (643, 'piperacillin', NULL, 'Topical', 'ITA', 'Viral Infections; Psoriatic Arthritis; Osteoporosis', 'Patients with renal impairment; Patients with hepatic impairment', '2009-05-03', NULL, 'Risk of tuberculosis reactivation', '2021-05-05'),
  (644, 'piperacillin', NULL, 'Subcutaneous', 'USA', 'Juvenile Idiopathic Arthritis; Chronic Obstructive Pulmonary Disease', 'Adults 65+ years; Patients with renal impairment', '1998-05-28', NULL, NULL, NULL),
  (645, 'piperacillin', NULL, 'Inhalation', 'UK', 'Bacterial Infections', 'Patients with obesity', '2015-01-26', NULL, NULL, NULL),
  (646, 'piperacillin', NULL, 'Intramuscular', 'AUS', 'Asthma; Osteoporosis; Bacterial Infections', 'Pediatric patients 6 months-2 years; Patients with hepatic impairment', '1994-08-03', NULL, NULL, NULL),
  (647, 'piperacillin', NULL, 'Oral', 'AUS', 'Migraine; Bacterial Infections', 'Patients with diabetes', '1999-02-28', '2023-01-01', NULL, NULL),
  (648, 'tazobactam', NULL, 'Inhalation', 'USA', 'Asthma; Psoriatic Arthritis', 'Patients with prior treatment failure; Adults with mild disease', '2000-09-13', NULL, NULL, NULL),
  (649, 'tazobactam', NULL, 'Oral', 'BRA', 'Crohn''s Disease', 'Adults with mild disease; Patients with cardiovascular disease', '2006-10-22', NULL, NULL, NULL),
  (650, 'tazobactam', NULL, 'Subcutaneous', 'ESP', 'Psoriatic Arthritis', 'Adults 65+ years; Patients with comorbidities', '2000-07-28', NULL, NULL, NULL),
  (651, 'tazobactam', NULL, 'Subcutaneous', 'ESP', 'Ulcerative Colitis; Multiple Sclerosis; Deep Vein Thrombosis', 'Pregnant women; Immunocompromised patients', '2020-12-06', NULL, NULL, NULL),
  (652, 'tazobactam', NULL, 'Inhalation', 'CAN', 'Deep Vein Thrombosis; HIV Infection', 'Adults with moderate to severe disease', '2008-02-08', NULL, 'Risk of liver injury', '2017-03-06'),
  (653, 'tazobactam', NULL, 'Topical', 'DEU', 'Schizophrenia; Plaque Psoriasis', 'Adults with moderate to severe disease; Patients with hepatic impairment', '2022-10-20', NULL, 'Risk of hepatitis B reactivation', '2022-10-07'),
  (654, 'tazobactam', NULL, 'Intravenous', 'ITA', 'Juvenile Idiopathic Arthritis', 'Immunocompromised patients', '2015-03-17', '2020-10-14', 'Risk of renal impairment', '2016-02-17'),
  (655, 'tazobactam', NULL, 'Transdermal', 'FRA', 'HIV Infection', 'Adults with mild disease', '2010-06-04', NULL, 'Risk of bone loss', '2022-09-16'),
  (656, 'tazobactam', NULL, 'Oral', 'FRA', 'Depression; Hepatitis C; Schizophrenia', 'Patients with cardiovascular disease', '1997-03-14', NULL, 'Risk of renal impairment', '2022-10-14'),
  (657, 'tazobactam', NULL, 'Oral', 'FRA', 'Cancer', 'Patients with hepatic impairment', '1997-07-28', NULL, NULL, NULL),
  (658, 'meropenem', NULL, 'Intramuscular', 'ITA', 'Rheumatoid Arthritis; Psoriatic Arthritis', 'Immunocompromised patients', '2001-02-05', NULL, NULL, NULL),
  (659, 'meropenem', NULL, 'Subcutaneous', 'FRA', 'Schizophrenia', 'Patients with comorbidities', '2007-07-17', NULL, 'Risk of peripheral neuropathy', '2019-06-04'),
  (660, 'meropenem', NULL, 'Transdermal', 'CAN', 'Cancer; Systemic Lupus Erythematosus; Hypertension', 'Adults 65+ years', '1990-05-12', NULL, NULL, NULL),
  (661, 'meropenem', NULL, 'Intravenous', 'JPN', 'Anxiety; Ankylosing Spondylitis', 'Pregnant women; Adults 65+ years', '2017-02-08', NULL, NULL, NULL),
  (662, 'meropenem', NULL, 'Transdermal', 'CAN', 'Bipolar Disorder', 'Patients with renal impairment', '2011-11-08', '2020-11-19', NULL, NULL),
  (663, 'meropenem', NULL, 'Inhalation', 'CAN', 'Hypertension; Pulmonary Embolism', 'Patients with renal impairment', '2000-05-21', NULL, NULL, NULL),
  (664, 'meropenem', NULL, 'Intravenous', 'ESP', 'Asthma; Schizophrenia; Hepatitis C', 'Patients with hepatic impairment', '2001-04-07', NULL, NULL, NULL),
  (665, 'meropenem', NULL, 'Transdermal', 'AUS', 'Pulmonary Embolism; Diabetes Mellitus Type 2', 'Pediatric patients 6 months-2 years; Adults with moderate to severe disease', '1999-08-12', NULL, NULL, NULL),
  (666, 'meropenem', NULL, 'Transdermal', 'UK', 'Crohn''s Disease; Ulcerative Colitis; Diabetes Mellitus Type 2', 'Pregnant women; Pediatric patients 2-17 years', '1997-12-24', NULL, NULL, NULL),
  (667, 'meropenem', NULL, 'Rectal', 'JPN', 'Anxiety', 'Patients with diabetes; Treatment-naive patients', '2015-04-08', NULL, NULL, NULL),
  (668, 'meropenem', NULL, 'Intravenous', 'BRA', 'Psoriatic Arthritis', 'Adults with moderate to severe disease', '1991-03-07', '2021-05-03', NULL, NULL),
  (669, 'linezolid', NULL, 'Subcutaneous', 'JPN', 'Fungal Infections; Multiple Sclerosis', 'Adults with moderate to severe disease', '2011-03-16', '2020-09-03', NULL, NULL),
  (670, 'linezolid', NULL, 'Nasal', 'CAN', 'Asthma', 'Pregnant women; Treatment-naive patients', '1999-06-10', NULL, NULL, NULL),
  (671, 'linezolid', NULL, 'Sublingual', 'UK', 'Anxiety; Psoriatic Arthritis', 'Patients with renal impairment; Treatment-naive patients', '2020-05-10', NULL, NULL, NULL),
  (672, 'linezolid', NULL, 'Intravenous', 'FRA', 'Osteoporosis', 'Adults 65+ years', '2012-09-16', NULL, 'Risk of hypersensitivity reactions', '2015-10-02'),
  (673, 'linezolid', NULL, 'Inhalation', 'ITA', 'Ulcerative Colitis; Rheumatoid Arthritis', 'Adults 65+ years; Patients with comorbidities', '2022-03-18', NULL, NULL, NULL),
  (674, 'linezolid', NULL, 'Sublingual', 'FRA', 'HIV Infection', 'Pediatric patients 6 months-2 years', '2001-01-04', NULL, 'Risk of anaphylaxis', '2024-08-15'),
  (675, 'linezolid', NULL, 'Nasal', 'BRA', 'Plaque Psoriasis', 'Adults 65+ years', '2020-04-02', NULL, NULL, NULL),
  (676, 'linezolid', NULL, 'Intravenous', 'FRA', 'Crohn''s Disease; Schizophrenia; Fungal Infections', 'Adults 65+ years', '2001-10-03', NULL, NULL, NULL),
  (677, 'linezolid', NULL, 'Intramuscular', 'BRA', 'Juvenile Idiopathic Arthritis; Pulmonary Embolism', 'Adults 18-65 years; Treatment-naive patients', '2011-06-04', NULL, NULL, NULL),
  (678, 'linezolid', NULL, 'Intravenous', 'JPN', 'Hypertension; Deep Vein Thrombosis', 'Patients with hepatic impairment', '2010-11-17', NULL, 'Risk of tuberculosis reactivation', '2024-01-11'),
  (679, 'linezolid', NULL, 'Nasal', 'CAN', 'Multiple Sclerosis', 'Patients with prior treatment failure; Treatment-naive patients', '2016-06-07', '2021-08-02', NULL, NULL),
  (680, 'linezolid', NULL, 'Topical', 'ITA', 'Chronic Obstructive Pulmonary Disease; Hepatitis C', 'Adults 18-65 years', '2021-09-17', NULL, 'Risk of central nervous system effects', '2015-09-14'),
  (681, 'linezolid', NULL, 'Intramuscular', 'ESP', 'Fungal Infections; Hypertension', 'Patients with hepatic impairment; Pediatric patients 2-17 years', '1994-06-12', NULL, NULL, NULL),
  (682, 'linezolid', NULL, 'Intramuscular', 'BRA', 'Asthma; Viral Infections', 'Patients with hepatic impairment', '2000-09-02', NULL, NULL, NULL),
  (683, 'oseltamivir', NULL, 'Intravenous', 'USA', 'Bipolar Disorder; Heart Failure; Anxiety', 'Adults 18-65 years; Adults with moderate to severe disease', '2001-01-03', '2023-07-03', 'Risk of liver injury', '2022-10-21'),
  (684, 'oseltamivir', NULL, 'Rectal', 'USA', 'Depression; Systemic Lupus Erythematosus; HIV Infection', 'Pregnant women', '2008-12-23', NULL, NULL, NULL),
  (685, 'oseltamivir', NULL, 'Intravenous', 'DEU', 'Depression; Deep Vein Thrombosis', 'Pregnant women', '1991-06-28', NULL, NULL, NULL),
  (686, 'oseltamivir', NULL, 'Intramuscular', 'CAN', 'Schizophrenia; Asthma; Crohn''s Disease', 'Adults with moderate to severe disease', '2016-09-20', NULL, 'Risk of blood disorders', '2020-01-12'),
  (687, 'oseltamivir', NULL, 'Topical', 'CAN', 'Pulmonary Embolism; Ankylosing Spondylitis', 'Adults with mild disease', '2020-02-10', NULL, NULL, NULL),
  (688, 'oseltamivir', NULL, 'Sublingual', 'BRA', 'Chronic Obstructive Pulmonary Disease', 'Patients with prior treatment failure', '2018-11-27', NULL, NULL, NULL),
  (689, 'oseltamivir', NULL, 'Rectal', 'FRA', 'Heart Failure; Fungal Infections', 'Patients with diabetes', '2011-09-13', NULL, NULL, NULL),
  (690, 'oseltamivir', NULL, 'Inhalation', 'USA', 'Bacterial Infections', 'Pregnant women; Patients with cardiovascular disease', '2006-01-20', NULL, 'Increased risk of malignancy', '2016-04-27'),
  (691, 'oseltamivir', NULL, 'Intravenous', 'ITA', 'Heart Failure', 'Adults 18-65 years', '1990-03-14', '2021-11-23', 'Risk of blood disorders', '2021-11-22'),
  (692, 'oseltamivir', NULL, 'Sublingual', 'ITA', 'Bipolar Disorder', 'Pediatric patients 6 months-2 years; Patients with comorbidities', '2017-10-14', NULL, NULL, NULL),
  (693, 'oseltamivir', NULL, 'Intramuscular', 'DEU', 'Systemic Lupus Erythematosus; Anxiety', 'Patients with prior treatment failure', '1993-12-03', NULL, NULL, NULL),
  (694, 'oseltamivir', NULL, 'Oral', 'ESP', 'Asthma; Ulcerative Colitis', 'Adults with mild disease; Patients with renal impairment', '1992-09-17', NULL, NULL, NULL),
  (695, 'oseltamivir', NULL, 'Topical', 'AUS', 'Multiple Sclerosis', 'Patients with obesity; Pediatric patients 6 months-2 years', '2017-11-17', NULL, NULL, NULL),
  (696, 'oseltamivir', NULL, 'Intravenous', 'DEU', 'Crohn''s Disease; Fungal Infections', 'Adults with moderate to severe disease', '2020-03-15', NULL, NULL, NULL),
  (697, 'oseltamivir', NULL, 'Inhalation', 'CAN', 'Psoriatic Arthritis; Anxiety; Multiple Sclerosis', 'Pregnant women', '2012-11-20', NULL, NULL, NULL),
  (698, 'oseltamivir', NULL, 'Transdermal', 'JPN', 'HIV Infection', 'Patients with comorbidities', '1997-11-23', NULL, NULL, NULL),
  (699, 'sofosbuvir', NULL, 'Intramuscular', 'BRA', 'Systemic Lupus Erythematosus; Osteoporosis; Bipolar Disorder', 'Adults 18-65 years; Patients with prior treatment failure', '2011-01-11', NULL, 'Risk of gastrointestinal perforation', '2023-05-12'),
  (700, 'sofosbuvir', NULL, 'Intramuscular', 'UK', 'Fungal Infections; Anxiety; Hepatitis C', 'Patients with hepatic impairment', '2001-10-01', NULL, NULL, NULL),
  (701, 'sofosbuvir', NULL, 'Oral', 'FRA', 'Migraine; Ulcerative Colitis; Viral Infections', 'Adults with mild disease', '2012-02-11', NULL, NULL, NULL),
  (702, 'sofosbuvir', NULL, 'Sublingual', 'BRA', 'Osteoporosis; Bacterial Infections', 'Adults 18-65 years; Immunocompromised patients', '1990-08-23', NULL, NULL, NULL),
  (703, 'sofosbuvir', NULL, 'Oral', 'DEU', 'Psoriatic Arthritis', 'Patients with hepatic impairment', '2016-07-10', NULL, NULL, NULL),
  (704, 'sofosbuvir', NULL, 'Sublingual', 'USA', 'Anxiety; Juvenile Idiopathic Arthritis', 'Pediatric patients 2-17 years; Adults 18-65 years', '2016-09-06', NULL, NULL, NULL),
  (705, 'sofosbuvir', NULL, 'Sublingual', 'AUS', 'Depression', 'Patients with obesity', '1992-10-05', NULL, NULL, NULL),
  (706, 'sofosbuvir', NULL, 'Subcutaneous', 'ITA', 'Cancer; Viral Infections; Plaque Psoriasis', 'Adults with moderate to severe disease; Patients with prior treatment failure', '2006-02-25', NULL, NULL, NULL),
  (707, 'sofosbuvir', NULL, 'Oral', 'FRA', 'Hypertension', 'Adults 65+ years; Patients with renal impairment', '1992-10-15', NULL, NULL, NULL),
  (708, 'ledipasvir', NULL, 'Nasal', 'DEU', 'Chronic Obstructive Pulmonary Disease; Asthma', 'Patients with obesity; Patients with comorbidities', '2002-05-28', NULL, NULL, NULL),
  (709, 'ledipasvir', NULL, 'Sublingual', 'UK', 'Bipolar Disorder; Bacterial Infections; Cancer', 'Pediatric patients 6 months-2 years', '2001-01-11', NULL, NULL, NULL),
  (710, 'ledipasvir', NULL, 'Intramuscular', 'UK', 'Depression', 'Immunocompromised patients; Patients with comorbidities', '2005-10-01', NULL, NULL, NULL),
  (711, 'ledipasvir', NULL, 'Transdermal', 'JPN', 'Depression; Bipolar Disorder; Systemic Lupus Erythematosus', 'Adults 18-65 years; Patients with renal impairment', '2009-01-03', NULL, 'Risk of liver injury', '2023-09-27'),
  (712, 'ledipasvir', NULL, 'Nasal', 'ESP', 'Heart Failure', 'Pediatric patients 6 months-2 years', '2009-05-28', NULL, 'Risk of bone loss', '2016-12-27'),
  (713, 'ledipasvir', NULL, 'Nasal', 'AUS', 'Juvenile Idiopathic Arthritis', 'Patients with comorbidities; Adults 18-65 years', '2007-08-07', NULL, NULL, NULL),
  (714, 'ledipasvir', NULL, 'Oral', 'USA', 'Psoriatic Arthritis; Multiple Sclerosis; Crohn''s Disease', 'Adults with moderate to severe disease; Pediatric patients 2-17 years', '2008-08-27', '2021-03-18', NULL, NULL),
  (715, 'ledipasvir', NULL, 'Sublingual', 'ITA', 'Juvenile Idiopathic Arthritis', 'Pediatric patients 6 months-2 years', '1997-12-04', NULL, NULL, NULL),
  (716, 'ledipasvir', NULL, 'Inhalation', 'ESP', 'Osteoporosis', 'Pediatric patients 6 months-2 years', '2004-07-03', NULL, NULL, NULL),
  (717, 'ledipasvir', NULL, 'Nasal', 'JPN', 'Schizophrenia; Hepatitis C', 'Treatment-naive patients; Adults 65+ years', '1993-05-12', NULL, NULL, NULL),
  (718, 'ledipasvir', NULL, 'Nasal', 'AUS', 'Ulcerative Colitis', 'Pregnant women', '1999-06-07', NULL, NULL, NULL),
  (719, 'ledipasvir', NULL, 'Inhalation', 'AUS', 'Heart Failure; Ankylosing Spondylitis; Chronic Obstructive Pulmonary Disease', 'Patients with comorbidities', '2007-01-13', NULL, NULL, NULL),
  (720, 'ledipasvir', NULL, 'Rectal', 'AUS', 'Multiple Sclerosis', 'Patients with renal impairment; Treatment-naive patients', '2018-02-08', NULL, NULL, NULL),
  (721, 'ledipasvir', NULL, 'Transdermal', 'AUS', 'Atrial Fibrillation; Psoriatic Arthritis', 'Pediatric patients 2-17 years', '1997-09-05', NULL, NULL, NULL),
  (722, 'ledipasvir', NULL, 'Sublingual', 'ESP', 'Hypertension; Viral Infections', 'Patients with prior treatment failure', '2000-02-02', NULL, NULL, NULL),
  (723, 'ledipasvir', NULL, 'Nasal', 'ESP', 'Viral Infections', 'Patients with comorbidities; Adults 65+ years', '1998-02-01', NULL, NULL, NULL),
  (724, 'ledipasvir', NULL, 'Sublingual', 'FRA', 'Asthma', 'Patients with prior treatment failure; Patients with obesity', '2001-12-14', NULL, NULL, NULL),
  (725, 'ledipasvir', NULL, 'Subcutaneous', 'ITA', 'Rheumatoid Arthritis; Ulcerative Colitis', 'Treatment-naive patients; Adults 65+ years', '2011-08-21', NULL, NULL, NULL),
  (726, 'ledipasvir', NULL, 'Topical', 'BRA', 'Migraine; HIV Infection', 'Adults with moderate to severe disease', '2002-10-26', '2020-10-10', NULL, NULL),
  (727, 'ledipasvir', NULL, 'Transdermal', 'USA', 'Heart Failure', 'Adults with moderate to severe disease', '2009-07-02', NULL, NULL, NULL),
  (728, 'ledipasvir', NULL, 'Nasal', 'CAN', 'Multiple Sclerosis', 'Adults 18-65 years', '2006-08-25', NULL, NULL, NULL),
  (729, 'ledipasvir', NULL, 'Topical', 'AUS', 'Ankylosing Spondylitis; Migraine', 'Adults with moderate to severe disease; Patients with renal impairment', '1995-05-16', '2022-07-14', 'Risk of peripheral neuropathy', '2020-03-24'),
  (730, 'efavirenz', NULL, 'Transdermal', 'UK', 'Asthma; Fungal Infections; Cancer', 'Adults with mild disease; Adults 18-65 years', '2007-09-02', NULL, NULL, NULL),
  (731, 'efavirenz', NULL, 'Subcutaneous', 'ITA', 'Bacterial Infections; Psoriatic Arthritis; Heart Failure', 'Pregnant women; Pediatric patients 6 months-2 years', '2012-01-22', NULL, NULL, NULL),
  (732, 'efavirenz', NULL, 'Topical', 'CAN', 'Chronic Obstructive Pulmonary Disease', 'Patients with hepatic impairment; Adults 18-65 years', '1992-04-12', NULL, NULL, NULL),
  (733, 'efavirenz', NULL, 'Subcutaneous', 'DEU', 'Pulmonary Embolism; Bacterial Infections; Heart Failure', 'Pregnant women', '1999-10-06', NULL, NULL, NULL),
  (734, 'efavirenz', NULL, 'Inhalation', 'ITA', 'Schizophrenia; Asthma', 'Patients with renal impairment; Pregnant women', '2005-12-28', NULL, 'Increased risk of malignancy', '2016-11-18'),
  (735, 'efavirenz', NULL, 'Sublingual', 'USA', 'Plaque Psoriasis; Juvenile Idiopathic Arthritis', 'Adults 65+ years', '2000-10-23', NULL, 'Risk of tuberculosis reactivation', '2024-03-07'),
  (736, 'efavirenz', NULL, 'Intravenous', 'UK', 'Ankylosing Spondylitis; Multiple Sclerosis', 'Patients with comorbidities; Adults 65+ years', '2016-01-07', NULL, NULL, NULL),
  (737, 'efavirenz', NULL, 'Inhalation', 'ESP', 'Atrial Fibrillation; Juvenile Idiopathic Arthritis', 'Patients with obesity', '2001-01-24', '2020-01-13', NULL, NULL),
  (738, 'efavirenz', NULL, 'Oral', 'FRA', 'Asthma; Migraine', 'Adults with moderate to severe disease', '1995-02-24', NULL, NULL, NULL),
  (739, 'efavirenz', NULL, 'Topical', 'CAN', 'Atrial Fibrillation; Ankylosing Spondylitis', 'Patients with hepatic impairment; Patients with renal impairment', '1997-07-14', NULL, NULL, NULL),
  (740, 'efavirenz', NULL, 'Inhalation', 'FRA', 'Viral Infections; Osteoporosis', 'Patients with hepatic impairment', '2007-12-25', NULL, NULL, NULL),
  (741, 'efavirenz', NULL, 'Intramuscular', 'FRA', 'Osteoporosis; Bacterial Infections', 'Treatment-naive patients', '2010-07-09', NULL, 'Risk of tuberculosis reactivation', '2015-04-23'),
  (742, 'efavirenz', NULL, 'Subcutaneous', 'ITA', 'HIV Infection; Multiple Sclerosis', 'Patients with hepatic impairment', '2021-12-28', '2024-05-20', 'Risk of hypersensitivity reactions', '2024-01-06'),
  (743, 'efavirenz', NULL, 'Transdermal', 'USA', 'Hypertension; Schizophrenia', 'Pediatric patients 6 months-2 years; Patients with obesity', '1992-01-10', NULL, NULL, NULL),
  (744, 'efavirenz', NULL, 'Inhalation', 'USA', 'Bipolar Disorder; Chronic Obstructive Pulmonary Disease', 'Patients with prior treatment failure; Immunocompromised patients', '2000-05-02', NULL, NULL, NULL),
  (745, 'efavirenz', NULL, 'Inhalation', 'JPN', 'Asthma; Hepatitis C', 'Patients with prior treatment failure; Adults with moderate to severe disease', '1999-06-17', NULL, NULL, NULL),
  (746, 'efavirenz', NULL, 'Inhalation', 'JPN', 'Rheumatoid Arthritis; Multiple Sclerosis', 'Adults with moderate to severe disease', '2002-05-26', NULL, NULL, NULL),
  (747, 'efavirenz', NULL, 'Transdermal', 'FRA', 'Anxiety; Juvenile Idiopathic Arthritis; Schizophrenia', 'Adults with moderate to severe disease; Immunocompromised patients', '1996-03-07', NULL, NULL, NULL),
  (748, 'tenofovir', NULL, 'Transdermal', 'DEU', 'Bacterial Infections; Ulcerative Colitis; Migraine', 'Pediatric patients 6 months-2 years', '2004-02-18', NULL, 'Risk of renal impairment', '2020-07-22'),
  (749, 'tenofovir', NULL, 'Subcutaneous', 'CAN', 'Migraine', 'Adults 18-65 years', '2020-04-13', NULL, NULL, NULL),
  (750, 'tenofovir', NULL, 'Sublingual', 'ESP', 'Schizophrenia', 'Adults with mild disease; Patients with hepatic impairment', '2015-03-28', NULL, NULL, NULL),
  (751, 'emtricitabine', NULL, 'Oral', 'AUS', 'Schizophrenia; Migraine', 'Immunocompromised patients; Patients with cardiovascular disease', '2010-11-02', NULL, NULL, NULL),
  (752, 'emtricitabine', NULL, 'Intravenous', 'USA', 'Ankylosing Spondylitis', 'Adults 65+ years; Patients with diabetes', '2020-12-21', NULL, 'Risk of blood disorders', '2015-07-25'),
  (753, 'emtricitabine', NULL, 'Intravenous', 'JPN', 'Diabetes Mellitus Type 2; Psoriatic Arthritis; Chronic Obstructive Pulmonary Disease', 'Patients with cardiovascular disease; Pregnant women', '2011-03-05', NULL, NULL, NULL),
  (754, 'emtricitabine', NULL, 'Subcutaneous', 'ESP', 'Asthma; Rheumatoid Arthritis; Diabetes Mellitus Type 2', 'Patients with renal impairment; Patients with prior treatment failure', '2018-06-04', NULL, NULL, NULL),
  (755, 'emtricitabine', NULL, 'Nasal', 'DEU', 'Plaque Psoriasis; Pulmonary Embolism; Deep Vein Thrombosis', 'Pregnant women; Patients with obesity', '1990-02-18', NULL, 'Risk of tuberculosis reactivation', '2023-12-05'),
  (756, 'emtricitabine', NULL, 'Topical', 'BRA', 'Diabetes Mellitus Type 2; Ulcerative Colitis', 'Adults 18-65 years', '1993-05-11', NULL, NULL, NULL),
  (757, 'emtricitabine', NULL, 'Topical', 'BRA', 'Anxiety', 'Pregnant women; Adults 65+ years', '2022-01-15', NULL, NULL, NULL),
  (758, 'emtricitabine', NULL, 'Intramuscular', 'JPN', 'Fungal Infections; Juvenile Idiopathic Arthritis', 'Pediatric patients 2-17 years; Treatment-naive patients', '2016-09-06', NULL, 'Risk of vision changes', '2019-12-15'),
  (759, 'abacavir', NULL, 'Inhalation', 'UK', 'Atrial Fibrillation; Fungal Infections', 'Patients with prior treatment failure', '1993-11-17', NULL, NULL, NULL),
  (760, 'abacavir', NULL, 'Rectal', 'ITA', 'Bipolar Disorder; Asthma', 'Pregnant women', '1997-09-11', NULL, NULL, NULL),
  (761, 'abacavir', NULL, 'Inhalation', 'AUS', 'Rheumatoid Arthritis; Psoriatic Arthritis; Juvenile Idiopathic Arthritis', 'Pediatric patients 2-17 years', '1997-07-20', NULL, 'Risk of serious cardiovascular events', '2017-12-28'),
  (762, 'abacavir', NULL, 'Topical', 'BRA', 'Ankylosing Spondylitis; Multiple Sclerosis', 'Patients with renal impairment; Treatment-naive patients', '2022-06-22', NULL, NULL, NULL),
  (763, 'abacavir', NULL, 'Oral', 'ITA', 'Juvenile Idiopathic Arthritis', 'Adults 18-65 years; Pediatric patients 6 months-2 years', '2019-12-02', '2020-04-20', NULL, NULL),
  (764, 'abacavir', NULL, 'Oral', 'CAN', 'Viral Infections', 'Adults 18-65 years; Patients with obesity', '2004-11-17', NULL, NULL, NULL),
  (765, 'abacavir', NULL, 'Rectal', 'AUS', 'Asthma; Atrial Fibrillation', 'Adults with moderate to severe disease; Pediatric patients 2-17 years', '2007-08-19', NULL, NULL, NULL),
  (766, 'abacavir', NULL, 'Rectal', 'DEU', 'Hepatitis C; Crohn''s Disease', 'Adults 65+ years', '2023-10-06', NULL, 'Increased risk of serious infections', '2024-10-25'),
  (767, 'abacavir', NULL, 'Inhalation', 'DEU', 'Fungal Infections; Psoriatic Arthritis; Asthma', 'Patients with prior treatment failure', '2023-02-15', NULL, 'Risk of hearing loss', '2021-06-27'),
  (768, 'abacavir', NULL, 'Transdermal', 'CAN', 'Depression; Rheumatoid Arthritis', 'Pediatric patients 2-17 years', '1995-06-22', NULL, NULL, NULL),
  (769, 'abacavir', NULL, 'Transdermal', 'FRA', 'Systemic Lupus Erythematosus', 'Adults with moderate to severe disease; Adults 18-65 years', '2016-10-20', NULL, NULL, NULL),
  (770, 'abacavir', NULL, 'Topical', 'CAN', 'Anxiety; Crohn''s Disease', 'Adults 65+ years; Patients with renal impairment', '2004-08-21', NULL, 'Risk of hypersensitivity reactions', '2024-09-10'),
  (771, 'abacavir', NULL, 'Intramuscular', 'JPN', 'Hepatitis C', 'Adults with mild disease; Adults 65+ years', '1991-07-27', NULL, NULL, NULL),
  (772, 'abacavir', NULL, 'Oral', 'DEU', 'Hepatitis C', 'Adults with moderate to severe disease; Patients with obesity', '2017-11-08', NULL, NULL, NULL),
  (773, 'abacavir', NULL, 'Topical', 'BRA', 'Migraine', 'Adults with mild disease; Adults 18-65 years', '1996-04-05', '2021-06-14', NULL, NULL),
  (774, 'abacavir', NULL, 'Intramuscular', 'FRA', 'Viral Infections; Cancer; Ankylosing Spondylitis', 'Immunocompromised patients', '2012-05-22', NULL, NULL, NULL),
  (775, 'abacavir', NULL, 'Inhalation', 'FRA', 'Ulcerative Colitis', 'Patients with obesity', '2022-01-16', NULL, 'Risk of central nervous system effects', '2015-05-14'),
  (776, 'abacavir', NULL, 'Transdermal', 'FRA', 'Ulcerative Colitis; Asthma; Viral Infections', 'Patients with diabetes', '1996-09-07', NULL, NULL, NULL),
  (777, 'abacavir', NULL, 'Topical', 'CAN', 'Psoriatic Arthritis', 'Patients with comorbidities; Treatment-naive patients', '2006-08-12', NULL, NULL, NULL),
  (778, 'abacavir', NULL, 'Sublingual', 'DEU', 'Viral Infections; Atrial Fibrillation', 'Adults with mild disease; Pediatric patients 2-17 years', '1990-03-03', NULL, NULL, NULL),
  (779, 'abacavir', NULL, 'Oral', 'BRA', 'Depression; Fungal Infections', 'Pediatric patients 6 months-2 years', '2014-12-22', NULL, 'Risk of vision changes', '2019-06-24'),
  (780, 'abacavir', NULL, 'Nasal', 'BRA', 'Deep Vein Thrombosis', 'Adults 65+ years; Patients with diabetes', '1995-10-02', NULL, NULL, NULL),
  (781, 'abacavir', NULL, 'Subcutaneous', 'ITA', 'Asthma', 'Patients with diabetes; Adults 18-65 years', '2009-09-16', '2020-08-08', NULL, NULL),
  (782, 'abacavir', NULL, 'Intramuscular', 'UK', 'Depression; Rheumatoid Arthritis; Schizophrenia', 'Patients with obesity; Pediatric patients 2-17 years', '1991-10-28', NULL, NULL, NULL),
  (783, 'abacavir', NULL, 'Intramuscular', 'UK', 'Diabetes Mellitus Type 2; Migraine', 'Patients with comorbidities', '2008-08-18', NULL, NULL, NULL),
  (784, 'abacavir', NULL, 'Nasal', 'AUS', 'Pulmonary Embolism; Bacterial Infections', 'Adults 18-65 years; Patients with prior treatment failure', '1992-06-20', NULL, NULL, NULL),
  (785, 'abacavir', NULL, 'Intravenous', 'FRA', 'Bacterial Infections; Osteoporosis', 'Adults 65+ years', '2014-04-27', NULL, NULL, NULL),
  (786, 'lamivudine', NULL, 'Inhalation', 'FRA', 'Bipolar Disorder', 'Adults with mild disease', '1994-08-02', NULL, 'Risk of tuberculosis reactivation', '2017-08-18'),
  (787, 'lamivudine', NULL, 'Subcutaneous', 'ESP', 'Atrial Fibrillation', 'Adults 65+ years; Pediatric patients 6 months-2 years', '2010-12-23', NULL, NULL, NULL),
  (788, 'lamivudine', NULL, 'Oral', 'JPN', 'Anxiety; Cancer; Bipolar Disorder', 'Pediatric patients 6 months-2 years; Patients with obesity', '1994-04-07', NULL, NULL, NULL),
  (789, 'lamivudine', NULL, 'Sublingual', 'DEU', 'Ulcerative Colitis; Osteoporosis', 'Pregnant women; Adults with mild disease', '1991-10-10', NULL, NULL, NULL),
  (790, 'lamivudine', NULL, 'Sublingual', 'FRA', 'Juvenile Idiopathic Arthritis; Depression', 'Patients with cardiovascular disease; Patients with diabetes', '1992-04-03', NULL, 'Risk of peripheral neuropathy', '2023-02-26'),
  (791, 'lamivudine', NULL, 'Subcutaneous', 'UK', 'Diabetes Mellitus Type 2; Viral Infections; Multiple Sclerosis', 'Adults 18-65 years', '1994-08-20', NULL, NULL, NULL),
  (792, 'lamivudine', NULL, 'Sublingual', 'ESP', 'HIV Infection', 'Patients with hepatic impairment', '2000-02-15', '2020-09-22', NULL, NULL),
  (793, 'lamivudine', NULL, 'Intravenous', 'CAN', 'Atrial Fibrillation; Systemic Lupus Erythematosus', 'Patients with hepatic impairment', '2005-06-25', NULL, NULL, NULL),
  (794, 'lamivudine', NULL, 'Sublingual', 'DEU', 'Migraine; Crohn''s Disease; Psoriatic Arthritis', 'Patients with comorbidities; Patients with prior treatment failure', '2014-04-10', NULL, NULL, NULL),
  (795, 'lamivudine', NULL, 'Inhalation', 'DEU', 'Ankylosing Spondylitis', 'Patients with obesity', '2020-04-03', NULL, NULL, NULL),
  (796, 'lamivudine', NULL, 'Oral', 'BRA', 'Systemic Lupus Erythematosus; Psoriatic Arthritis; Multiple Sclerosis', 'Immunocompromised patients', '1992-07-17', NULL, NULL, NULL),
  (797, 'lamivudine', NULL, 'Sublingual', 'DEU', 'Fungal Infections', 'Immunocompromised patients', '1995-10-06', NULL, NULL, NULL),
  (798, 'lamivudine', NULL, 'Intramuscular', 'UK', 'Crohn''s Disease; Systemic Lupus Erythematosus; Hepatitis C', 'Adults with mild disease; Patients with diabetes', '2023-06-25', NULL, NULL, NULL),
  (799, 'lamivudine', NULL, 'Intramuscular', 'UK', 'Migraine; Chronic Obstructive Pulmonary Disease', 'Patients with obesity', '2009-05-05', NULL, 'Risk of progressive multifocal leukoencephalopathy', '2021-06-20'),
  (800, 'lamivudine', NULL, 'Oral', 'JPN', 'Asthma; Psoriatic Arthritis; Deep Vein Thrombosis', 'Patients with comorbidities; Patients with renal impairment', '2007-03-13', NULL, NULL, NULL),
  (801, 'lamivudine', NULL, 'Inhalation', 'UK', 'Systemic Lupus Erythematosus', 'Patients with comorbidities', '1998-11-05', NULL, 'Risk of vision changes', '2020-11-09'),
  (802, 'lamivudine', NULL, 'Topical', 'JPN', 'Heart Failure', 'Patients with prior treatment failure', '1999-05-23', NULL, NULL, NULL),
  (803, 'zidovudine', NULL, 'Transdermal', 'USA', 'Juvenile Idiopathic Arthritis; Ulcerative Colitis', 'Pregnant women; Adults 65+ years', '2000-06-04', NULL, NULL, NULL),
  (804, 'zidovudine', NULL, 'Oral', 'ITA', 'Anxiety; Schizophrenia', 'Adults 65+ years; Pediatric patients 6 months-2 years', '1994-04-17', NULL, NULL, NULL),
  (805, 'zidovudine', NULL, 'Inhalation', 'ITA', 'Systemic Lupus Erythematosus; Plaque Psoriasis; Depression', 'Patients with comorbidities', '2004-01-14', '2021-10-15', 'Risk of hypersensitivity reactions', '2016-03-22'),
  (806, 'zidovudine', NULL, 'Intramuscular', 'USA', 'HIV Infection; Depression', 'Patients with obesity', '1998-03-01', NULL, NULL, NULL),
  (807, 'zidovudine', NULL, 'Sublingual', 'ESP', 'Bacterial Infections; Deep Vein Thrombosis', 'Adults 65+ years', '1997-07-13', NULL, 'Risk of renal impairment', '2015-07-26'),
  (808, 'zidovudine', NULL, 'Nasal', 'CAN', 'Viral Infections', 'Pregnant women; Treatment-naive patients', '2008-09-16', NULL, 'Risk of renal impairment', '2018-10-26'),
  (809, 'zidovudine', NULL, 'Rectal', 'ESP', 'Psoriatic Arthritis; Chronic Obstructive Pulmonary Disease; Asthma', 'Patients with cardiovascular disease', '2010-06-05', NULL, NULL, NULL),
  (810, 'zidovudine', NULL, 'Intravenous', 'AUS', 'Crohn''s Disease', 'Patients with obesity', '2004-03-10', NULL, NULL, NULL),
  (811, 'zidovudine', NULL, 'Oral', 'AUS', 'Juvenile Idiopathic Arthritis', 'Adults 65+ years', '1998-02-28', NULL, NULL, NULL),
  (812, 'zidovudine', NULL, 'Oral', 'UK', 'Psoriatic Arthritis; Heart Failure', 'Treatment-naive patients; Adults with moderate to severe disease', '2021-04-03', NULL, NULL, NULL),
  (813, 'zidovudine', NULL, 'Intravenous', 'AUS', 'Multiple Sclerosis', 'Patients with obesity', '2008-12-20', NULL, 'Risk of hepatitis B reactivation', '2019-06-13'),
  (814, 'atazanavir', NULL, 'Inhalation', 'AUS', 'Asthma; Systemic Lupus Erythematosus; Juvenile Idiopathic Arthritis', 'Patients with prior treatment failure; Pregnant women', '2015-01-04', NULL, NULL, NULL),
  (815, 'atazanavir', NULL, 'Subcutaneous', 'FRA', 'HIV Infection; Viral Infections', 'Pediatric patients 6 months-2 years; Patients with obesity', '2007-05-01', NULL, NULL, NULL),
  (816, 'atazanavir', NULL, 'Inhalation', 'JPN', 'Migraine; Asthma', 'Pregnant women', '2023-04-18', NULL, 'Risk of central nervous system effects', '2021-06-10'),
  (817, 'atazanavir', NULL, 'Rectal', 'UK', 'Heart Failure; Osteoporosis', 'Pediatric patients 2-17 years', '2023-10-21', NULL, NULL, NULL),
  (818, 'atazanavir', NULL, 'Transdermal', 'ESP', 'Crohn''s Disease; Pulmonary Embolism; Diabetes Mellitus Type 2', 'Adults 18-65 years; Patients with renal impairment', '1994-09-16', NULL, 'Risk of hepatitis B reactivation', '2023-12-25'),
  (819, 'atazanavir', NULL, 'Intramuscular', 'JPN', 'Atrial Fibrillation', 'Treatment-naive patients; Adults with mild disease', '1990-02-13', NULL, 'Risk of gastrointestinal perforation', '2017-11-03'),
  (820, 'atazanavir', NULL, 'Topical', 'BRA', 'Juvenile Idiopathic Arthritis; Heart Failure', 'Patients with comorbidities; Pediatric patients 2-17 years', '2002-02-28', NULL, NULL, NULL),
  (821, 'atazanavir', NULL, 'Intravenous', 'DEU', 'Depression; Systemic Lupus Erythematosus; Rheumatoid Arthritis', 'Patients with prior treatment failure; Treatment-naive patients', '2018-11-09', NULL, NULL, NULL),
  (822, 'atazanavir', NULL, 'Rectal', 'ESP', 'Deep Vein Thrombosis; Rheumatoid Arthritis', 'Patients with renal impairment; Adults with moderate to severe disease', '1992-03-01', NULL, NULL, NULL),
  (823, 'atazanavir', NULL, 'Intramuscular', 'ITA', 'Pulmonary Embolism; Bacterial Infections; Cancer', 'Pediatric patients 6 months-2 years', '1994-09-05', NULL, 'Risk of vision changes', '2022-02-17'),
  (824, 'atazanavir', NULL, 'Intravenous', 'FRA', 'Juvenile Idiopathic Arthritis', 'Patients with diabetes', '2009-10-14', NULL, NULL, NULL),
  (825, 'atazanavir', NULL, 'Subcutaneous', 'ITA', 'Ankylosing Spondylitis; Viral Infections; Pulmonary Embolism', 'Patients with obesity', '1998-07-21', NULL, NULL, NULL),
  (826, 'atazanavir', NULL, 'Intramuscular', 'BRA', 'Chronic Obstructive Pulmonary Disease', 'Patients with obesity', '2004-02-25', '2023-08-14', NULL, NULL),
  (827, 'atazanavir', NULL, 'Subcutaneous', 'FRA', 'Schizophrenia; Multiple Sclerosis; Psoriatic Arthritis', 'Adults 18-65 years; Adults with moderate to severe disease', '2008-01-12', NULL, NULL, NULL),
  (828, 'atazanavir', NULL, 'Intramuscular', 'UK', 'Fungal Infections; Hypertension; Psoriatic Arthritis', 'Pediatric patients 6 months-2 years', '2023-04-15', NULL, 'Increased risk of serious infections', '2016-12-01'),
  (829, 'atazanavir', NULL, 'Inhalation', 'FRA', 'Osteoporosis', 'Pregnant women', '2010-08-15', NULL, 'Risk of hearing loss', '2019-03-06'),
  (830, 'atazanavir', NULL, 'Inhalation', 'UK', 'Viral Infections', 'Adults with moderate to severe disease; Immunocompromised patients', '2017-01-22', NULL, NULL, NULL),
  (831, 'atazanavir', NULL, 'Sublingual', 'AUS', 'Asthma', 'Patients with diabetes; Pediatric patients 6 months-2 years', '2019-07-07', '2021-01-04', NULL, NULL),
  (832, 'atazanavir', NULL, 'Sublingual', 'BRA', 'Bipolar Disorder; Atrial Fibrillation; Hepatitis C', 'Pregnant women; Adults 18-65 years', '2021-03-13', NULL, NULL, NULL),
  (833, 'atazanavir', NULL, 'Rectal', 'JPN', 'Hepatitis C; Viral Infections; Pulmonary Embolism', 'Patients with cardiovascular disease', '2010-12-26', NULL, NULL, NULL),
  (834, 'atazanavir', NULL, 'Topical', 'DEU', 'Juvenile Idiopathic Arthritis; Hepatitis C', 'Pediatric patients 6 months-2 years', '2023-03-03', NULL, 'Risk of central nervous system effects', '2017-07-10'),
  (835, 'atazanavir', NULL, 'Rectal', 'JPN', 'Migraine; Multiple Sclerosis; Psoriatic Arthritis', 'Adults 65+ years; Treatment-naive patients', '2000-04-18', '2021-10-11', 'Risk of tuberculosis reactivation', '2023-04-23'),
  (836, 'atazanavir', NULL, 'Intravenous', 'ITA', 'Crohn''s Disease; Hepatitis C', 'Adults with moderate to severe disease; Patients with diabetes', '1994-08-15', NULL, NULL, NULL),
  (837, 'atazanavir', NULL, 'Oral', 'FRA', 'Bacterial Infections', 'Patients with comorbidities', '1999-01-16', NULL, NULL, NULL),
  (838, 'atazanavir', NULL, 'Intravenous', 'BRA', 'Crohn''s Disease', 'Pediatric patients 6 months-2 years; Adults with moderate to severe disease', '1990-01-01', NULL, NULL, NULL),
  (839, 'atazanavir', NULL, 'Oral', 'UK', 'Atrial Fibrillation; Crohn''s Disease; Migraine', 'Pediatric patients 2-17 years', '1991-02-25', NULL, NULL, NULL),
  (840, 'darunavir', NULL, 'Intravenous', 'JPN', 'Rheumatoid Arthritis; Migraine', 'Adults 65+ years', '2018-01-19', NULL, NULL, NULL),
  (841, 'darunavir', NULL, 'Sublingual', 'FRA', 'Deep Vein Thrombosis; Anxiety; Rheumatoid Arthritis', 'Adults 18-65 years; Patients with obesity', '2018-01-03', NULL, NULL, NULL),
  (842, 'darunavir', NULL, 'Topical', 'DEU', 'Bacterial Infections', 'Pediatric patients 6 months-2 years; Patients with prior treatment failure', '2007-01-08', NULL, NULL, NULL),
  (843, 'darunavir', NULL, 'Oral', 'USA', 'Pulmonary Embolism; Heart Failure', 'Patients with obesity; Pregnant women', '2006-08-27', NULL, NULL, NULL),
  (844, 'darunavir', NULL, 'Intravenous', 'AUS', 'Atrial Fibrillation; Chronic Obstructive Pulmonary Disease', 'Pregnant women; Patients with renal impairment', '2006-02-13', NULL, NULL, NULL),
  (845, 'darunavir', NULL, 'Subcutaneous', 'FRA', 'Hepatitis C; HIV Infection; Anxiety', 'Patients with hepatic impairment', '1996-09-26', '2024-12-23', NULL, NULL),
  (846, 'darunavir', NULL, 'Intramuscular', 'CAN', 'Rheumatoid Arthritis; Atrial Fibrillation', 'Patients with prior treatment failure; Patients with renal impairment', '2014-12-27', NULL, 'Risk of hypersensitivity reactions', '2020-11-20'),
  (847, 'darunavir', NULL, 'Nasal', 'JPN', 'Bacterial Infections; Psoriatic Arthritis; Plaque Psoriasis', 'Adults 18-65 years', '2008-04-07', NULL, NULL, NULL),
  (848, 'darunavir', NULL, 'Topical', 'USA', 'Multiple Sclerosis; Ulcerative Colitis; Heart Failure', 'Adults 18-65 years; Pregnant women', '1997-05-09', NULL, NULL, NULL),
  (849, 'darunavir', NULL, 'Transdermal', 'AUS', 'Bacterial Infections; Fungal Infections', 'Patients with hepatic impairment; Adults with moderate to severe disease', '2004-10-22', NULL, NULL, NULL),
  (850, 'lopinavir', NULL, 'Sublingual', 'ITA', 'Asthma', 'Patients with hepatic impairment', '1994-06-12', NULL, NULL, NULL),
  (851, 'lopinavir', NULL, 'Intravenous', 'FRA', 'Diabetes Mellitus Type 2', 'Treatment-naive patients; Adults 18-65 years', '2018-08-21', NULL, 'Risk of hearing loss', '2022-02-11'),
  (852, 'lopinavir', NULL, 'Transdermal', 'ITA', 'Bacterial Infections; Multiple Sclerosis', 'Patients with prior treatment failure', '1991-04-11', '2022-05-27', NULL, NULL),
  (853, 'lopinavir', NULL, 'Transdermal', 'ITA', 'Fungal Infections', 'Patients with hepatic impairment', '2020-02-01', NULL, NULL, NULL),
  (854, 'lopinavir', NULL, 'Nasal', 'ESP', 'Heart Failure; Multiple Sclerosis', 'Patients with obesity; Adults with mild disease', '2019-10-13', NULL, NULL, NULL),
  (855, 'lopinavir', NULL, 'Subcutaneous', 'AUS', 'HIV Infection; Diabetes Mellitus Type 2', 'Patients with diabetes', '2004-02-23', NULL, 'Risk of vision changes', '2015-05-27'),
  (856, 'lopinavir', NULL, 'Sublingual', 'AUS', 'Hypertension; Fungal Infections; Hepatitis C', 'Patients with renal impairment', '1990-12-17', NULL, 'Risk of hypersensitivity reactions', '2019-07-14'),
  (857, 'lopinavir', NULL, 'Topical', 'UK', 'Osteoporosis', 'Patients with renal impairment; Adults with mild disease', '2007-09-14', NULL, NULL, NULL),
  (858, 'lopinavir', NULL, 'Transdermal', 'DEU', 'Anxiety', 'Pediatric patients 2-17 years; Adults 18-65 years', '2018-08-22', NULL, 'Risk of hepatitis B reactivation', '2019-02-12'),
  (859, 'lopinavir', NULL, 'Rectal', 'BRA', 'Schizophrenia; Psoriatic Arthritis; Plaque Psoriasis', 'Adults with moderate to severe disease', '2021-03-06', NULL, NULL, NULL),
  (860, 'ritonavir', NULL, 'Sublingual', 'USA', 'Hypertension; Osteoporosis', 'Immunocompromised patients', '2011-12-28', NULL, NULL, NULL),
  (861, 'ritonavir', NULL, 'Intravenous', 'ITA', 'Anxiety; Bipolar Disorder; Chronic Obstructive Pulmonary Disease', 'Pediatric patients 6 months-2 years', '2024-10-27', NULL, NULL, NULL),
  (862, 'ritonavir', NULL, 'Subcutaneous', 'FRA', 'Ulcerative Colitis; Depression; Psoriatic Arthritis', 'Adults with moderate to severe disease; Patients with diabetes', '2000-07-27', NULL, NULL, NULL),
  (863, 'ritonavir', NULL, 'Rectal', 'UK', 'Depression; Psoriatic Arthritis', 'Pediatric patients 6 months-2 years; Treatment-naive patients', '2018-10-18', '2020-05-03', NULL, NULL),
  (864, 'ritonavir', NULL, 'Nasal', 'DEU', 'Migraine', 'Adults 18-65 years; Pediatric patients 2-17 years', '2013-11-07', NULL, NULL, NULL),
  (865, 'ritonavir', NULL, 'Inhalation', 'ESP', 'Ankylosing Spondylitis', 'Patients with diabetes; Adults 65+ years', '2018-12-09', NULL, NULL, NULL),
  (866, 'ritonavir', NULL, 'Subcutaneous', 'USA', 'Chronic Obstructive Pulmonary Disease; Rheumatoid Arthritis', 'Patients with prior treatment failure', '2015-05-18', NULL, NULL, NULL),
  (867, 'ritonavir', NULL, 'Oral', 'AUS', 'Ulcerative Colitis', 'Adults with moderate to severe disease', '1995-10-02', NULL, 'Risk of bone loss', '2020-11-23'),
  (868, 'ritonavir', NULL, 'Rectal', 'BRA', 'Bipolar Disorder; Psoriatic Arthritis', 'Patients with comorbidities; Patients with cardiovascular disease', '2010-08-08', NULL, 'Risk of serious cardiovascular events', '2015-09-19'),
  (869, 'ritonavir', NULL, 'Nasal', 'CAN', 'Osteoporosis', 'Pregnant women; Patients with prior treatment failure', '1993-01-25', NULL, NULL, NULL),
  (870, 'ritonavir', NULL, 'Transdermal', 'JPN', 'Asthma', 'Treatment-naive patients; Patients with obesity', '1990-12-21', NULL, NULL, NULL),
  (871, 'ritonavir', NULL, 'Nasal', 'ESP', 'Rheumatoid Arthritis; Heart Failure', 'Adults with moderate to severe disease; Adults with mild disease', '1999-05-25', NULL, NULL, NULL),
  (872, 'ritonavir', NULL, 'Rectal', 'ITA', 'Schizophrenia; Rheumatoid Arthritis; Cancer', 'Patients with comorbidities', '1991-09-16', NULL, NULL, NULL),
  (873, 'ritonavir', NULL, 'Inhalation', 'ESP', 'Diabetes Mellitus Type 2; Pulmonary Embolism', 'Patients with renal impairment; Pediatric patients 6 months-2 years', '2013-02-20', NULL, NULL, NULL),
  (874, 'ritonavir', NULL, 'Oral', 'ESP', 'Asthma', 'Pregnant women; Pediatric patients 6 months-2 years', '2020-06-10', NULL, 'Increased risk of malignancy', '2021-05-14'),
  (875, 'ritonavir', NULL, 'Oral', 'FRA', 'Systemic Lupus Erythematosus', 'Patients with renal impairment; Adults 65+ years', '1992-10-04', NULL, 'Risk of vision changes', '2015-12-27'),
  (876, 'ritonavir', NULL, 'Nasal', 'UK', 'Depression', 'Adults 18-65 years', '2017-12-09', NULL, 'Risk of renal impairment', '2018-12-20'),
  (877, 'ritonavir', NULL, 'Inhalation', 'JPN', 'Bipolar Disorder; Heart Failure', 'Patients with cardiovascular disease; Immunocompromised patients', '2013-09-13', NULL, 'Risk of serious cardiovascular events', '2024-04-22'),
  (878, 'ritonavir', NULL, 'Rectal', 'BRA', 'Hypertension', 'Adults 18-65 years; Immunocompromised patients', '2023-12-01', NULL, NULL, NULL),
  (879, 'ritonavir', NULL, 'Topical', 'AUS', 'Schizophrenia', 'Pregnant women', '2020-06-09', NULL, NULL, NULL),
  (880, 'ritonavir', NULL, 'Subcutaneous', 'CAN', 'Hypertension; Chronic Obstructive Pulmonary Disease', 'Adults with moderate to severe disease', '2023-08-21', NULL, NULL, NULL),
  (881, 'ritonavir', NULL, 'Transdermal', 'CAN', 'Ankylosing Spondylitis; Viral Infections', 'Adults with mild disease; Pediatric patients 6 months-2 years', '2011-04-04', NULL, 'Risk of vision changes', '2021-11-17'),
  (882, 'ritonavir', NULL, 'Transdermal', 'FRA', 'Juvenile Idiopathic Arthritis; Fungal Infections; Schizophrenia', 'Pediatric patients 6 months-2 years', '2015-02-28', NULL, NULL, NULL),
  (883, 'ritonavir', NULL, 'Intravenous', 'BRA', 'Psoriatic Arthritis; Rheumatoid Arthritis; Bacterial Infections', 'Adults 65+ years; Pediatric patients 6 months-2 years', '2023-10-10', NULL, NULL, NULL),
  (884, 'ritonavir', NULL, 'Nasal', 'USA', 'Rheumatoid Arthritis; Fungal Infections; Heart Failure', 'Adults 65+ years; Adults 18-65 years', '2024-08-15', NULL, NULL, NULL),
  (885, 'raltegravir', NULL, 'Transdermal', 'DEU', 'Rheumatoid Arthritis', 'Treatment-naive patients', '1999-10-25', NULL, NULL, NULL),
  (886, 'raltegravir', NULL, 'Subcutaneous', 'DEU', 'Juvenile Idiopathic Arthritis; Migraine', 'Adults 18-65 years; Treatment-naive patients', '2001-05-16', NULL, 'Risk of hypersensitivity reactions', '2018-06-18'),
  (887, 'raltegravir', NULL, 'Transdermal', 'ITA', 'Fungal Infections; Psoriatic Arthritis', 'Adults 65+ years', '1993-10-12', NULL, 'Risk of hearing loss', '2023-04-20'),
  (888, 'raltegravir', NULL, 'Transdermal', 'ITA', 'Crohn''s Disease; Ulcerative Colitis; Asthma', 'Patients with obesity', '2009-04-25', NULL, 'Risk of gastrointestinal perforation', '2021-05-21'),
  (889, 'raltegravir', NULL, 'Intravenous', 'AUS', 'Heart Failure', 'Patients with comorbidities', '2006-07-13', NULL, NULL, NULL),
  (890, 'raltegravir', NULL, 'Subcutaneous', 'CAN', 'Cancer', 'Treatment-naive patients; Patients with renal impairment', '2022-05-04', NULL, NULL, NULL),
  (891, 'raltegravir', NULL, 'Subcutaneous', 'DEU', 'Hepatitis C; Crohn''s Disease', 'Adults 18-65 years', '2010-09-13', NULL, NULL, NULL),
  (892, 'dolutegravir', NULL, 'Subcutaneous', 'CAN', 'Multiple Sclerosis; Anxiety; Plaque Psoriasis', 'Patients with obesity; Adults with mild disease', '1999-06-04', NULL, NULL, NULL),
  (893, 'dolutegravir', NULL, 'Oral', 'BRA', 'Viral Infections; Plaque Psoriasis', 'Patients with renal impairment; Patients with comorbidities', '2013-10-10', NULL, NULL, NULL),
  (894, 'dolutegravir', NULL, 'Topical', 'USA', 'Hypertension; Osteoporosis', 'Pregnant women', '2021-07-07', NULL, 'Risk of renal impairment', '2018-05-02'),
  (895, 'dolutegravir', NULL, 'Nasal', 'AUS', 'Hepatitis C; Diabetes Mellitus Type 2', 'Patients with prior treatment failure; Adults 18-65 years', '2017-09-12', NULL, NULL, NULL),
  (896, 'dolutegravir', NULL, 'Intramuscular', 'FRA', 'Viral Infections; Diabetes Mellitus Type 2; Cancer', 'Patients with hepatic impairment; Treatment-naive patients', '2010-08-11', NULL, NULL, NULL),
  (897, 'dolutegravir', NULL, 'Oral', 'UK', 'Asthma; Crohn''s Disease', 'Pediatric patients 6 months-2 years', '2011-12-12', NULL, NULL, NULL),
  (898, 'dolutegravir', NULL, 'Topical', 'BRA', 'Deep Vein Thrombosis; Juvenile Idiopathic Arthritis', 'Adults with mild disease; Adults 18-65 years', '1994-03-23', NULL, NULL, NULL),
  (899, 'dolutegravir', NULL, 'Topical', 'ESP', 'Hypertension', 'Patients with cardiovascular disease', '2023-05-05', '2022-06-06', 'Risk of blood disorders', '2018-11-04'),
  (900, 'dolutegravir', NULL, 'Transdermal', 'BRA', 'HIV Infection; Depression; Deep Vein Thrombosis', 'Treatment-naive patients', '1999-10-12', NULL, NULL, NULL),
  (901, 'dolutegravir', NULL, 'Inhalation', 'DEU', 'Osteoporosis; Ulcerative Colitis; Fungal Infections', 'Patients with comorbidities', '2006-07-26', NULL, NULL, NULL),
  (902, 'dolutegravir', NULL, 'Sublingual', 'DEU', 'Pulmonary Embolism', 'Patients with renal impairment; Immunocompromised patients', '2012-11-24', NULL, NULL, NULL),
  (903, 'dolutegravir', NULL, 'Transdermal', 'UK', 'Ankylosing Spondylitis; Depression; Hepatitis C', 'Patients with hepatic impairment', '2017-01-15', NULL, NULL, NULL),
  (904, 'dolutegravir', NULL, 'Oral', 'UK', 'Systemic Lupus Erythematosus; Hypertension', 'Pregnant women; Patients with comorbidities', '1993-08-07', NULL, NULL, NULL),
  (905, 'dolutegravir', NULL, 'Intramuscular', 'ESP', 'Psoriatic Arthritis', 'Patients with comorbidities', '2005-02-10', NULL, NULL, NULL),
  (906, 'dolutegravir', NULL, 'Topical', 'JPN', 'Bacterial Infections; Viral Infections; Systemic Lupus Erythematosus', 'Patients with comorbidities', '1997-02-19', NULL, 'Increased risk of malignancy', '2016-11-22'),
  (907, 'dolutegravir', NULL, 'Rectal', 'JPN', 'Multiple Sclerosis', 'Patients with obesity', '2021-12-14', '2022-05-16', NULL, NULL),
  (908, 'dolutegravir', NULL, 'Oral', 'JPN', 'Depression; Heart Failure; Psoriatic Arthritis', 'Immunocompromised patients; Adults 18-65 years', '2008-08-05', NULL, 'Risk of liver injury', '2015-12-19'),
  (909, 'dolutegravir', NULL, 'Sublingual', 'DEU', 'Multiple Sclerosis', 'Patients with cardiovascular disease; Patients with hepatic impairment', '1998-09-28', NULL, 'Risk of liver injury', '2017-06-15'),
  (910, 'dolutegravir', NULL, 'Sublingual', 'ESP', 'Depression; Plaque Psoriasis; Osteoporosis', 'Treatment-naive patients', '1997-11-07', NULL, 'Risk of central nervous system effects', '2020-01-01'),
  (911, 'dolutegravir', NULL, 'Sublingual', 'DEU', 'Hypertension', 'Adults 18-65 years; Adults 65+ years', '1994-04-23', NULL, NULL, NULL),
  (912, 'dolutegravir', NULL, 'Nasal', 'JPN', 'Atrial Fibrillation', 'Patients with prior treatment failure', '2007-12-20', '2020-02-17', NULL, NULL),
  (913, 'elvitegravir', NULL, 'Subcutaneous', 'USA', 'Depression; Heart Failure; Hypertension', 'Patients with comorbidities', '2023-05-28', NULL, 'Risk of hearing loss', '2015-03-16'),
  (914, 'elvitegravir', NULL, 'Rectal', 'AUS', 'Depression; Psoriatic Arthritis', 'Adults 65+ years; Patients with diabetes', '1995-04-12', NULL, NULL, NULL),
  (915, 'elvitegravir', NULL, 'Nasal', 'CAN', 'Asthma', 'Pediatric patients 6 months-2 years', '2018-06-09', '2024-06-14', NULL, NULL),
  (916, 'elvitegravir', NULL, 'Nasal', 'ESP', 'Fungal Infections; Heart Failure', 'Patients with renal impairment', '2016-02-02', NULL, NULL, NULL),
  (917, 'elvitegravir', NULL, 'Nasal', 'CAN', 'Heart Failure; Bipolar Disorder; HIV Infection', 'Pediatric patients 2-17 years; Patients with cardiovascular disease', '1991-01-14', NULL, NULL, NULL),
  (918, 'elvitegravir', NULL, 'Transdermal', 'AUS', 'Chronic Obstructive Pulmonary Disease', 'Immunocompromised patients; Adults with mild disease', '2019-04-18', NULL, NULL, NULL),
  (919, 'elvitegravir', NULL, 'Intravenous', 'AUS', 'Diabetes Mellitus Type 2; Pulmonary Embolism', 'Pediatric patients 6 months-2 years', '1992-09-11', NULL, NULL, NULL),
  (920, 'elvitegravir', NULL, 'Subcutaneous', 'CAN', 'Juvenile Idiopathic Arthritis; HIV Infection; Atrial Fibrillation', 'Patients with comorbidities', '2005-03-26', NULL, NULL, NULL),
  (921, 'elvitegravir', NULL, 'Sublingual', 'AUS', 'Osteoporosis; Heart Failure; Atrial Fibrillation', 'Patients with renal impairment', '2019-01-02', NULL, 'Risk of renal impairment', '2017-11-06'),
  (922, 'elvitegravir', NULL, 'Transdermal', 'ITA', 'Psoriatic Arthritis', 'Pediatric patients 2-17 years', '2006-01-15', NULL, NULL, NULL),
  (923, 'elvitegravir', NULL, 'Transdermal', 'UK', 'Hypertension; Pulmonary Embolism', 'Adults 18-65 years', '2017-03-03', NULL, 'Risk of blood disorders', '2020-07-16'),
  (924, 'elvitegravir', NULL, 'Intravenous', 'JPN', 'Heart Failure; Osteoporosis', 'Patients with diabetes; Patients with renal impairment', '2006-06-14', '2024-11-11', NULL, NULL),
  (925, 'elvitegravir', NULL, 'Inhalation', 'USA', 'Cancer; Ulcerative Colitis; Anxiety', 'Patients with obesity', '1991-05-18', NULL, 'Risk of hepatitis B reactivation', '2016-11-07'),
  (926, 'elvitegravir', NULL, 'Rectal', 'DEU', 'HIV Infection; Ulcerative Colitis', 'Patients with renal impairment; Patients with hepatic impairment', '1994-08-09', NULL, NULL, NULL),
  (927, 'elvitegravir', NULL, 'Sublingual', 'USA', 'Migraine; Deep Vein Thrombosis', 'Patients with cardiovascular disease', '2020-12-16', NULL, NULL, NULL),
  (928, 'elvitegravir', NULL, 'Transdermal', 'DEU', 'Plaque Psoriasis', 'Patients with prior treatment failure', '1991-09-26', NULL, NULL, NULL),
  (929, 'elvitegravir', NULL, 'Subcutaneous', 'BRA', 'Pulmonary Embolism; HIV Infection; Multiple Sclerosis', 'Pregnant women; Patients with diabetes', '2014-07-16', NULL, NULL, NULL),
  (930, 'elvitegravir', NULL, 'Intramuscular', 'ITA', 'Osteoporosis; Juvenile Idiopathic Arthritis', 'Pregnant women', '2006-07-06', NULL, NULL, NULL),
  (931, 'elvitegravir', NULL, 'Sublingual', 'USA', 'Hepatitis C', 'Adults with mild disease; Patients with renal impairment', '2004-04-09', NULL, 'Risk of hearing loss', '2016-07-12'),
  (932, 'elvitegravir', NULL, 'Subcutaneous', 'ESP', 'Chronic Obstructive Pulmonary Disease', 'Adults with mild disease', '2022-12-14', NULL, 'Risk of central nervous system effects', '2020-03-06'),
  (933, 'elvitegravir', NULL, 'Intramuscular', 'BRA', 'Psoriatic Arthritis; Heart Failure', 'Pregnant women', '2015-10-18', NULL, NULL, NULL),
  (934, 'elvitegravir', NULL, 'Topical', 'DEU', 'Osteoporosis', 'Patients with cardiovascular disease; Patients with obesity', '1995-11-18', NULL, 'Increased risk of serious infections', '2022-03-23'),
  (935, 'elvitegravir', NULL, 'Oral', 'BRA', 'Asthma; Depression', 'Pediatric patients 6 months-2 years', '2022-12-23', NULL, 'Increased risk of malignancy', '2024-08-11'),
  (936, 'elvitegravir', NULL, 'Nasal', 'ESP', 'Chronic Obstructive Pulmonary Disease', 'Pediatric patients 6 months-2 years; Patients with hepatic impairment', '2009-07-21', NULL, 'Risk of tuberculosis reactivation', '2015-11-07'),
  (937, 'elvitegravir', NULL, 'Sublingual', 'AUS', 'Ulcerative Colitis; Multiple Sclerosis', 'Adults with moderate to severe disease', '1994-12-25', NULL, NULL, NULL),
  (938, 'elvitegravir', NULL, 'Sublingual', 'FRA', 'Plaque Psoriasis; Bacterial Infections', 'Pediatric patients 2-17 years; Pediatric patients 6 months-2 years', '1990-07-26', NULL, NULL, NULL),
  (939, 'maraviroc', NULL, 'Inhalation', 'FRA', 'Rheumatoid Arthritis; Asthma', 'Patients with prior treatment failure', '1996-11-01', NULL, NULL, NULL),
  (940, 'maraviroc', NULL, 'Intravenous', 'DEU', 'Diabetes Mellitus Type 2', 'Patients with comorbidities; Adults 65+ years', '2010-01-16', NULL, NULL, NULL),
  (941, 'maraviroc', NULL, 'Oral', 'AUS', 'Juvenile Idiopathic Arthritis', 'Adults 65+ years', '2006-12-22', NULL, 'Risk of progressive multifocal leukoencephalopathy', '2023-03-05'),
  (942, 'maraviroc', NULL, 'Oral', 'USA', 'Psoriatic Arthritis; Migraine', 'Adults 65+ years; Adults 18-65 years', '2010-03-27', NULL, 'Risk of progressive multifocal leukoencephalopathy', '2016-05-04'),
  (943, 'maraviroc', NULL, 'Rectal', 'ESP', 'Migraine', 'Adults 18-65 years', '2005-09-17', NULL, NULL, NULL),
  (944, 'maraviroc', NULL, 'Topical', 'ITA', 'Asthma; Fungal Infections', 'Patients with prior treatment failure; Patients with diabetes', '2007-10-11', NULL, NULL, NULL),
  (945, 'maraviroc', NULL, 'Intramuscular', 'JPN', 'Crohn''s Disease; Atrial Fibrillation', 'Adults with mild disease; Patients with comorbidities', '2005-02-04', NULL, NULL, NULL),
  (946, 'maraviroc', NULL, 'Inhalation', 'UK', 'Fungal Infections; Bacterial Infections', 'Patients with comorbidities', '1998-09-11', NULL, NULL, NULL),
  (947, 'maraviroc', NULL, 'Inhalation', 'AUS', 'Heart Failure; Psoriatic Arthritis', 'Patients with obesity', '2019-12-12', NULL, NULL, NULL),
  (948, 'maraviroc', NULL, 'Transdermal', 'ITA', 'Atrial Fibrillation; Schizophrenia; Bipolar Disorder', 'Patients with diabetes; Patients with hepatic impairment', '1994-02-05', NULL, 'Risk of bone loss', '2021-04-16'),
  (949, 'maraviroc', NULL, 'Topical', 'BRA', 'Hypertension; Cancer', 'Patients with cardiovascular disease', '1992-04-26', NULL, NULL, NULL),
  (950, 'maraviroc', NULL, 'Sublingual', 'AUS', 'Bipolar Disorder; Diabetes Mellitus Type 2', 'Adults with moderate to severe disease', '2000-11-24', NULL, NULL, NULL),
  (951, 'enfuvirtide', NULL, 'Rectal', 'JPN', 'Bipolar Disorder; Viral Infections; HIV Infection', 'Patients with comorbidities; Pregnant women', '2017-12-16', NULL, 'Risk of vision changes', '2016-06-09'),
  (952, 'enfuvirtide', NULL, 'Subcutaneous', 'UK', 'Migraine', 'Pediatric patients 2-17 years; Adults 18-65 years', '2008-11-26', NULL, NULL, NULL),
  (953, 'enfuvirtide', NULL, 'Rectal', 'UK', 'Heart Failure; Chronic Obstructive Pulmonary Disease', 'Pediatric patients 6 months-2 years; Adults with moderate to severe disease', '2006-09-27', NULL, NULL, NULL),
  (954, 'ribavirin', NULL, 'Nasal', 'ESP', 'Deep Vein Thrombosis', 'Adults with mild disease; Pregnant women', '2018-04-10', NULL, NULL, NULL),
  (955, 'ribavirin', NULL, 'Intramuscular', 'BRA', 'Heart Failure; Rheumatoid Arthritis; Psoriatic Arthritis', 'Patients with comorbidities; Pediatric patients 2-17 years', '2001-07-05', NULL, NULL, NULL),
  (956, 'ribavirin', NULL, 'Nasal', 'DEU', 'Hypertension; Diabetes Mellitus Type 2', 'Patients with prior treatment failure; Pediatric patients 2-17 years', '2024-11-15', NULL, NULL, NULL),
  (957, 'ribavirin', NULL, 'Nasal', 'DEU', 'Viral Infections; HIV Infection; Deep Vein Thrombosis', 'Pediatric patients 6 months-2 years', '2010-04-28', NULL, NULL, NULL),
  (958, 'ribavirin', NULL, 'Inhalation', 'USA', 'Juvenile Idiopathic Arthritis; Plaque Psoriasis; Crohn''s Disease', 'Pediatric patients 6 months-2 years', '1998-04-24', NULL, NULL, NULL),
  (959, 'ribavirin', NULL, 'Transdermal', 'BRA', 'Hypertension; Atrial Fibrillation', 'Adults with moderate to severe disease; Treatment-naive patients', '1992-11-19', NULL, NULL, NULL),
  (960, 'ribavirin', NULL, 'Intravenous', 'UK', 'Systemic Lupus Erythematosus', 'Immunocompromised patients; Adults 18-65 years', '2006-12-13', NULL, 'Risk of blood disorders', '2024-10-22'),
  (961, 'ribavirin', NULL, 'Oral', 'USA', 'Bacterial Infections', 'Adults 65+ years', '2021-10-10', NULL, 'Risk of central nervous system effects', '2019-11-24'),
  (962, 'ribavirin', NULL, 'Intramuscular', 'ITA', 'Systemic Lupus Erythematosus; Atrial Fibrillation; Viral Infections', 'Treatment-naive patients', '2011-12-03', NULL, NULL, NULL),
  (963, 'ribavirin', NULL, 'Intravenous', 'ESP', 'Pulmonary Embolism; Chronic Obstructive Pulmonary Disease; Fungal Infections', 'Patients with cardiovascular disease; Pregnant women', '2017-06-09', NULL, NULL, NULL),
  (964, 'ribavirin', NULL, 'Oral', 'USA', 'Systemic Lupus Erythematosus', 'Patients with comorbidities', '1996-10-09', '2021-03-12', NULL, NULL),
  (965, 'ribavirin', NULL, 'Intramuscular', 'UK', 'Asthma', 'Pregnant women; Adults 65+ years', '2022-02-17', NULL, NULL, NULL),
  (966, 'ribavirin', NULL, 'Nasal', 'DEU', 'Bacterial Infections; Psoriatic Arthritis', 'Patients with renal impairment', '1999-02-07', NULL, NULL, NULL),
  (967, 'ribavirin', NULL, 'Topical', 'BRA', 'Atrial Fibrillation', 'Immunocompromised patients', '2005-11-15', NULL, NULL, NULL),
  (968, 'ribavirin', NULL, 'Rectal', 'BRA', 'Cancer; Psoriatic Arthritis', 'Patients with cardiovascular disease', '1990-03-16', NULL, 'Risk of serious cardiovascular events', '2015-09-23'),
  (969, 'ribavirin', NULL, 'Oral', 'CAN', 'Fungal Infections; Bacterial Infections; Hypertension', 'Patients with renal impairment; Adults with moderate to severe disease', '2008-05-24', NULL, NULL, NULL),
  (970, 'remdesivir', NULL, 'Nasal', 'CAN', 'Hepatitis C', 'Patients with comorbidities', '2023-06-24', NULL, NULL, NULL),
  (971, 'remdesivir', NULL, 'Rectal', 'USA', 'Psoriatic Arthritis; Atrial Fibrillation; Depression', 'Patients with hepatic impairment', '2020-01-11', NULL, NULL, NULL),
  (972, 'remdesivir', NULL, 'Transdermal', 'BRA', 'Depression; Hypertension', 'Pregnant women', '2000-01-25', NULL, 'Increased risk of malignancy', '2017-07-02'),
  (973, 'remdesivir', NULL, 'Intravenous', 'ESP', 'Pulmonary Embolism; Osteoporosis; Bipolar Disorder', 'Adults 65+ years; Immunocompromised patients', '2009-09-13', NULL, 'Risk of anaphylaxis', '2015-05-20'),
  (974, 'remdesivir', NULL, 'Intravenous', 'BRA', 'Osteoporosis', 'Adults with moderate to severe disease', '2004-07-27', NULL, NULL, NULL),
  (975, 'remdesivir', NULL, 'Subcutaneous', 'JPN', 'Viral Infections; Pulmonary Embolism', 'Pediatric patients 2-17 years; Pregnant women', '1994-03-03', NULL, 'Risk of gastrointestinal perforation', '2022-01-11'),
  (976, 'remdesivir', NULL, 'Intramuscular', 'ITA', 'Heart Failure', 'Pediatric patients 6 months-2 years', '2016-12-13', NULL, NULL, NULL),
  (977, 'remdesivir', NULL, 'Transdermal', 'ITA', 'Fungal Infections', 'Treatment-naive patients; Adults 18-65 years', '2023-11-14', '2023-05-28', 'Risk of hearing loss', '2019-03-17'),
  (978, 'remdesivir', NULL, 'Subcutaneous', 'DEU', 'Heart Failure; Atrial Fibrillation', 'Pediatric patients 2-17 years; Pregnant women', '2003-10-10', NULL, NULL, NULL),
  (979, 'remdesivir', NULL, 'Inhalation', 'ITA', 'Ankylosing Spondylitis', 'Pediatric patients 6 months-2 years', '2017-02-28', NULL, NULL, NULL),
  (980, 'favipiravir', NULL, 'Transdermal', 'DEU', 'Viral Infections', 'Patients with hepatic impairment; Adults 65+ years', '2001-09-03', NULL, NULL, NULL),
  (981, 'favipiravir', NULL, 'Inhalation', 'USA', 'Migraine', 'Patients with diabetes', '1998-05-23', NULL, 'Increased risk of malignancy', '2024-12-11'),
  (982, 'favipiravir', NULL, 'Inhalation', 'AUS', 'Chronic Obstructive Pulmonary Disease; Anxiety; Plaque Psoriasis', 'Pediatric patients 6 months-2 years; Patients with obesity', '2013-05-14', '2020-01-04', NULL, NULL),
  (983, 'favipiravir', NULL, 'Sublingual', 'DEU', 'Rheumatoid Arthritis', 'Patients with cardiovascular disease', '2006-08-12', NULL, 'Risk of central nervous system effects', '2022-07-19'),
  (984, 'favipiravir', NULL, 'Intravenous', 'USA', 'Fungal Infections; Asthma; Psoriatic Arthritis', 'Patients with obesity', '1990-04-06', NULL, NULL, NULL),
  (985, 'favipiravir', NULL, 'Intramuscular', 'CAN', 'Ulcerative Colitis; Fungal Infections; Schizophrenia', 'Patients with obesity', '2007-09-20', NULL, NULL, NULL),
  (986, 'favipiravir', NULL, 'Intravenous', 'FRA', 'Osteoporosis; Bacterial Infections; Anxiety', 'Pregnant women', '1994-11-03', NULL, NULL, NULL),
  (987, 'favipiravir', NULL, 'Rectal', 'DEU', 'Anxiety', 'Pediatric patients 6 months-2 years; Patients with comorbidities', '2008-03-10', NULL, NULL, NULL),
  (988, 'favipiravir', NULL, 'Inhalation', 'FRA', 'Bipolar Disorder; Hepatitis C; Osteoporosis', 'Pediatric patients 2-17 years; Adults with moderate to severe disease', '2005-06-24', NULL, NULL, NULL),
  (989, 'favipiravir', NULL, 'Transdermal', 'UK', 'Bacterial Infections; Bipolar Disorder', 'Adults with mild disease', '1995-02-14', '2020-09-13', NULL, NULL),
  (990, 'favipiravir', NULL, 'Topical', 'UK', 'Multiple Sclerosis; Ulcerative Colitis', 'Immunocompromised patients; Pediatric patients 6 months-2 years', '2010-01-15', NULL, NULL, NULL),
  (991, 'favipiravir', NULL, 'Transdermal', 'ITA', 'Crohn''s Disease; Bipolar Disorder', 'Patients with comorbidities; Adults with mild disease', '1991-09-14', NULL, NULL, NULL),
  (992, 'favipiravir', NULL, 'Oral', 'AUS', 'Ankylosing Spondylitis', 'Patients with prior treatment failure; Pediatric patients 2-17 years', '2021-02-20', NULL, 'Risk of vision changes', '2015-07-15'),
  (993, 'favipiravir', NULL, 'Oral', 'AUS', 'Schizophrenia', 'Patients with cardiovascular disease; Patients with renal impairment', '2004-12-02', NULL, 'Risk of hypersensitivity reactions', '2015-10-03'),
  (994, 'favipiravir', NULL, 'Transdermal', 'FRA', 'Osteoporosis', 'Adults 65+ years; Patients with hepatic impairment', '2016-12-04', NULL, NULL, NULL),
  (995, 'favipiravir', NULL, 'Intravenous', 'FRA', 'Asthma', 'Adults with moderate to severe disease', '2010-03-06', NULL, 'Risk of liver injury', '2018-01-18'),
  (996, 'favipiravir', NULL, 'Subcutaneous', 'DEU', 'Systemic Lupus Erythematosus; HIV Infection', 'Patients with prior treatment failure', '2006-07-02', '2024-08-13', NULL, NULL),
  (997, 'favipiravir', NULL, 'Intravenous', 'ITA', 'Anxiety', 'Patients with prior treatment failure', '1996-08-18', NULL, NULL, NULL),
  (998, 'favipiravir', NULL, 'Oral', 'ESP', 'Systemic Lupus Erythematosus; Hypertension; Bacterial Infections', 'Adults 18-65 years', '2012-05-08', NULL, NULL, NULL),
  (999, 'favipiravir', NULL, 'Intravenous', 'ITA', 'Depression', 'Patients with prior treatment failure; Pediatric patients 2-17 years', '2018-11-08', NULL, 'Risk of vision changes', '2019-07-19'),
  (1000, 'favipiravir', NULL, 'Subcutaneous', 'DEU', 'Bipolar Disorder', 'Adults 18-65 years', '2001-09-01', NULL, 'Risk of gastrointestinal perforation', '2016-06-01'),
  (1001, 'favipiravir', NULL, 'Transdermal', 'BRA', 'Diabetes Mellitus Type 2; Atrial Fibrillation', 'Patients with hepatic impairment', '2001-08-15', NULL, 'Risk of serious cardiovascular events', '2017-01-10'),
  (1002, 'hydrocortisone', NULL, 'Subcutaneous', 'DEU', 'Hepatitis C; Ankylosing Spondylitis; Diabetes Mellitus Type 2', 'Pediatric patients 6 months-2 years', '2005-11-06', NULL, NULL, NULL),
  (1003, 'hydrocortisone', NULL, 'Rectal', 'USA', 'Deep Vein Thrombosis; Bacterial Infections; Asthma', 'Patients with hepatic impairment', '1990-12-11', NULL, 'Risk of hypersensitivity reactions', '2017-11-23'),
  (1004, 'hydrocortisone', NULL, 'Intramuscular', 'UK', 'Osteoporosis; Depression; Multiple Sclerosis', 'Immunocompromised patients', '2016-03-06', NULL, NULL, NULL),
  (1005, 'hydrocortisone', NULL, 'Intravenous', 'AUS', 'HIV Infection', 'Treatment-naive patients', '2022-08-20', NULL, NULL, NULL),
  (1006, 'hydrocortisone', NULL, 'Sublingual', 'USA', 'Psoriatic Arthritis; Multiple Sclerosis', 'Immunocompromised patients', '2021-12-28', NULL, 'Risk of tuberculosis reactivation', '2019-07-07'),
  (1007, 'hydrocortisone', NULL, 'Subcutaneous', 'AUS', 'Psoriatic Arthritis', 'Pediatric patients 2-17 years', '2021-02-13', NULL, NULL, NULL),
  (1008, 'hydrocortisone', NULL, 'Subcutaneous', 'ITA', 'Deep Vein Thrombosis; Fungal Infections', 'Patients with diabetes', '2021-08-17', NULL, 'Risk of anaphylaxis', '2016-02-13'),
  (1009, 'hydrocortisone', NULL, 'Oral', 'FRA', 'Cancer', 'Immunocompromised patients', '2022-11-06', NULL, NULL, NULL),
  (1010, 'hydrocortisone', NULL, 'Subcutaneous', 'DEU', 'Heart Failure; Anxiety', 'Adults with moderate to severe disease; Adults with mild disease', '2009-01-20', NULL, NULL, NULL),
  (1011, 'hydrocortisone', NULL, 'Rectal', 'BRA', 'HIV Infection', 'Immunocompromised patients', '2017-10-07', '2024-02-27', NULL, NULL),
  (1012, 'hydrocortisone', NULL, 'Nasal', 'ITA', 'Depression', 'Patients with renal impairment', '2011-11-08', NULL, NULL, NULL),
  (1013, 'hydrocortisone', NULL, 'Topical', 'ITA', 'Psoriatic Arthritis; Ankylosing Spondylitis; Hepatitis C', 'Patients with comorbidities', '2002-03-18', NULL, NULL, NULL),
  (1014, 'hydrocortisone', NULL, 'Intravenous', 'JPN', 'Depression', 'Patients with hepatic impairment', '2003-02-25', NULL, 'Risk of gastrointestinal perforation', '2017-10-05'),
  (1015, 'hydrocortisone', NULL, 'Inhalation', 'USA', 'Viral Infections; Schizophrenia', 'Patients with renal impairment', '2008-11-20', NULL, NULL, NULL),
  (1016, 'hydrocortisone', NULL, 'Nasal', 'UK', 'Plaque Psoriasis; Crohn''s Disease', 'Adults 18-65 years; Adults with moderate to severe disease', '2024-02-05', NULL, NULL, NULL),
  (1017, 'hydrocortisone', NULL, 'Intramuscular', 'ESP', 'Psoriatic Arthritis', 'Patients with cardiovascular disease', '2006-03-17', NULL, NULL, NULL),
  (1018, 'hydrocortisone', NULL, 'Subcutaneous', 'DEU', 'Depression', 'Adults with moderate to severe disease; Patients with renal impairment', '1992-12-25', NULL, NULL, NULL),
  (1019, 'hydrocortisone', NULL, 'Intramuscular', 'ESP', 'Ulcerative Colitis', 'Immunocompromised patients', '2019-10-14', NULL, NULL, NULL),
  (1020, 'hydrocortisone', NULL, 'Intramuscular', 'UK', 'Hypertension; Psoriatic Arthritis', 'Adults with moderate to severe disease', '2001-06-13', NULL, NULL, NULL),
  (1021, 'hydrocortisone', NULL, 'Intramuscular', 'UK', 'Schizophrenia; Asthma', 'Patients with cardiovascular disease', '1995-01-09', NULL, 'Risk of progressive multifocal leukoencephalopathy', '2023-05-06'),
  (1022, 'hydrocortisone', NULL, 'Rectal', 'UK', 'Rheumatoid Arthritis; Schizophrenia; Ulcerative Colitis', 'Pregnant women', '2021-03-07', NULL, NULL, NULL),
  (1023, 'hydrocortisone', NULL, 'Intravenous', 'ESP', 'Systemic Lupus Erythematosus; Viral Infections', 'Immunocompromised patients; Patients with obesity', '2014-06-19', NULL, NULL, NULL),
  (1024, 'hydrocortisone', NULL, 'Sublingual', 'DEU', 'Juvenile Idiopathic Arthritis', 'Patients with obesity; Patients with diabetes', '1992-01-11', NULL, NULL, NULL),
  (1025, 'hydrocortisone', NULL, 'Rectal', 'CAN', 'Ulcerative Colitis; Bacterial Infections; Hepatitis C', 'Patients with comorbidities; Patients with hepatic impairment', '1993-05-15', NULL, NULL, NULL),
  (1026, 'hydrocortisone', NULL, 'Rectal', 'ITA', 'Rheumatoid Arthritis; Diabetes Mellitus Type 2; Fungal Infections', 'Patients with obesity; Patients with comorbidities', '2003-09-14', NULL, NULL, NULL),
  (1027, 'hydrocortisone', NULL, 'Nasal', 'ITA', 'Bipolar Disorder; Ankylosing Spondylitis', 'Patients with renal impairment', '1997-07-20', NULL, NULL, NULL),
  (1028, 'hydrocortisone', NULL, 'Sublingual', 'CAN', 'Depression', 'Patients with cardiovascular disease', '2018-08-18', NULL, NULL, NULL),
  (1029, 'hydrocortisone', NULL, 'Subcutaneous', 'DEU', 'Systemic Lupus Erythematosus; Psoriatic Arthritis', 'Patients with diabetes', '2005-12-03', NULL, 'Risk of tuberculosis reactivation', '2018-12-05'),
  (1030, 'prednisone', NULL, 'Intramuscular', 'UK', 'Deep Vein Thrombosis', 'Pediatric patients 2-17 years', '2003-09-04', NULL, NULL, NULL),
  (1031, 'prednisone', NULL, 'Topical', 'FRA', 'Migraine; Schizophrenia; Plaque Psoriasis', 'Immunocompromised patients', '2017-05-17', NULL, NULL, NULL),
  (1032, 'prednisone', NULL, 'Oral', 'UK', 'Chronic Obstructive Pulmonary Disease; HIV Infection; Ankylosing Spondylitis', 'Patients with renal impairment; Pediatric patients 2-17 years', '2022-11-15', NULL, NULL, NULL),
  (1033, 'prednisone', NULL, 'Nasal', 'FRA', 'Heart Failure; Bacterial Infections; Migraine', 'Adults with moderate to severe disease; Patients with hepatic impairment', '1997-12-01', '2022-10-02', NULL, NULL),
  (1034, 'prednisone', NULL, 'Intramuscular', 'ESP', 'Rheumatoid Arthritis; Depression; Ankylosing Spondylitis', 'Patients with diabetes; Adults with moderate to severe disease', '2019-09-07', NULL, 'Risk of liver injury', '2019-09-25'),
  (1035, 'prednisone', NULL, 'Rectal', 'CAN', 'Osteoporosis', 'Adults 65+ years', '2014-08-09', NULL, NULL, NULL),
  (1036, 'prednisone', NULL, 'Oral', 'AUS', 'Fungal Infections; Multiple Sclerosis; Osteoporosis', 'Adults with mild disease', '2013-05-01', NULL, NULL, NULL),
  (1037, 'prednisone', NULL, 'Inhalation', 'CAN', 'Systemic Lupus Erythematosus; Depression; Ulcerative Colitis', 'Patients with prior treatment failure', '2017-02-05', NULL, NULL, NULL),
  (1038, 'prednisone', NULL, 'Sublingual', 'CAN', 'HIV Infection; Chronic Obstructive Pulmonary Disease', 'Patients with prior treatment failure; Patients with renal impairment', '1998-08-03', NULL, 'Risk of blood disorders', '2017-01-10'),
  (1039, 'prednisone', NULL, 'Subcutaneous', 'ITA', 'Depression; Bacterial Infections', 'Adults 65+ years; Adults with mild disease', '2015-02-07', NULL, 'Risk of blood disorders', '2020-08-01'),
  (1040, 'prednisone', NULL, 'Intravenous', 'ESP', 'Schizophrenia', 'Pediatric patients 2-17 years; Immunocompromised patients', '2007-05-28', NULL, NULL, NULL),
  (1041, 'prednisone', NULL, 'Intramuscular', 'FRA', 'Hepatitis C; Psoriatic Arthritis; Cancer', 'Treatment-naive patients', '2015-03-12', NULL, NULL, NULL),
  (1042, 'prednisone', NULL, 'Subcutaneous', 'DEU', 'Pulmonary Embolism; Systemic Lupus Erythematosus', 'Pediatric patients 2-17 years', '2013-03-04', NULL, NULL, NULL),
  (1043, 'prednisone', NULL, 'Intravenous', 'DEU', 'Atrial Fibrillation', 'Patients with comorbidities; Pediatric patients 6 months-2 years', '2013-03-04', NULL, 'Risk of serious cardiovascular events', '2018-12-11'),
  (1044, 'prednisone', NULL, 'Oral', 'ESP', 'Hepatitis C; Atrial Fibrillation', 'Pediatric patients 6 months-2 years', '1998-05-10', NULL, NULL, NULL),
  (1045, 'dexamethasone', NULL, 'Rectal', 'DEU', 'Pulmonary Embolism; Diabetes Mellitus Type 2; Anxiety', 'Patients with comorbidities; Patients with cardiovascular disease', '2019-08-16', NULL, NULL, NULL),
  (1046, 'dexamethasone', NULL, 'Nasal', 'AUS', 'Asthma; Pulmonary Embolism; Atrial Fibrillation', 'Adults with moderate to severe disease; Patients with cardiovascular disease', '1998-09-10', NULL, NULL, NULL),
  (1047, 'dexamethasone', NULL, 'Oral', 'UK', 'Psoriatic Arthritis; Juvenile Idiopathic Arthritis; Migraine', 'Adults with moderate to severe disease', '2004-11-02', NULL, 'Risk of peripheral neuropathy', '2018-08-15'),
  (1048, 'dexamethasone', NULL, 'Intravenous', 'BRA', 'Psoriatic Arthritis', 'Patients with prior treatment failure', '2009-09-02', NULL, NULL, NULL),
  (1049, 'dexamethasone', NULL, 'Inhalation', 'DEU', 'Hypertension', 'Adults with mild disease; Adults with moderate to severe disease', '2020-11-15', NULL, NULL, NULL),
  (1050, 'dexamethasone', NULL, 'Transdermal', 'ESP', 'Juvenile Idiopathic Arthritis; Psoriatic Arthritis; Migraine', 'Adults 65+ years', '1998-12-26', NULL, NULL, NULL),
  (1051, 'dexamethasone', NULL, 'Intramuscular', 'UK', 'Viral Infections; Systemic Lupus Erythematosus', 'Patients with hepatic impairment', '2023-07-08', NULL, NULL, NULL),
  (1052, 'dexamethasone', NULL, 'Oral', 'UK', 'Juvenile Idiopathic Arthritis', 'Patients with obesity; Patients with cardiovascular disease', '2001-01-10', NULL, NULL, NULL),
  (1053, 'dexamethasone', NULL, 'Rectal', 'UK', 'Viral Infections; Hypertension; Plaque Psoriasis', 'Patients with prior treatment failure; Pregnant women', '2001-08-19', NULL, NULL, NULL),
  (1054, 'dexamethasone', NULL, 'Nasal', 'CAN', 'Cancer', 'Adults 18-65 years', '2022-11-23', NULL, NULL, NULL),
  (1055, 'dexamethasone', NULL, 'Subcutaneous', 'BRA', 'Heart Failure', 'Patients with obesity; Pregnant women', '1996-09-21', NULL, NULL, NULL),
  (1056, 'dexamethasone', NULL, 'Transdermal', 'UK', 'Juvenile Idiopathic Arthritis; Bipolar Disorder; Plaque Psoriasis', 'Patients with diabetes', '2001-11-10', NULL, 'Risk of gastrointestinal perforation', '2023-06-14'),
  (1057, 'dexamethasone', NULL, 'Oral', 'USA', 'Bipolar Disorder; Psoriatic Arthritis; Asthma', 'Adults with mild disease; Adults 65+ years', '2012-10-09', NULL, NULL, NULL),
  (1058, 'dexamethasone', NULL, 'Intramuscular', 'JPN', 'Pulmonary Embolism; Psoriatic Arthritis; Bipolar Disorder', 'Treatment-naive patients', '2007-11-26', NULL, 'Risk of tuberculosis reactivation', '2016-04-13'),
  (1059, 'dexamethasone', NULL, 'Sublingual', 'USA', 'Multiple Sclerosis', 'Patients with obesity', '2014-06-15', NULL, NULL, NULL),
  (1060, 'dexamethasone', NULL, 'Rectal', 'USA', 'Cancer; Fungal Infections', 'Patients with hepatic impairment; Adults 65+ years', '2017-04-13', NULL, NULL, NULL),
  (1061, 'fluticasone', NULL, 'Subcutaneous', 'CAN', 'Ulcerative Colitis; Psoriatic Arthritis; Heart Failure', 'Patients with cardiovascular disease; Patients with renal impairment', '2006-08-24', NULL, 'Risk of anaphylaxis', '2017-10-26'),
  (1062, 'fluticasone', NULL, 'Rectal', 'FRA', 'Cancer; Juvenile Idiopathic Arthritis; Ulcerative Colitis', 'Adults 65+ years; Patients with hepatic impairment', '2005-12-14', NULL, NULL, NULL),
  (1063, 'fluticasone', NULL, 'Transdermal', 'AUS', 'Psoriatic Arthritis', 'Pregnant women; Adults 65+ years', '2018-03-21', NULL, NULL, NULL),
  (1064, 'fluticasone', NULL, 'Intravenous', 'UK', 'Hepatitis C', 'Adults 18-65 years', '1999-04-14', NULL, 'Risk of bone loss', '2022-12-21'),
  (1065, 'fluticasone', NULL, 'Intramuscular', 'AUS', 'Migraine; Bacterial Infections', 'Pediatric patients 2-17 years', '2007-10-13', NULL, NULL, NULL),
  (1066, 'budesonide', NULL, 'Topical', 'DEU', 'Cancer; Heart Failure; Psoriatic Arthritis', 'Patients with renal impairment', '2000-11-18', NULL, NULL, NULL),
  (1067, 'budesonide', NULL, 'Intravenous', 'ESP', 'Schizophrenia; Hypertension', 'Pediatric patients 6 months-2 years; Patients with prior treatment failure', '1991-06-21', NULL, 'Risk of blood disorders', '2017-09-16'),
  (1068, 'budesonide', NULL, 'Oral', 'FRA', 'Bipolar Disorder; Cancer', 'Patients with renal impairment; Adults 65+ years', '1993-10-14', NULL, NULL, NULL),
  (1069, 'budesonide', NULL, 'Intravenous', 'ITA', 'Cancer; Multiple Sclerosis; Plaque Psoriasis', 'Immunocompromised patients; Treatment-naive patients', '1996-02-09', NULL, NULL, NULL),
  (1070, 'budesonide', NULL, 'Inhalation', 'DEU', 'Viral Infections; Rheumatoid Arthritis; HIV Infection', 'Adults with moderate to severe disease', '2008-05-19', NULL, NULL, NULL),
  (1071, 'albuterol', NULL, 'Intravenous', 'ITA', 'Viral Infections; Atrial Fibrillation', 'Patients with prior treatment failure; Pregnant women', '1995-10-20', NULL, NULL, NULL),
  (1072, 'albuterol', NULL, 'Subcutaneous', 'UK', 'Depression; Atrial Fibrillation; Psoriatic Arthritis', 'Patients with comorbidities; Treatment-naive patients', '2015-02-24', NULL, NULL, NULL),
  (1073, 'albuterol', NULL, 'Intramuscular', 'FRA', 'Fungal Infections; Migraine; Cancer', 'Patients with hepatic impairment; Treatment-naive patients', '2011-10-04', NULL, NULL, NULL),
  (1074, 'albuterol', NULL, 'Intramuscular', 'JPN', 'Cancer; HIV Infection; Diabetes Mellitus Type 2', 'Adults 65+ years; Treatment-naive patients', '2017-08-06', NULL, 'Risk of central nervous system effects', '2021-01-10'),
  (1075, 'albuterol', NULL, 'Topical', 'ESP', 'Atrial Fibrillation; Fungal Infections; Osteoporosis', 'Adults 65+ years; Adults with moderate to severe disease', '2022-02-08', NULL, NULL, NULL),
  (1076, 'albuterol', NULL, 'Sublingual', 'ESP', 'Ankylosing Spondylitis', 'Pregnant women; Adults 65+ years', '1991-07-01', NULL, NULL, NULL),
  (1077, 'albuterol', NULL, 'Rectal', 'USA', 'Hepatitis C', 'Patients with comorbidities; Adults 18-65 years', '2015-12-09', NULL, 'Risk of serious cardiovascular events', '2019-01-04'),
  (1078, 'albuterol', NULL, 'Intramuscular', 'UK', 'Juvenile Idiopathic Arthritis; Anxiety; Bacterial Infections', 'Adults with mild disease', '2019-10-14', '2023-05-20', 'Risk of hearing loss', '2018-07-22'),
  (1079, 'albuterol', NULL, 'Oral', 'CAN', 'Depression; Viral Infections; Multiple Sclerosis', 'Patients with diabetes; Adults 18-65 years', '2012-04-04', NULL, NULL, NULL),
  (1080, 'albuterol', NULL, 'Rectal', 'JPN', 'Heart Failure; Anxiety; Atrial Fibrillation', 'Pregnant women', '2019-12-06', NULL, NULL, NULL),
  (1081, 'albuterol', NULL, 'Oral', 'ESP', 'Ulcerative Colitis; Bipolar Disorder; Juvenile Idiopathic Arthritis', 'Patients with comorbidities; Patients with renal impairment', '2023-12-21', NULL, NULL, NULL),
  (1082, 'albuterol', NULL, 'Inhalation', 'ESP', 'Plaque Psoriasis; Hepatitis C', 'Patients with hepatic impairment', '2011-02-15', NULL, NULL, NULL),
  (1083, 'albuterol', NULL, 'Intravenous', 'UK', 'Systemic Lupus Erythematosus; Heart Failure', 'Adults with mild disease; Pediatric patients 2-17 years', '2002-05-20', '2021-11-10', 'Risk of bone loss', '2017-01-01'),
  (1084, 'albuterol', NULL, 'Transdermal', 'BRA', 'Rheumatoid Arthritis', 'Immunocompromised patients', '1996-01-21', '2023-03-06', NULL, NULL),
  (1085, 'albuterol', NULL, 'Rectal', 'CAN', 'Migraine', 'Patients with hepatic impairment; Adults with mild disease', '2024-11-26', NULL, NULL, NULL),
  (1086, 'albuterol', NULL, 'Intramuscular', 'ESP', 'Pulmonary Embolism; Crohn''s Disease', 'Adults with mild disease; Patients with diabetes', '1994-08-16', NULL, NULL, NULL),
  (1087, 'albuterol', NULL, 'Sublingual', 'FRA', 'Osteoporosis', 'Patients with renal impairment; Patients with diabetes', '2001-04-02', NULL, NULL, NULL),
  (1088, 'albuterol', NULL, 'Transdermal', 'ESP', 'Pulmonary Embolism; Multiple Sclerosis; HIV Infection', 'Patients with cardiovascular disease', '2021-01-16', NULL, NULL, NULL),
  (1089, 'albuterol', NULL, 'Transdermal', 'UK', 'Atrial Fibrillation', 'Patients with comorbidities', '2012-12-17', NULL, NULL, NULL),
  (1090, 'albuterol', NULL, 'Sublingual', 'AUS', 'Depression; Hypertension; Psoriatic Arthritis', 'Adults with mild disease; Pediatric patients 2-17 years', '2005-11-05', NULL, 'Risk of hearing loss', '2018-04-06'),
  (1091, 'albuterol', NULL, 'Intravenous', 'ESP', 'Psoriatic Arthritis', 'Adults 65+ years; Treatment-naive patients', '2011-05-08', NULL, NULL, NULL),
  (1092, 'albuterol', NULL, 'Transdermal', 'USA', 'HIV Infection; Osteoporosis; Systemic Lupus Erythematosus', 'Immunocompromised patients; Patients with cardiovascular disease', '2013-05-19', NULL, 'Risk of hypersensitivity reactions', '2019-02-05'),
  (1093, 'albuterol', NULL, 'Topical', 'CAN', 'Rheumatoid Arthritis; Ankylosing Spondylitis', 'Pediatric patients 6 months-2 years; Patients with obesity', '2013-02-19', NULL, NULL, NULL),
  (1094, 'albuterol', NULL, 'Oral', 'JPN', 'Plaque Psoriasis; Diabetes Mellitus Type 2', 'Adults with moderate to severe disease; Adults 65+ years', '1990-08-26', NULL, 'Risk of progressive multifocal leukoencephalopathy', '2018-10-13'),
  (1095, 'albuterol', NULL, 'Intramuscular', 'BRA', 'Atrial Fibrillation; Migraine; Osteoporosis', 'Patients with prior treatment failure', '2005-06-23', NULL, NULL, NULL),
  (1096, 'albuterol', NULL, 'Transdermal', 'FRA', 'Bacterial Infections; Migraine', 'Adults with moderate to severe disease', '1990-04-20', NULL, NULL, NULL),
  (1097, 'albuterol', NULL, 'Rectal', 'USA', 'Hypertension; Deep Vein Thrombosis', 'Patients with diabetes; Pediatric patients 2-17 years', '1991-10-16', NULL, 'Risk of liver injury', '2022-01-04'),
  (1098, 'albuterol', NULL, 'Nasal', 'DEU', 'Depression; Plaque Psoriasis', 'Pediatric patients 6 months-2 years; Adults with moderate to severe disease', '2003-10-04', NULL, NULL, NULL),
  (1099, 'albuterol', NULL, 'Topical', 'AUS', 'Fungal Infections; Chronic Obstructive Pulmonary Disease; Pulmonary Embolism', 'Adults 65+ years', '2018-08-27', NULL, NULL, NULL),
  (1100, 'salmeterol', NULL, 'Nasal', 'JPN', 'Atrial Fibrillation; Migraine; Ulcerative Colitis', 'Adults with mild disease', '2014-03-02', NULL, NULL, NULL),
  (1101, 'salmeterol', NULL, 'Rectal', 'UK', 'Crohn''s Disease; Schizophrenia', 'Patients with diabetes; Patients with renal impairment', '2013-04-17', NULL, 'Risk of progressive multifocal leukoencephalopathy', '2020-12-09'),
  (1102, 'salmeterol', NULL, 'Intravenous', 'ESP', 'Hepatitis C; Rheumatoid Arthritis', 'Patients with prior treatment failure; Adults 65+ years', '1992-02-10', NULL, NULL, NULL),
  (1103, 'salmeterol', NULL, 'Transdermal', 'DEU', 'Cancer', 'Patients with prior treatment failure; Pregnant women', '2015-04-22', NULL, NULL, NULL),
  (1104, 'salmeterol', NULL, 'Rectal', 'FRA', 'Psoriatic Arthritis', 'Adults 18-65 years', '2015-10-09', NULL, 'Risk of progressive multifocal leukoencephalopathy', '2019-03-21'),
  (1105, 'formoterol', NULL, 'Inhalation', 'BRA', 'Systemic Lupus Erythematosus', 'Adults with mild disease; Patients with renal impairment', '2005-12-01', NULL, NULL, NULL),
  (1106, 'formoterol', NULL, 'Topical', 'UK', 'Bacterial Infections; Osteoporosis', 'Immunocompromised patients', '1990-07-21', NULL, 'Risk of blood disorders', '2016-02-08'),
  (1107, 'formoterol', NULL, 'Oral', 'CAN', 'Systemic Lupus Erythematosus; Hepatitis C', 'Patients with hepatic impairment; Treatment-naive patients', '2009-07-15', NULL, 'Risk of gastrointestinal perforation', '2016-09-07'),
  (1108, 'formoterol', NULL, 'Oral', 'USA', 'Depression', 'Patients with hepatic impairment', '2023-11-28', NULL, NULL, NULL),
  (1109, 'formoterol', NULL, 'Intramuscular', 'DEU', 'Heart Failure; Diabetes Mellitus Type 2', 'Pediatric patients 2-17 years; Treatment-naive patients', '2019-02-27', NULL, NULL, NULL),
  (1110, 'formoterol', NULL, 'Inhalation', 'DEU', 'Fungal Infections; Atrial Fibrillation', 'Pediatric patients 2-17 years', '2010-06-24', NULL, 'Risk of hypersensitivity reactions', '2019-11-04'),
  (1111, 'formoterol', NULL, 'Rectal', 'ITA', 'Psoriatic Arthritis', 'Adults 18-65 years', '2009-04-22', NULL, NULL, NULL),
  (1112, 'formoterol', NULL, 'Intravenous', 'ESP', 'Hypertension; Depression', 'Patients with prior treatment failure; Pediatric patients 6 months-2 years', '2002-08-21', '2024-12-07', NULL, NULL),
  (1113, 'formoterol', NULL, 'Sublingual', 'FRA', 'Cancer', 'Patients with comorbidities; Patients with diabetes', '1998-11-26', NULL, NULL, NULL),
  (1114, 'formoterol', NULL, 'Intramuscular', 'DEU', 'Atrial Fibrillation; Juvenile Idiopathic Arthritis; Psoriatic Arthritis', 'Adults 18-65 years; Patients with cardiovascular disease', '2019-10-25', NULL, NULL, NULL),
  (1115, 'formoterol', NULL, 'Transdermal', 'BRA', 'Deep Vein Thrombosis; Bacterial Infections; Systemic Lupus Erythematosus', 'Treatment-naive patients', '1992-01-28', NULL, NULL, NULL),
  (1116, 'ipratropium', NULL, 'Rectal', 'AUS', 'Depression; Crohn''s Disease', 'Patients with obesity', '1998-01-05', '2022-12-18', NULL, NULL),
  (1117, 'ipratropium', NULL, 'Inhalation', 'UK', 'Bipolar Disorder; Rheumatoid Arthritis; Plaque Psoriasis', 'Adults with moderate to severe disease; Patients with hepatic impairment', '1992-02-20', NULL, NULL, NULL),
  (1118, 'ipratropium', NULL, 'Intramuscular', 'DEU', 'Crohn''s Disease; Diabetes Mellitus Type 2; Chronic Obstructive Pulmonary Disease', 'Adults 65+ years', '2011-06-24', '2020-01-26', 'Risk of vision changes', '2021-07-15'),
  (1119, 'ipratropium', NULL, 'Nasal', 'BRA', 'Osteoporosis', 'Pediatric patients 2-17 years; Pregnant women', '1996-01-19', NULL, NULL, NULL),
  (1120, 'tiotropium', NULL, 'Rectal', 'USA', 'Fungal Infections', 'Patients with prior treatment failure; Immunocompromised patients', '2020-03-10', NULL, NULL, NULL),
  (1121, 'tiotropium', NULL, 'Oral', 'USA', 'Ulcerative Colitis; Crohn''s Disease', 'Pregnant women; Adults with mild disease', '2009-11-20', NULL, NULL, NULL),
  (1122, 'tiotropium', NULL, 'Intravenous', 'ITA', 'Psoriatic Arthritis; Pulmonary Embolism; Plaque Psoriasis', 'Patients with renal impairment; Patients with obesity', '1990-09-06', NULL, NULL, NULL),
  (1123, 'tiotropium', NULL, 'Intramuscular', 'FRA', 'Depression', 'Patients with diabetes', '2015-07-26', NULL, 'Risk of blood disorders', '2020-07-19'),
  (1124, 'tiotropium', NULL, 'Subcutaneous', 'DEU', 'Diabetes Mellitus Type 2; Fungal Infections', 'Adults with moderate to severe disease', '1995-08-08', NULL, NULL, NULL),
  (1125, 'tiotropium', NULL, 'Oral', 'CAN', 'Hypertension', 'Adults 18-65 years; Adults 65+ years', '2012-03-09', NULL, NULL, NULL),
  (1126, 'tiotropium', NULL, 'Intramuscular', 'ESP', 'Hepatitis C', 'Patients with renal impairment; Adults with mild disease', '2009-01-01', NULL, NULL, NULL),
  (1127, 'tiotropium', NULL, 'Inhalation', 'BRA', 'Juvenile Idiopathic Arthritis; Heart Failure; Viral Infections', 'Adults 18-65 years; Pediatric patients 6 months-2 years', '2014-08-03', NULL, 'Risk of peripheral neuropathy', '2024-06-03'),
  (1128, 'tiotropium', NULL, 'Sublingual', 'USA', 'Osteoporosis; Schizophrenia; Bacterial Infections', 'Immunocompromised patients; Adults 18-65 years', '2024-03-28', '2021-12-17', NULL, NULL),
  (1129, 'tiotropium', NULL, 'Transdermal', 'UK', 'Anxiety', 'Patients with renal impairment; Adults with moderate to severe disease', '1996-05-04', NULL, 'Risk of peripheral neuropathy', '2019-08-26'),
  (1130, 'tiotropium', NULL, 'Intramuscular', 'ESP', 'Psoriatic Arthritis; Hepatitis C', 'Treatment-naive patients; Patients with renal impairment', '2015-04-25', NULL, NULL, NULL),
  (1131, 'tiotropium', NULL, 'Topical', 'ITA', 'Atrial Fibrillation; Cancer; Hepatitis C', 'Pediatric patients 2-17 years', '2024-11-11', NULL, NULL, NULL),
  (1132, 'tiotropium', NULL, 'Intravenous', 'USA', 'Psoriatic Arthritis', 'Patients with hepatic impairment; Adults with mild disease', '2002-09-23', NULL, 'Risk of blood disorders', '2024-05-24'),
  (1133, 'tiotropium', NULL, 'Subcutaneous', 'JPN', 'Cancer; Rheumatoid Arthritis', 'Pediatric patients 2-17 years; Adults 65+ years', '2008-09-09', NULL, NULL, NULL),
  (1134, 'tiotropium', NULL, 'Topical', 'ITA', 'Pulmonary Embolism', 'Pregnant women; Adults with mild disease', '2000-09-02', NULL, NULL, NULL),
  (1135, 'montelukast', NULL, 'Inhalation', 'CAN', 'Atrial Fibrillation; Schizophrenia; Chronic Obstructive Pulmonary Disease', 'Adults 65+ years; Patients with obesity', '2023-05-07', '2024-11-12', 'Risk of renal impairment', '2019-09-01'),
  (1136, 'montelukast', NULL, 'Inhalation', 'BRA', 'Crohn''s Disease; Heart Failure; Schizophrenia', 'Patients with diabetes; Adults with moderate to severe disease', '2020-09-23', NULL, NULL, NULL),
  (1137, 'montelukast', NULL, 'Subcutaneous', 'BRA', 'Crohn''s Disease; Viral Infections', 'Immunocompromised patients', '2007-04-17', '2022-07-18', NULL, NULL),
  (1138, 'montelukast', NULL, 'Topical', 'CAN', 'Bacterial Infections; Migraine; Osteoporosis', 'Patients with prior treatment failure', '2015-07-07', NULL, NULL, NULL),
  (1139, 'montelukast', NULL, 'Nasal', 'BRA', 'Asthma; Diabetes Mellitus Type 2', 'Patients with renal impairment', '2002-07-08', '2022-09-10', 'Risk of blood disorders', '2023-06-28'),
  (1140, 'montelukast', NULL, 'Sublingual', 'ESP', 'Crohn''s Disease; Hepatitis C', 'Patients with cardiovascular disease', '1999-09-22', NULL, 'Increased risk of serious infections', '2020-03-02'),
  (1141, 'montelukast', NULL, 'Inhalation', 'ITA', 'Pulmonary Embolism', 'Adults 18-65 years', '1994-03-19', NULL, 'Risk of bone loss', '2024-09-16'),
  (1142, 'montelukast', NULL, 'Sublingual', 'JPN', 'Depression; Atrial Fibrillation', 'Adults with moderate to severe disease; Patients with cardiovascular disease', '2010-10-27', NULL, NULL, NULL),
  (1143, 'montelukast', NULL, 'Transdermal', 'JPN', 'Multiple Sclerosis; Atrial Fibrillation; Crohn''s Disease', 'Pediatric patients 2-17 years', '2022-10-05', '2020-06-13', 'Risk of liver injury', '2022-06-12'),
  (1144, 'montelukast', NULL, 'Intravenous', 'AUS', 'Juvenile Idiopathic Arthritis; Cancer', 'Adults with moderate to severe disease; Adults 65+ years', '2011-06-12', '2023-03-20', NULL, NULL),
  (1145, 'montelukast', NULL, 'Subcutaneous', 'BRA', 'Multiple Sclerosis; Crohn''s Disease; Pulmonary Embolism', 'Patients with cardiovascular disease', '2006-11-13', NULL, NULL, NULL),
  (1146, 'montelukast', NULL, 'Intravenous', 'FRA', 'Ulcerative Colitis; Atrial Fibrillation', 'Pediatric patients 2-17 years', '2022-12-26', NULL, NULL, NULL),
  (1147, 'montelukast', NULL, 'Subcutaneous', 'JPN', 'Anxiety; HIV Infection; Cancer', 'Pregnant women', '2021-06-21', NULL, 'Risk of hepatitis B reactivation', '2020-03-09'),
  (1148, 'montelukast', NULL, 'Rectal', 'UK', 'Hepatitis C; Juvenile Idiopathic Arthritis', 'Pediatric patients 2-17 years; Patients with obesity', '2011-11-28', NULL, NULL, NULL),
  (1149, 'montelukast', NULL, 'Intramuscular', 'BRA', 'Schizophrenia', 'Adults 65+ years; Adults with moderate to severe disease', '2017-12-23', NULL, 'Risk of blood disorders', '2018-11-03'),
  (1150, 'montelukast', NULL, 'Topical', 'CAN', 'Schizophrenia; Multiple Sclerosis; Heart Failure', 'Pregnant women', '2022-09-22', NULL, NULL, NULL),
  (1151, 'montelukast', NULL, 'Rectal', 'UK', 'Viral Infections', 'Adults 65+ years; Pregnant women', '1990-02-21', NULL, 'Risk of renal impairment', '2023-01-12'),
  (1152, 'montelukast', NULL, 'Topical', 'USA', 'Viral Infections', 'Patients with obesity', '1994-09-17', NULL, NULL, NULL),
  (1153, 'montelukast', NULL, 'Intramuscular', 'ITA', 'Deep Vein Thrombosis', 'Patients with obesity', '2015-05-26', NULL, NULL, NULL),
  (1154, 'montelukast', NULL, 'Oral', 'JPN', 'Rheumatoid Arthritis', 'Patients with comorbidities', '2020-04-22', NULL, NULL, NULL),
  (1155, 'montelukast', NULL, 'Sublingual', 'DEU', 'Ankylosing Spondylitis', 'Patients with renal impairment; Treatment-naive patients', '1999-02-22', NULL, NULL, NULL),
  (1156, 'montelukast', NULL, 'Subcutaneous', 'UK', 'Chronic Obstructive Pulmonary Disease', 'Pediatric patients 2-17 years; Patients with comorbidities', '1998-08-12', NULL, NULL, NULL),
  (1157, 'montelukast', NULL, 'Nasal', 'UK', 'Ankylosing Spondylitis', 'Patients with renal impairment; Pediatric patients 2-17 years', '2002-05-13', NULL, 'Risk of blood disorders', '2022-03-25'),
  (1158, 'montelukast', NULL, 'Inhalation', 'ITA', 'Ankylosing Spondylitis; Schizophrenia; Ulcerative Colitis', 'Immunocompromised patients; Pediatric patients 2-17 years', '2008-02-18', NULL, 'Risk of hepatitis B reactivation', '2015-03-04'),
  (1159, 'montelukast', NULL, 'Topical', 'USA', 'Asthma', 'Patients with renal impairment', '1995-07-28', '2024-01-25', NULL, NULL),
  (1160, 'montelukast', NULL, 'Topical', 'UK', 'Osteoporosis; Psoriatic Arthritis; Hypertension', 'Treatment-naive patients', '2016-07-14', NULL, 'Risk of hearing loss', '2020-08-24'),
  (1161, 'montelukast', NULL, 'Topical', 'FRA', 'Anxiety; Heart Failure', 'Immunocompromised patients; Pediatric patients 6 months-2 years', '2023-08-04', NULL, NULL, NULL),
  (1162, 'montelukast', NULL, 'Nasal', 'AUS', 'Atrial Fibrillation', 'Immunocompromised patients', '2022-03-24', NULL, NULL, NULL),
  (1163, 'montelukast', NULL, 'Transdermal', 'JPN', 'Hepatitis C; Plaque Psoriasis; Chronic Obstructive Pulmonary Disease', 'Patients with obesity; Treatment-naive patients', '1993-12-15', NULL, NULL, NULL),
  (1164, 'montelukast', NULL, 'Intramuscular', 'FRA', 'Pulmonary Embolism; Systemic Lupus Erythematosus; Psoriatic Arthritis', 'Pediatric patients 6 months-2 years', '2013-06-28', NULL, NULL, NULL),
  (1165, 'omeprazole', NULL, 'Intramuscular', 'CAN', 'Hypertension; Juvenile Idiopathic Arthritis', 'Patients with cardiovascular disease; Adults 65+ years', '2004-11-07', NULL, NULL, NULL),
  (1166, 'omeprazole', NULL, 'Inhalation', 'DEU', 'HIV Infection; Heart Failure; Asthma', 'Pediatric patients 2-17 years', '2014-04-04', NULL, NULL, NULL),
  (1167, 'omeprazole', NULL, 'Topical', 'ITA', 'Osteoporosis', 'Patients with comorbidities; Patients with prior treatment failure', '1990-09-15', NULL, NULL, NULL),
  (1168, 'omeprazole', NULL, 'Nasal', 'FRA', 'Diabetes Mellitus Type 2', 'Immunocompromised patients; Adults 65+ years', '1992-10-18', '2020-05-02', NULL, NULL),
  (1169, 'omeprazole', NULL, 'Inhalation', 'AUS', 'Heart Failure', 'Pregnant women', '2007-11-28', NULL, NULL, NULL),
  (1170, 'omeprazole', NULL, 'Sublingual', 'CAN', 'Plaque Psoriasis; Juvenile Idiopathic Arthritis; Bacterial Infections', 'Pediatric patients 6 months-2 years', '2012-09-28', '2024-02-28', NULL, NULL),
  (1171, 'omeprazole', NULL, 'Intramuscular', 'CAN', 'Juvenile Idiopathic Arthritis; Bacterial Infections', 'Patients with renal impairment', '2007-03-07', NULL, 'Risk of progressive multifocal leukoencephalopathy', '2015-01-17'),
  (1172, 'omeprazole', NULL, 'Topical', 'DEU', 'Rheumatoid Arthritis; Viral Infections', 'Patients with prior treatment failure', '2003-12-06', NULL, NULL, NULL),
  (1173, 'pantoprazole', NULL, 'Transdermal', 'DEU', 'Diabetes Mellitus Type 2; Osteoporosis; Anxiety', 'Patients with diabetes', '2013-04-28', NULL, NULL, NULL),
  (1174, 'pantoprazole', NULL, 'Inhalation', 'ESP', 'Osteoporosis; Ankylosing Spondylitis', 'Adults 65+ years; Adults with moderate to severe disease', '2024-04-05', NULL, 'Increased risk of serious infections', '2019-04-17'),
  (1175, 'pantoprazole', NULL, 'Rectal', 'DEU', 'Hypertension; Bacterial Infections; Ulcerative Colitis', 'Patients with diabetes', '1993-06-24', NULL, NULL, NULL),
  (1176, 'pantoprazole', NULL, 'Subcutaneous', 'CAN', 'Hypertension', 'Adults 65+ years; Adults 18-65 years', '2004-08-16', NULL, NULL, NULL),
  (1177, 'pantoprazole', NULL, 'Inhalation', 'UK', 'Hypertension; Anxiety; Cancer', 'Adults 18-65 years; Immunocompromised patients', '1997-05-25', NULL, NULL, NULL),
  (1178, 'pantoprazole', NULL, 'Topical', 'CAN', 'Ankylosing Spondylitis', 'Adults with moderate to severe disease', '1999-08-05', NULL, NULL, NULL),
  (1179, 'pantoprazole', NULL, 'Nasal', 'AUS', 'Systemic Lupus Erythematosus; Chronic Obstructive Pulmonary Disease', 'Patients with prior treatment failure; Treatment-naive patients', '2014-12-16', NULL, NULL, NULL),
  (1180, 'pantoprazole', NULL, 'Intravenous', 'USA', 'Migraine; Diabetes Mellitus Type 2', 'Patients with renal impairment; Adults with moderate to severe disease', '2013-12-09', NULL, NULL, NULL),
  (1181, 'pantoprazole', NULL, 'Sublingual', 'ITA', 'Migraine; Bacterial Infections', 'Adults 65+ years', '1994-05-05', '2024-01-26', NULL, NULL),
  (1182, 'pantoprazole', NULL, 'Oral', 'AUS', 'Bacterial Infections; Psoriatic Arthritis', 'Pediatric patients 6 months-2 years; Adults 65+ years', '1997-08-01', NULL, NULL, NULL),
  (1183, 'pantoprazole', NULL, 'Transdermal', 'DEU', 'Viral Infections; Anxiety; Bipolar Disorder', 'Patients with obesity; Patients with cardiovascular disease', '2024-07-14', NULL, NULL, NULL),
  (1184, 'pantoprazole', NULL, 'Topical', 'BRA', 'Systemic Lupus Erythematosus; Asthma', 'Patients with prior treatment failure', '2019-11-11', NULL, 'Risk of hepatitis B reactivation', '2016-05-12'),
  (1185, 'pantoprazole', NULL, 'Sublingual', 'USA', 'Plaque Psoriasis', 'Patients with prior treatment failure', '1995-01-19', NULL, NULL, NULL),
  (1186, 'pantoprazole', NULL, 'Intramuscular', 'DEU', 'Depression; Asthma; Multiple Sclerosis', 'Pediatric patients 2-17 years', '1996-03-08', '2020-03-12', NULL, NULL),
  (1187, 'pantoprazole', NULL, 'Inhalation', 'AUS', 'Systemic Lupus Erythematosus; Hepatitis C; Juvenile Idiopathic Arthritis', 'Pediatric patients 2-17 years', '2020-01-20', NULL, NULL, NULL),
  (1188, 'pantoprazole', NULL, 'Topical', 'ESP', 'Systemic Lupus Erythematosus; Multiple Sclerosis; Depression', 'Adults 18-65 years; Adults with moderate to severe disease', '2023-01-01', NULL, NULL, NULL),
  (1189, 'pantoprazole', NULL, 'Inhalation', 'AUS', 'HIV Infection; Plaque Psoriasis', 'Patients with cardiovascular disease', '1991-08-04', NULL, NULL, NULL),
  (1190, 'pantoprazole', NULL, 'Subcutaneous', 'CAN', 'Juvenile Idiopathic Arthritis; Systemic Lupus Erythematosus; Multiple Sclerosis', 'Adults 18-65 years; Adults with mild disease', '2021-08-21', NULL, 'Risk of hypersensitivity reactions', '2019-12-20'),
  (1191, 'pantoprazole', NULL, 'Intramuscular', 'UK', 'Anxiety; Psoriatic Arthritis; Rheumatoid Arthritis', 'Patients with obesity', '2004-08-04', NULL, 'Risk of hepatitis B reactivation', '2015-06-24'),
  (1192, 'pantoprazole', NULL, 'Inhalation', 'FRA', 'Psoriatic Arthritis; Pulmonary Embolism', 'Immunocompromised patients', '2006-01-22', NULL, 'Risk of peripheral neuropathy', '2024-10-13'),
  (1193, 'pantoprazole', NULL, 'Intravenous', 'FRA', 'Cancer', 'Pediatric patients 6 months-2 years', '1998-05-16', NULL, NULL, NULL),
  (1194, 'pantoprazole', NULL, 'Sublingual', 'BRA', 'Juvenile Idiopathic Arthritis; Plaque Psoriasis; Bacterial Infections', 'Adults 18-65 years; Patients with diabetes', '1991-08-01', '2024-07-22', NULL, NULL),
  (1195, 'pantoprazole', NULL, 'Inhalation', 'FRA', 'Schizophrenia; Asthma; Ulcerative Colitis', 'Pregnant women; Immunocompromised patients', '2019-06-24', NULL, 'Risk of hypersensitivity reactions', '2016-05-26'),
  (1196, 'pantoprazole', NULL, 'Topical', 'BRA', 'Anxiety; Bipolar Disorder; Asthma', 'Patients with obesity; Patients with cardiovascular disease', '2008-08-01', NULL, 'Risk of anaphylaxis', '2015-08-24'),
  (1197, 'pantoprazole', NULL, 'Intramuscular', 'CAN', 'Viral Infections; Schizophrenia', 'Adults with moderate to severe disease; Adults 18-65 years', '1996-05-23', NULL, NULL, NULL),
  (1198, 'pantoprazole', NULL, 'Intravenous', 'CAN', 'Pulmonary Embolism; Depression', 'Patients with prior treatment failure; Adults 18-65 years', '2013-01-07', NULL, NULL, NULL),
  (1199, 'lansoprazole', NULL, 'Subcutaneous', 'AUS', 'Cancer', 'Pregnant women; Adults 65+ years', '1999-08-18', '2024-12-14', NULL, NULL),
  (1200, 'lansoprazole', NULL, 'Intravenous', 'USA', 'Diabetes Mellitus Type 2', 'Adults 65+ years', '2002-01-17', NULL, NULL, NULL),
  (1201, 'lansoprazole', NULL, 'Nasal', 'JPN', 'Schizophrenia; Systemic Lupus Erythematosus', 'Adults 65+ years; Patients with diabetes', '2015-08-05', NULL, NULL, NULL),
  (1202, 'lansoprazole', NULL, 'Intravenous', 'BRA', 'Hepatitis C; Bipolar Disorder; Deep Vein Thrombosis', 'Patients with hepatic impairment', '1992-04-01', NULL, NULL, NULL),
  (1203, 'lansoprazole', NULL, 'Topical', 'DEU', 'Asthma; Schizophrenia; Hepatitis C', 'Adults 18-65 years', '2002-10-10', NULL, 'Risk of progressive multifocal leukoencephalopathy', '2018-01-20'),
  (1204, 'lansoprazole', NULL, 'Topical', 'AUS', 'Psoriatic Arthritis; Hypertension', 'Immunocompromised patients; Patients with renal impairment', '2011-02-04', NULL, 'Risk of blood disorders', '2015-02-16'),
  (1205, 'lansoprazole', NULL, 'Transdermal', 'ITA', 'Chronic Obstructive Pulmonary Disease; Hypertension; Multiple Sclerosis', 'Patients with cardiovascular disease', '2014-11-08', NULL, NULL, NULL),
  (1206, 'lansoprazole', NULL, 'Oral', 'FRA', 'Heart Failure', 'Immunocompromised patients; Patients with diabetes', '1999-05-26', NULL, NULL, NULL),
  (1207, 'lansoprazole', NULL, 'Nasal', 'JPN', 'Rheumatoid Arthritis; Bacterial Infections; Diabetes Mellitus Type 2', 'Patients with prior treatment failure', '1995-04-27', NULL, NULL, NULL),
  (1208, 'lansoprazole', NULL, 'Topical', 'JPN', 'Juvenile Idiopathic Arthritis; Bacterial Infections', 'Pregnant women', '2009-02-06', NULL, NULL, NULL),
  (1209, 'lansoprazole', NULL, 'Oral', 'CAN', 'Systemic Lupus Erythematosus; Ankylosing Spondylitis; Rheumatoid Arthritis', 'Treatment-naive patients; Adults 65+ years', '2023-06-07', NULL, NULL, NULL),
  (1210, 'lansoprazole', NULL, 'Nasal', 'ITA', 'Ulcerative Colitis', 'Patients with renal impairment; Treatment-naive patients', '2001-08-07', NULL, NULL, NULL),
  (1211, 'lansoprazole', NULL, 'Sublingual', 'CAN', 'Asthma; Depression', 'Adults with moderate to severe disease; Patients with diabetes', '2000-02-19', NULL, NULL, NULL),
  (1212, 'lansoprazole', NULL, 'Subcutaneous', 'CAN', 'Systemic Lupus Erythematosus; Heart Failure; Fungal Infections', 'Treatment-naive patients; Adults 18-65 years', '1999-04-28', NULL, NULL, NULL),
  (1213, 'lansoprazole', NULL, 'Topical', 'UK', 'Ankylosing Spondylitis; Deep Vein Thrombosis', 'Adults 18-65 years; Patients with prior treatment failure', '2012-06-19', NULL, NULL, NULL),
  (1214, 'lansoprazole', NULL, 'Nasal', 'ITA', 'Atrial Fibrillation', 'Patients with comorbidities; Treatment-naive patients', '1998-05-19', NULL, 'Risk of renal impairment', '2020-08-21'),
  (1215, 'lansoprazole', NULL, 'Intramuscular', 'AUS', 'Bacterial Infections', 'Patients with prior treatment failure', '2006-05-12', NULL, 'Risk of gastrointestinal perforation', '2024-08-10'),
  (1216, 'lansoprazole', NULL, 'Transdermal', 'ITA', 'Bipolar Disorder', 'Patients with obesity; Patients with hepatic impairment', '2002-10-22', NULL, NULL, NULL),
  (1217, 'lansoprazole', NULL, 'Intravenous', 'UK', 'Psoriatic Arthritis; Ankylosing Spondylitis', 'Pediatric patients 2-17 years; Patients with prior treatment failure', '2009-12-17', '2024-01-11', NULL, NULL),
  (1218, 'lansoprazole', NULL, 'Subcutaneous', 'DEU', 'Schizophrenia; Ulcerative Colitis', 'Pediatric patients 2-17 years; Patients with comorbidities', '2008-11-11', NULL, NULL, NULL),
  (1219, 'lansoprazole', NULL, 'Inhalation', 'AUS', 'Psoriatic Arthritis', 'Patients with renal impairment', '2002-08-03', NULL, NULL, NULL),
  (1220, 'lansoprazole', NULL, 'Oral', 'ITA', 'Fungal Infections', 'Adults with moderate to severe disease', '2021-10-15', NULL, NULL, NULL),
  (1221, 'lansoprazole', NULL, 'Oral', 'AUS', 'Ankylosing Spondylitis; Hypertension', 'Adults 65+ years; Adults 18-65 years', '2020-01-08', NULL, NULL, NULL),
  (1222, 'ranitidine', NULL, 'Intramuscular', 'USA', 'Depression; Crohn''s Disease', 'Pregnant women; Patients with comorbidities', '2018-10-09', NULL, NULL, NULL),
  (1223, 'ranitidine', NULL, 'Inhalation', 'DEU', 'HIV Infection', 'Adults with moderate to severe disease; Patients with prior treatment failure', '2014-12-16', NULL, NULL, NULL),
  (1224, 'ranitidine', NULL, 'Subcutaneous', 'DEU', 'Osteoporosis', 'Patients with renal impairment', '2006-09-04', NULL, NULL, NULL),
  (1225, 'ranitidine', NULL, 'Rectal', 'FRA', 'Crohn''s Disease; Hepatitis C', 'Patients with obesity; Treatment-naive patients', '2000-03-28', NULL, NULL, NULL),
  (1226, 'ranitidine', NULL, 'Oral', 'ITA', 'Hepatitis C; Heart Failure', 'Patients with hepatic impairment', '1994-10-27', NULL, NULL, NULL),
  (1227, 'ranitidine', NULL, 'Subcutaneous', 'UK', 'Atrial Fibrillation; Hypertension', 'Adults with mild disease', '2017-10-19', NULL, NULL, NULL),
  (1228, 'ranitidine', NULL, 'Sublingual', 'JPN', 'HIV Infection; Crohn''s Disease', 'Patients with cardiovascular disease', '2013-11-17', NULL, 'Risk of serious cardiovascular events', '2021-06-16'),
  (1229, 'ranitidine', NULL, 'Oral', 'JPN', 'Chronic Obstructive Pulmonary Disease; Crohn''s Disease; Rheumatoid Arthritis', 'Patients with hepatic impairment', '2014-02-10', NULL, NULL, NULL),
  (1230, 'ranitidine', NULL, 'Transdermal', 'AUS', 'Atrial Fibrillation', 'Adults 18-65 years; Immunocompromised patients', '2004-02-19', NULL, NULL, NULL),
  (1231, 'ranitidine', NULL, 'Inhalation', 'AUS', 'Cancer; Asthma', 'Adults 65+ years', '2004-01-19', NULL, NULL, NULL),
  (1232, 'ranitidine', NULL, 'Nasal', 'BRA', 'Ankylosing Spondylitis; Asthma; Crohn''s Disease', 'Pediatric patients 6 months-2 years', '2013-06-04', NULL, 'Risk of bone loss', '2021-08-16'),
  (1233, 'ranitidine', NULL, 'Oral', 'ITA', 'Psoriatic Arthritis; Depression', 'Adults with moderate to severe disease; Patients with cardiovascular disease', '2008-07-11', '2020-06-04', NULL, NULL),
  (1234, 'ranitidine', NULL, 'Intravenous', 'AUS', 'HIV Infection', 'Pediatric patients 6 months-2 years; Adults 65+ years', '1996-11-22', NULL, NULL, NULL),
  (1235, 'ranitidine', NULL, 'Topical', 'ESP', 'Rheumatoid Arthritis; HIV Infection', 'Patients with hepatic impairment', '2016-02-26', '2020-12-10', NULL, NULL),
  (1236, 'ranitidine', NULL, 'Nasal', 'UK', 'Juvenile Idiopathic Arthritis; Fungal Infections; Osteoporosis', 'Immunocompromised patients; Pediatric patients 2-17 years', '2023-12-28', NULL, NULL, NULL),
  (1237, 'ranitidine', NULL, 'Nasal', 'JPN', 'Schizophrenia; Depression; Asthma', 'Patients with diabetes', '1996-12-09', NULL, NULL, NULL),
  (1238, 'ranitidine', NULL, 'Oral', 'UK', 'Bipolar Disorder; Atrial Fibrillation', 'Adults 18-65 years; Immunocompromised patients', '2009-02-13', NULL, NULL, NULL),
  (1239, 'ranitidine', NULL, 'Intravenous', 'AUS', 'Anxiety; Chronic Obstructive Pulmonary Disease', 'Patients with prior treatment failure', '2018-05-13', NULL, NULL, NULL),
  (1240, 'ranitidine', NULL, 'Inhalation', 'ITA', 'Crohn''s Disease; Schizophrenia', 'Adults with moderate to severe disease', '1997-10-04', NULL, NULL, NULL),
  (1241, 'ranitidine', NULL, 'Intravenous', 'ESP', 'Deep Vein Thrombosis', 'Immunocompromised patients', '2015-10-15', NULL, NULL, NULL),
  (1242, 'ranitidine', NULL, 'Transdermal', 'JPN', 'Bipolar Disorder; HIV Infection', 'Patients with prior treatment failure; Patients with diabetes', '2005-05-14', NULL, NULL, NULL),
  (1243, 'ranitidine', NULL, 'Nasal', 'JPN', 'Psoriatic Arthritis', 'Pregnant women', '1998-08-03', NULL, 'Risk of liver injury', '2022-12-10'),
  (1244, 'ranitidine', NULL, 'Inhalation', 'JPN', 'Deep Vein Thrombosis', 'Adults with mild disease; Pediatric patients 6 months-2 years', '2004-05-24', NULL, NULL, NULL),
  (1245, 'ranitidine', NULL, 'Inhalation', 'FRA', 'Migraine; Anxiety', 'Adults with mild disease; Pregnant women', '2012-06-10', NULL, NULL, NULL),
  (1246, 'ranitidine', NULL, 'Sublingual', 'USA', 'Osteoporosis', 'Patients with hepatic impairment; Adults 65+ years', '2015-03-20', NULL, NULL, NULL),
  (1247, 'ranitidine', NULL, 'Nasal', 'DEU', 'Deep Vein Thrombosis; Migraine', 'Patients with hepatic impairment', '2002-08-28', NULL, NULL, NULL),
  (1248, 'ranitidine', NULL, 'Subcutaneous', 'USA', 'Hepatitis C; Atrial Fibrillation; Chronic Obstructive Pulmonary Disease', 'Patients with comorbidities', '2016-10-14', NULL, NULL, NULL),
  (1249, 'ranitidine', NULL, 'Topical', 'UK', 'Asthma; Bipolar Disorder', 'Adults 18-65 years; Patients with obesity', '2004-09-21', NULL, NULL, NULL),
  (1250, 'ranitidine', NULL, 'Inhalation', 'AUS', 'Plaque Psoriasis', 'Patients with cardiovascular disease', '2023-05-10', NULL, NULL, NULL),
  (1251, 'famotidine', NULL, 'Inhalation', 'BRA', 'Crohn''s Disease', 'Patients with diabetes; Pediatric patients 2-17 years', '2021-09-19', NULL, 'Risk of serious cardiovascular events', '2019-06-13'),
  (1252, 'famotidine', NULL, 'Transdermal', 'UK', 'Systemic Lupus Erythematosus; Hepatitis C', 'Immunocompromised patients; Pregnant women', '2003-08-23', NULL, NULL, NULL),
  (1253, 'famotidine', NULL, 'Subcutaneous', 'AUS', 'Atrial Fibrillation', 'Adults with moderate to severe disease', '1996-10-23', NULL, NULL, NULL),
  (1254, 'famotidine', NULL, 'Oral', 'USA', 'Multiple Sclerosis; Pulmonary Embolism; Migraine', 'Patients with prior treatment failure; Pediatric patients 6 months-2 years', '2006-11-25', NULL, NULL, NULL),
  (1255, 'famotidine', NULL, 'Rectal', 'UK', 'Cancer', 'Patients with hepatic impairment', '2013-06-07', NULL, NULL, NULL),
  (1256, 'famotidine', NULL, 'Intramuscular', 'BRA', 'Hypertension; Deep Vein Thrombosis', 'Pregnant women; Patients with prior treatment failure', '2011-06-06', NULL, 'Risk of renal impairment', '2022-05-27'),
  (1257, 'famotidine', NULL, 'Nasal', 'CAN', 'Schizophrenia; Deep Vein Thrombosis', 'Immunocompromised patients', '2013-08-02', NULL, NULL, NULL),
  (1258, 'famotidine', NULL, 'Sublingual', 'ITA', 'Cancer', 'Immunocompromised patients', '1995-12-25', NULL, NULL, NULL),
  (1259, 'famotidine', NULL, 'Subcutaneous', 'USA', 'Osteoporosis', 'Immunocompromised patients; Patients with obesity', '2009-06-28', NULL, 'Risk of progressive multifocal leukoencephalopathy', '2020-02-12'),
  (1260, 'famotidine', NULL, 'Sublingual', 'BRA', 'Deep Vein Thrombosis; Asthma', 'Pediatric patients 6 months-2 years', '1990-09-08', NULL, 'Risk of liver injury', '2015-07-10'),
  (1261, 'famotidine', NULL, 'Intramuscular', 'JPN', 'HIV Infection', 'Adults with moderate to severe disease', '2023-03-16', '2021-07-26', NULL, NULL),
  (1262, 'famotidine', NULL, 'Oral', 'CAN', 'Deep Vein Thrombosis', 'Patients with prior treatment failure; Patients with cardiovascular disease', '2008-12-10', NULL, NULL, NULL),
  (1263, 'famotidine', NULL, 'Sublingual', 'UK', 'Anxiety; Multiple Sclerosis; Depression', 'Adults 65+ years', '1992-11-08', NULL, NULL, NULL),
  (1264, 'famotidine', NULL, 'Inhalation', 'CAN', 'Psoriatic Arthritis; Heart Failure', 'Adults 65+ years', '2023-11-18', NULL, NULL, NULL),
  (1265, 'famotidine', NULL, 'Topical', 'DEU', 'Cancer; Diabetes Mellitus Type 2', 'Adults with mild disease; Pediatric patients 6 months-2 years', '2016-11-27', NULL, NULL, NULL),
  (1266, 'famotidine', NULL, 'Transdermal', 'FRA', 'Diabetes Mellitus Type 2', 'Pediatric patients 2-17 years', '1993-02-27', NULL, 'Increased risk of serious infections', '2023-05-20'),
  (1267, 'famotidine', NULL, 'Topical', 'UK', 'Schizophrenia; Psoriatic Arthritis', 'Adults with mild disease', '2000-12-28', NULL, NULL, NULL),
  (1268, 'famotidine', NULL, 'Subcutaneous', 'FRA', 'Heart Failure; Hepatitis C; Cancer', 'Adults with mild disease; Pediatric patients 2-17 years', '2024-07-03', NULL, NULL, NULL),
  (1269, 'famotidine', NULL, 'Rectal', 'AUS', 'Plaque Psoriasis; Juvenile Idiopathic Arthritis', 'Patients with cardiovascular disease', '2010-12-18', NULL, NULL, NULL),
  (1270, 'famotidine', NULL, 'Rectal', 'CAN', 'Psoriatic Arthritis; Plaque Psoriasis', 'Patients with obesity', '1997-08-09', NULL, NULL, NULL),
  (1271, 'famotidine', NULL, 'Sublingual', 'USA', 'Chronic Obstructive Pulmonary Disease', 'Adults 18-65 years', '1997-04-19', NULL, NULL, NULL),
  (1272, 'famotidine', NULL, 'Nasal', 'ESP', 'Schizophrenia; Asthma; Fungal Infections', 'Patients with cardiovascular disease', '2003-10-23', NULL, NULL, NULL),
  (1273, 'famotidine', NULL, 'Inhalation', 'CAN', 'Pulmonary Embolism', 'Patients with cardiovascular disease; Patients with prior treatment failure', '2011-05-17', NULL, NULL, NULL),
  (1274, 'famotidine', NULL, 'Topical', 'FRA', 'Psoriatic Arthritis', 'Immunocompromised patients', '2006-03-02', NULL, NULL, NULL),
  (1275, 'famotidine', NULL, 'Transdermal', 'CAN', 'Crohn''s Disease', 'Patients with renal impairment', '1993-01-10', NULL, 'Risk of gastrointestinal perforation', '2016-02-05'),
  (1276, 'famotidine', NULL, 'Topical', 'AUS', 'Hypertension; Chronic Obstructive Pulmonary Disease; Depression', 'Patients with cardiovascular disease; Immunocompromised patients', '2007-11-23', NULL, NULL, NULL),
  (1277, 'famotidine', NULL, 'Inhalation', 'AUS', 'Psoriatic Arthritis', 'Adults with mild disease; Patients with hepatic impairment', '1997-06-17', NULL, NULL, NULL),
  (1278, 'famotidine', NULL, 'Inhalation', 'JPN', 'Pulmonary Embolism', 'Patients with comorbidities', '2001-09-10', '2021-10-08', 'Risk of gastrointestinal perforation', '2024-10-06'),
  (1279, 'metformin', NULL, 'Intravenous', 'UK', 'Chronic Obstructive Pulmonary Disease; Depression; Atrial Fibrillation', 'Adults 18-65 years', '1999-07-25', NULL, NULL, NULL),
  (1280, 'metformin', NULL, 'Intramuscular', 'ESP', 'Osteoporosis; Psoriatic Arthritis', 'Immunocompromised patients; Treatment-naive patients', '1997-11-05', NULL, NULL, NULL),
  (1281, 'metformin', NULL, 'Transdermal', 'USA', 'Asthma; Cancer; Hepatitis C', 'Adults with moderate to severe disease', '1994-02-23', NULL, NULL, NULL),
  (1282, 'metformin', NULL, 'Topical', 'ITA', 'Ulcerative Colitis; Chronic Obstructive Pulmonary Disease', 'Adults with mild disease', '2005-05-08', NULL, 'Risk of blood disorders', '2015-06-13'),
  (1283, 'metformin', NULL, 'Oral', 'ESP', 'Anxiety; Hypertension; Diabetes Mellitus Type 2', 'Patients with cardiovascular disease; Pediatric patients 6 months-2 years', '1994-12-25', NULL, NULL, NULL),
  (1284, 'metformin', NULL, 'Nasal', 'ESP', 'Osteoporosis', 'Patients with comorbidities', '2004-01-07', '2023-11-28', NULL, NULL),
  (1285, 'metformin', NULL, 'Nasal', 'ITA', 'Psoriatic Arthritis', 'Immunocompromised patients; Pediatric patients 6 months-2 years', '2019-04-10', NULL, NULL, NULL),
  (1286, 'metformin', NULL, 'Transdermal', 'ESP', 'Hypertension; Systemic Lupus Erythematosus; Schizophrenia', 'Adults with mild disease', '2009-06-22', NULL, 'Risk of liver injury', '2021-05-24'),
  (1287, 'metformin', NULL, 'Topical', 'DEU', 'Migraine; Plaque Psoriasis; Depression', 'Adults with mild disease; Patients with obesity', '1992-05-19', NULL, NULL, NULL),
  (1288, 'metformin', NULL, 'Topical', 'ITA', 'Heart Failure; Hypertension', 'Adults 18-65 years; Pediatric patients 6 months-2 years', '2016-12-08', NULL, 'Risk of anaphylaxis', '2017-12-25'),
  (1289, 'metformin', NULL, 'Topical', 'FRA', 'Hepatitis C; Rheumatoid Arthritis', 'Patients with cardiovascular disease; Patients with obesity', '2004-04-09', NULL, NULL, NULL),
  (1290, 'metformin', NULL, 'Inhalation', 'ESP', 'Deep Vein Thrombosis; Anxiety', 'Adults with mild disease; Treatment-naive patients', '2002-01-27', NULL, 'Risk of central nervous system effects', '2020-02-28'),
  (1291, 'metformin', NULL, 'Subcutaneous', 'ITA', 'HIV Infection; Crohn''s Disease; Deep Vein Thrombosis', 'Adults 65+ years', '2009-10-13', NULL, 'Increased risk of serious infections', '2016-05-19'),
  (1292, 'metformin', NULL, 'Inhalation', 'DEU', 'HIV Infection', 'Adults 18-65 years; Adults with mild disease', '1993-03-12', NULL, NULL, NULL),
  (1293, 'glipizide', NULL, 'Nasal', 'UK', 'HIV Infection; Anxiety; Osteoporosis', 'Adults 18-65 years; Treatment-naive patients', '2014-07-11', '2020-11-21', 'Risk of central nervous system effects', '2021-11-24'),
  (1294, 'glipizide', NULL, 'Oral', 'ITA', 'Psoriatic Arthritis; Diabetes Mellitus Type 2', 'Adults with mild disease', '2003-12-27', NULL, 'Increased risk of malignancy', '2024-07-21'),
  (1295, 'glipizide', NULL, 'Sublingual', 'AUS', 'Bipolar Disorder; Osteoporosis; Plaque Psoriasis', 'Treatment-naive patients; Pregnant women', '2010-06-16', NULL, NULL, NULL),
  (1296, 'glipizide', NULL, 'Transdermal', 'ITA', 'Juvenile Idiopathic Arthritis; Ankylosing Spondylitis; Systemic Lupus Erythematosus', 'Patients with obesity; Adults with mild disease', '1995-12-23', NULL, NULL, NULL),
  (1297, 'glipizide', NULL, 'Intramuscular', 'DEU', 'Hepatitis C; Juvenile Idiopathic Arthritis; Bipolar Disorder', 'Patients with comorbidities; Pediatric patients 6 months-2 years', '1991-06-16', NULL, 'Risk of central nervous system effects', '2017-02-15'),
  (1298, 'glipizide', NULL, 'Oral', 'JPN', 'Ankylosing Spondylitis; Ulcerative Colitis; Bipolar Disorder', 'Patients with prior treatment failure', '1993-04-26', NULL, NULL, NULL),
  (1299, 'glipizide', NULL, 'Inhalation', 'ESP', 'Crohn''s Disease; Systemic Lupus Erythematosus; Chronic Obstructive Pulmonary Disease', 'Pediatric patients 2-17 years', '2004-02-18', NULL, NULL, NULL),
  (1300, 'glipizide', NULL, 'Rectal', 'DEU', 'Multiple Sclerosis; Cancer; Anxiety', 'Adults 65+ years', '2008-11-14', NULL, NULL, NULL),
  (1301, 'glipizide', NULL, 'Rectal', 'DEU', 'Ulcerative Colitis; Plaque Psoriasis', 'Treatment-naive patients; Pediatric patients 2-17 years', '1996-10-08', NULL, NULL, NULL),
  (1302, 'glipizide', NULL, 'Sublingual', 'ESP', 'Osteoporosis; HIV Infection; Rheumatoid Arthritis', 'Patients with prior treatment failure; Pregnant women', '2010-02-17', NULL, 'Risk of central nervous system effects', '2016-08-03'),
  (1303, 'glipizide', NULL, 'Topical', 'ITA', 'Atrial Fibrillation; Multiple Sclerosis', 'Patients with diabetes', '2003-10-25', NULL, NULL, NULL),
  (1304, 'glipizide', NULL, 'Intramuscular', 'AUS', 'HIV Infection; Hepatitis C', 'Pediatric patients 6 months-2 years', '2024-01-23', NULL, NULL, NULL),
  (1305, 'glipizide', NULL, 'Nasal', 'FRA', 'Heart Failure; Psoriatic Arthritis', 'Adults 18-65 years', '2003-06-25', NULL, NULL, NULL),
  (1306, 'glipizide', NULL, 'Sublingual', 'FRA', 'Chronic Obstructive Pulmonary Disease; Bacterial Infections; Schizophrenia', 'Pediatric patients 2-17 years', '2005-01-26', NULL, 'Risk of serious cardiovascular events', '2015-05-18'),
  (1307, 'glipizide', NULL, 'Topical', 'DEU', 'Viral Infections; Fungal Infections', 'Adults 18-65 years', '2002-01-11', NULL, 'Risk of renal impairment', '2018-05-07'),
  (1308, 'glipizide', NULL, 'Intravenous', 'USA', 'HIV Infection; Juvenile Idiopathic Arthritis', 'Pediatric patients 2-17 years', '1995-08-27', NULL, NULL, NULL),
  (1309, 'glipizide', NULL, 'Inhalation', 'DEU', 'Fungal Infections', 'Patients with cardiovascular disease; Pediatric patients 6 months-2 years', '2016-05-23', '2024-11-05', 'Increased risk of malignancy', '2022-11-03'),
  (1310, 'glipizide', NULL, 'Nasal', 'BRA', 'Psoriatic Arthritis; Viral Infections', 'Adults with mild disease', '2010-12-12', NULL, NULL, NULL),
  (1311, 'glipizide', NULL, 'Intravenous', 'ESP', 'Asthma', 'Patients with comorbidities; Adults with mild disease', '1992-07-15', NULL, 'Risk of tuberculosis reactivation', '2019-12-03'),
  (1312, 'glipizide', NULL, 'Sublingual', 'USA', 'Atrial Fibrillation; Pulmonary Embolism; Ankylosing Spondylitis', 'Adults with mild disease; Patients with cardiovascular disease', '2021-05-10', NULL, NULL, NULL),
  (1313, 'glipizide', NULL, 'Nasal', 'CAN', 'Atrial Fibrillation; Pulmonary Embolism; Psoriatic Arthritis', 'Patients with comorbidities', '2024-12-07', NULL, 'Risk of hepatitis B reactivation', '2024-05-14'),
  (1314, 'glipizide', NULL, 'Subcutaneous', 'UK', 'Systemic Lupus Erythematosus', 'Treatment-naive patients; Adults 65+ years', '1999-09-23', NULL, 'Risk of gastrointestinal perforation', '2021-05-20'),
  (1315, 'glipizide', NULL, 'Nasal', 'FRA', 'Cancer; Rheumatoid Arthritis; Diabetes Mellitus Type 2', 'Adults with mild disease; Treatment-naive patients', '2005-11-17', NULL, 'Risk of liver injury', '2022-02-21'),
  (1316, 'glipizide', NULL, 'Sublingual', 'FRA', 'Atrial Fibrillation', 'Patients with comorbidities; Patients with prior treatment failure', '2020-01-04', NULL, 'Risk of renal impairment', '2021-09-28'),
  (1317, 'glipizide', NULL, 'Nasal', 'DEU', 'Bipolar Disorder; Psoriatic Arthritis; Juvenile Idiopathic Arthritis', 'Adults 18-65 years; Patients with prior treatment failure', '2003-09-17', '2021-12-13', NULL, NULL),
  (1318, 'glipizide', NULL, 'Nasal', 'AUS', 'Fungal Infections; Rheumatoid Arthritis; Anxiety', 'Adults 65+ years', '2003-05-07', NULL, NULL, NULL),
  (1319, 'glyburide', NULL, 'Nasal', 'AUS', 'Chronic Obstructive Pulmonary Disease', 'Pediatric patients 6 months-2 years', '2008-09-01', NULL, NULL, NULL),
  (1320, 'glyburide', NULL, 'Inhalation', 'FRA', 'Juvenile Idiopathic Arthritis; Multiple Sclerosis', 'Adults 65+ years; Pregnant women', '2019-04-08', NULL, 'Risk of blood disorders', '2016-05-11'),
  (1321, 'glyburide', NULL, 'Transdermal', 'ESP', 'Fungal Infections; Ankylosing Spondylitis; Psoriatic Arthritis', 'Patients with diabetes', '2006-02-14', NULL, NULL, NULL),
  (1322, 'glyburide', NULL, 'Nasal', 'JPN', 'Psoriatic Arthritis; Schizophrenia', 'Patients with cardiovascular disease; Adults with mild disease', '1998-11-09', NULL, NULL, NULL),
  (1323, 'glyburide', NULL, 'Intravenous', 'BRA', 'Juvenile Idiopathic Arthritis; Ulcerative Colitis', 'Immunocompromised patients; Treatment-naive patients', '2022-04-26', '2020-07-13', NULL, NULL),
  (1324, 'glyburide', NULL, 'Topical', 'UK', 'Hepatitis C; Ankylosing Spondylitis', 'Adults with moderate to severe disease; Adults 18-65 years', '2017-04-08', '2024-06-24', NULL, NULL),
  (1325, 'glyburide', NULL, 'Rectal', 'ESP', 'Anxiety; Chronic Obstructive Pulmonary Disease; Crohn''s Disease', 'Patients with diabetes', '2002-06-17', NULL, NULL, NULL),
  (1326, 'glyburide', NULL, 'Oral', 'AUS', 'HIV Infection', 'Patients with hepatic impairment; Adults 18-65 years', '1998-09-26', '2023-11-26', 'Risk of gastrointestinal perforation', '2020-11-05'),
  (1327, 'glyburide', NULL, 'Rectal', 'AUS', 'Rheumatoid Arthritis; Deep Vein Thrombosis; Hepatitis C', 'Immunocompromised patients; Patients with prior treatment failure', '1999-09-15', NULL, NULL, NULL),
  (1328, 'glyburide', NULL, 'Rectal', 'UK', 'HIV Infection; Depression', 'Adults with mild disease; Patients with diabetes', '1994-06-20', NULL, NULL, NULL),
  (1329, 'glyburide', NULL, 'Sublingual', 'BRA', 'Rheumatoid Arthritis; Juvenile Idiopathic Arthritis; Heart Failure', 'Pediatric patients 2-17 years; Patients with cardiovascular disease', '2004-08-10', NULL, NULL, NULL),
  (1330, 'pioglitazone', NULL, 'Topical', 'AUS', 'Asthma', 'Adults with mild disease; Pediatric patients 2-17 years', '2024-11-24', NULL, NULL, NULL),
  (1331, 'pioglitazone', NULL, 'Topical', 'DEU', 'Osteoporosis; Plaque Psoriasis', 'Patients with prior treatment failure', '1996-09-17', NULL, NULL, NULL),
  (1332, 'pioglitazone', NULL, 'Rectal', 'AUS', 'HIV Infection', 'Adults with mild disease; Pediatric patients 6 months-2 years', '2021-05-10', NULL, 'Increased risk of malignancy', '2021-07-07'),
  (1333, 'pioglitazone', NULL, 'Transdermal', 'AUS', 'Depression; Osteoporosis', 'Treatment-naive patients; Patients with cardiovascular disease', '1991-01-28', NULL, 'Risk of progressive multifocal leukoencephalopathy', '2024-08-13'),
  (1334, 'pioglitazone', NULL, 'Oral', 'AUS', 'Heart Failure; Hypertension', 'Pregnant women', '1998-06-26', NULL, NULL, NULL),
  (1335, 'pioglitazone', NULL, 'Sublingual', 'USA', 'Psoriatic Arthritis; Diabetes Mellitus Type 2', 'Patients with diabetes', '2018-03-27', NULL, NULL, NULL),
  (1336, 'pioglitazone', NULL, 'Inhalation', 'AUS', 'Diabetes Mellitus Type 2; Ulcerative Colitis; Schizophrenia', 'Pediatric patients 2-17 years', '2015-06-18', '2022-03-03', NULL, NULL),
  (1337, 'pioglitazone', NULL, 'Intravenous', 'CAN', 'Migraine; Diabetes Mellitus Type 2; HIV Infection', 'Immunocompromised patients; Patients with obesity', '1996-04-19', NULL, NULL, NULL),
  (1338, 'pioglitazone', NULL, 'Intramuscular', 'DEU', 'Pulmonary Embolism; Rheumatoid Arthritis', 'Immunocompromised patients', '2001-05-01', NULL, NULL, NULL),
  (1339, 'pioglitazone', NULL, 'Subcutaneous', 'UK', 'Heart Failure; Ankylosing Spondylitis', 'Pediatric patients 6 months-2 years', '2003-11-03', NULL, NULL, NULL),
  (1340, 'pioglitazone', NULL, 'Rectal', 'JPN', 'Ankylosing Spondylitis; Psoriatic Arthritis', 'Adults with moderate to severe disease; Patients with renal impairment', '2021-12-11', '2023-01-27', NULL, NULL),
  (1341, 'pioglitazone', NULL, 'Intravenous', 'FRA', 'Crohn''s Disease; Psoriatic Arthritis; Plaque Psoriasis', 'Patients with comorbidities', '2005-05-01', NULL, NULL, NULL),
  (1342, 'pioglitazone', NULL, 'Sublingual', 'FRA', 'Schizophrenia; Pulmonary Embolism', 'Pediatric patients 2-17 years; Patients with obesity', '1996-08-25', NULL, 'Increased risk of serious infections', '2017-12-26'),
  (1343, 'pioglitazone', NULL, 'Nasal', 'FRA', 'Schizophrenia', 'Patients with renal impairment', '2003-08-07', NULL, NULL, NULL),
  (1344, 'pioglitazone', NULL, 'Transdermal', 'USA', 'HIV Infection; Viral Infections; Rheumatoid Arthritis', 'Patients with comorbidities; Adults with moderate to severe disease', '1991-06-12', NULL, NULL, NULL),
  (1345, 'pioglitazone', NULL, 'Intramuscular', 'ESP', 'Ankylosing Spondylitis; Plaque Psoriasis; Hypertension', 'Adults with moderate to severe disease', '1997-11-09', '2020-07-12', NULL, NULL),
  (1346, 'pioglitazone', NULL, 'Rectal', 'BRA', 'Systemic Lupus Erythematosus', 'Immunocompromised patients; Patients with cardiovascular disease', '2023-03-12', NULL, NULL, NULL),
  (1347, 'pioglitazone', NULL, 'Inhalation', 'ESP', 'Juvenile Idiopathic Arthritis; Bacterial Infections', 'Patients with prior treatment failure; Treatment-naive patients', '2014-03-11', NULL, NULL, NULL),
  (1348, 'pioglitazone', NULL, 'Sublingual', 'CAN', 'Pulmonary Embolism; Psoriatic Arthritis', 'Adults with mild disease; Adults with moderate to severe disease', '2001-07-23', '2020-06-01', NULL, NULL),
  (1349, 'pioglitazone', NULL, 'Nasal', 'AUS', 'Migraine; Diabetes Mellitus Type 2', 'Patients with renal impairment; Pediatric patients 2-17 years', '2009-03-03', NULL, NULL, NULL),
  (1350, 'rosiglitazone', NULL, 'Subcutaneous', 'ITA', 'Psoriatic Arthritis', 'Patients with comorbidities', '2008-05-05', NULL, 'Increased risk of serious infections', '2017-12-02'),
  (1351, 'rosiglitazone', NULL, 'Nasal', 'CAN', 'Psoriatic Arthritis', 'Adults with mild disease', '2011-11-16', NULL, NULL, NULL),
  (1352, 'sitagliptin', NULL, 'Intramuscular', 'UK', 'Heart Failure; Fungal Infections; Diabetes Mellitus Type 2', 'Patients with obesity; Patients with prior treatment failure', '2005-12-09', NULL, NULL, NULL),
  (1353, 'sitagliptin', NULL, 'Transdermal', 'JPN', 'Osteoporosis; Asthma', 'Adults 18-65 years', '1996-11-12', NULL, NULL, NULL),
  (1354, 'sitagliptin', NULL, 'Intramuscular', 'ITA', 'Plaque Psoriasis', 'Treatment-naive patients', '1990-01-19', NULL, NULL, NULL),
  (1355, 'sitagliptin', NULL, 'Rectal', 'FRA', 'Ankylosing Spondylitis; Psoriatic Arthritis', 'Patients with renal impairment', '2023-12-16', NULL, 'Risk of progressive multifocal leukoencephalopathy', '2022-07-14'),
  (1356, 'sitagliptin', NULL, 'Intravenous', 'AUS', 'Migraine; Viral Infections; Juvenile Idiopathic Arthritis', 'Patients with obesity; Adults 65+ years', '1995-03-20', NULL, NULL, NULL),
  (1357, 'sitagliptin', NULL, 'Sublingual', 'FRA', 'Ankylosing Spondylitis; Diabetes Mellitus Type 2', 'Treatment-naive patients', '2014-10-22', NULL, NULL, NULL),
  (1358, 'sitagliptin', NULL, 'Topical', 'AUS', 'Crohn''s Disease', 'Patients with obesity; Patients with cardiovascular disease', '2010-12-11', NULL, NULL, NULL),
  (1359, 'sitagliptin', NULL, 'Inhalation', 'JPN', 'Deep Vein Thrombosis; Ulcerative Colitis', 'Patients with hepatic impairment', '1999-03-14', NULL, 'Risk of hypersensitivity reactions', '2017-01-12'),
  (1360, 'sitagliptin', NULL, 'Rectal', 'BRA', 'Pulmonary Embolism', 'Pediatric patients 6 months-2 years', '2008-04-15', NULL, NULL, NULL),
  (1361, 'sitagliptin', NULL, 'Transdermal', 'FRA', 'Cancer; Heart Failure', 'Patients with diabetes; Patients with cardiovascular disease', '2011-09-02', NULL, 'Risk of progressive multifocal leukoencephalopathy', '2017-10-14'),
  (1362, 'sitagliptin', NULL, 'Rectal', 'JPN', 'Chronic Obstructive Pulmonary Disease', 'Adults with mild disease; Pediatric patients 6 months-2 years', '2010-12-16', NULL, NULL, NULL),
  (1363, 'sitagliptin', NULL, 'Oral', 'CAN', 'Asthma; Cancer; Bacterial Infections', 'Patients with renal impairment', '2018-09-13', NULL, NULL, NULL),
  (1364, 'sitagliptin', NULL, 'Topical', 'ITA', 'Heart Failure; Depression; Fungal Infections', 'Adults with mild disease', '1993-01-21', NULL, 'Risk of hepatitis B reactivation', '2020-06-03'),
  (1365, 'sitagliptin', NULL, 'Sublingual', 'UK', 'Plaque Psoriasis', 'Adults 18-65 years', '2003-11-08', NULL, NULL, NULL),
  (1366, 'sitagliptin', NULL, 'Subcutaneous', 'ESP', 'Multiple Sclerosis', 'Pediatric patients 6 months-2 years; Adults with moderate to severe disease', '2021-03-18', NULL, NULL, NULL),
  (1367, 'sitagliptin', NULL, 'Nasal', 'CAN', 'Atrial Fibrillation; Psoriatic Arthritis', 'Patients with comorbidities; Pregnant women', '2009-05-02', '2024-04-10', 'Risk of central nervous system effects', '2019-04-11'),
  (1368, 'sitagliptin', NULL, 'Sublingual', 'CAN', 'Crohn''s Disease', 'Patients with cardiovascular disease; Adults with moderate to severe disease', '2004-02-19', NULL, NULL, NULL),
  (1369, 'sitagliptin', NULL, 'Oral', 'AUS', 'Rheumatoid Arthritis; Systemic Lupus Erythematosus; Cancer', 'Treatment-naive patients; Pregnant women', '2002-09-09', NULL, NULL, NULL),
  (1370, 'linagliptin', NULL, 'Topical', 'JPN', 'Fungal Infections; Schizophrenia', 'Pregnant women', '1991-10-09', NULL, NULL, NULL),
  (1371, 'linagliptin', NULL, 'Intramuscular', 'UK', 'Diabetes Mellitus Type 2; Atrial Fibrillation', 'Adults 18-65 years', '1998-03-01', NULL, NULL, NULL),
  (1372, 'linagliptin', NULL, 'Topical', 'DEU', 'Depression; Juvenile Idiopathic Arthritis', 'Pregnant women; Patients with comorbidities', '2000-12-03', NULL, NULL, NULL),
  (1373, 'linagliptin', NULL, 'Inhalation', 'DEU', 'Hepatitis C; Depression', 'Adults with mild disease; Pediatric patients 6 months-2 years', '1996-04-19', NULL, NULL, NULL),
  (1374, 'linagliptin', NULL, 'Intravenous', 'AUS', 'Heart Failure; Ankylosing Spondylitis', 'Patients with renal impairment; Adults 65+ years', '2009-12-17', NULL, NULL, NULL),
  (1375, 'linagliptin', NULL, 'Inhalation', 'FRA', 'Depression; HIV Infection', 'Adults 65+ years', '1992-07-05', NULL, NULL, NULL),
  (1376, 'linagliptin', NULL, 'Intramuscular', 'DEU', 'Cancer; Chronic Obstructive Pulmonary Disease', 'Pediatric patients 6 months-2 years', '1995-07-14', NULL, NULL, NULL),
  (1377, 'linagliptin', NULL, 'Inhalation', 'BRA', 'Plaque Psoriasis; Systemic Lupus Erythematosus; Asthma', 'Immunocompromised patients', '2011-11-24', NULL, NULL, NULL),
  (1378, 'linagliptin', NULL, 'Transdermal', 'ITA', 'Depression; Crohn''s Disease; Ulcerative Colitis', 'Treatment-naive patients; Pregnant women', '2002-02-01', NULL, NULL, NULL),
  (1379, 'linagliptin', NULL, 'Oral', 'ESP', 'Juvenile Idiopathic Arthritis', 'Pediatric patients 2-17 years; Patients with diabetes', '1991-03-23', NULL, NULL, NULL),
  (1380, 'linagliptin', NULL, 'Sublingual', 'USA', 'Heart Failure; Depression', 'Adults with moderate to severe disease; Patients with obesity', '2009-02-13', NULL, NULL, NULL),
  (1381, 'linagliptin', NULL, 'Subcutaneous', 'ITA', 'Heart Failure; Psoriatic Arthritis', 'Adults 65+ years', '1990-02-24', NULL, NULL, NULL),
  (1382, 'linagliptin', NULL, 'Nasal', 'UK', 'Anxiety; Migraine; Bipolar Disorder', 'Patients with obesity', '1996-09-20', NULL, NULL, NULL),
  (1383, 'linagliptin', NULL, 'Subcutaneous', 'UK', 'Rheumatoid Arthritis; Atrial Fibrillation', 'Treatment-naive patients', '2006-12-27', NULL, NULL, NULL),
  (1384, 'linagliptin', NULL, 'Inhalation', 'ESP', 'Schizophrenia; Heart Failure; Hypertension', 'Adults with moderate to severe disease', '2016-08-06', NULL, 'Risk of progressive multifocal leukoencephalopathy', '2020-08-17'),
  (1385, 'linagliptin', NULL, 'Inhalation', 'CAN', 'Pulmonary Embolism', 'Adults with moderate to severe disease', '1992-02-14', NULL, 'Risk of central nervous system effects', '2017-09-04'),
  (1386, 'linagliptin', NULL, 'Oral', 'ESP', 'Bipolar Disorder', 'Patients with comorbidities', '1992-05-13', NULL, 'Risk of hepatitis B reactivation', '2023-06-23'),
  (1387, 'linagliptin', NULL, 'Oral', 'DEU', 'Deep Vein Thrombosis', 'Pediatric patients 6 months-2 years; Patients with diabetes', '1994-08-15', NULL, NULL, NULL),
  (1388, 'linagliptin', NULL, 'Rectal', 'FRA', 'Multiple Sclerosis; Psoriatic Arthritis; Diabetes Mellitus Type 2', 'Patients with cardiovascular disease; Patients with renal impairment', '2022-09-27', NULL, NULL, NULL),
  (1389, 'linagliptin', NULL, 'Topical', 'UK', 'Deep Vein Thrombosis; Migraine', 'Pediatric patients 2-17 years', '2015-02-10', NULL, 'Risk of peripheral neuropathy', '2018-12-14'),
  (1390, 'linagliptin', NULL, 'Oral', 'FRA', 'Ankylosing Spondylitis', 'Adults 65+ years; Pediatric patients 6 months-2 years', '2024-07-16', NULL, NULL, NULL),
  (1391, 'linagliptin', NULL, 'Subcutaneous', 'AUS', 'Osteoporosis', 'Patients with prior treatment failure; Adults 18-65 years', '2019-11-07', NULL, 'Increased risk of malignancy', '2018-06-24'),
  (1392, 'linagliptin', NULL, 'Oral', 'BRA', 'Anxiety; Migraine', 'Treatment-naive patients; Pediatric patients 6 months-2 years', '2007-10-21', NULL, NULL, NULL),
  (1393, 'linagliptin', NULL, 'Topical', 'AUS', 'Ankylosing Spondylitis; Psoriatic Arthritis; Cancer', 'Pediatric patients 6 months-2 years; Treatment-naive patients', '2008-09-20', NULL, NULL, NULL),
  (1394, 'linagliptin', NULL, 'Sublingual', 'DEU', 'Psoriatic Arthritis', 'Pediatric patients 6 months-2 years', '2009-08-01', NULL, NULL, NULL),
  (1395, 'linagliptin', NULL, 'Transdermal', 'USA', 'Fungal Infections', 'Patients with hepatic impairment; Immunocompromised patients', '2024-01-09', NULL, NULL, NULL),
  (1396, 'linagliptin', NULL, 'Transdermal', 'ITA', 'Anxiety; Hypertension', 'Treatment-naive patients; Adults with moderate to severe disease', '2014-12-27', NULL, NULL, NULL),
  (1397, 'linagliptin', NULL, 'Subcutaneous', 'DEU', 'Cancer; Viral Infections', 'Patients with obesity', '1999-11-13', '2020-06-23', 'Risk of renal impairment', '2016-11-16'),
  (1398, 'linagliptin', NULL, 'Subcutaneous', 'DEU', 'Systemic Lupus Erythematosus; Asthma', 'Patients with hepatic impairment; Patients with renal impairment', '1998-02-11', NULL, NULL, NULL),
  (1399, 'canagliflozin', NULL, 'Inhalation', 'ITA', 'Psoriatic Arthritis', 'Patients with diabetes; Patients with hepatic impairment', '2010-07-09', NULL, NULL, NULL),
  (1400, 'canagliflozin', NULL, 'Sublingual', 'DEU', 'Hepatitis C; Diabetes Mellitus Type 2', 'Pregnant women; Adults 65+ years', '2008-12-03', NULL, NULL, NULL),
  (1401, 'canagliflozin', NULL, 'Intramuscular', 'BRA', 'Schizophrenia; Psoriatic Arthritis', 'Patients with obesity', '1991-01-17', NULL, NULL, NULL),
  (1402, 'canagliflozin', NULL, 'Sublingual', 'DEU', 'Atrial Fibrillation', 'Patients with renal impairment', '1996-10-24', NULL, NULL, NULL),
  (1403, 'canagliflozin', NULL, 'Intramuscular', 'DEU', 'Cancer', 'Pregnant women', '2006-09-12', NULL, NULL, NULL),
  (1404, 'canagliflozin', NULL, 'Intramuscular', 'FRA', 'Pulmonary Embolism; Crohn''s Disease; HIV Infection', 'Patients with hepatic impairment; Pediatric patients 6 months-2 years', '1997-07-02', NULL, NULL, NULL),
  (1405, 'canagliflozin', NULL, 'Sublingual', 'USA', 'Ulcerative Colitis', 'Patients with obesity', '2021-06-10', NULL, NULL, NULL),
  (1406, 'canagliflozin', NULL, 'Oral', 'CAN', 'Deep Vein Thrombosis; Multiple Sclerosis', 'Adults 65+ years', '2005-02-27', NULL, 'Risk of blood disorders', '2022-05-16'),
  (1407, 'canagliflozin', NULL, 'Rectal', 'FRA', 'Atrial Fibrillation; Hepatitis C; Plaque Psoriasis', 'Pregnant women; Patients with obesity', '2014-01-25', NULL, NULL, NULL),
  (1408, 'canagliflozin', NULL, 'Nasal', 'DEU', 'Anxiety', 'Patients with diabetes', '1992-04-10', NULL, NULL, NULL),
  (1409, 'canagliflozin', NULL, 'Inhalation', 'ESP', 'Heart Failure; Psoriatic Arthritis; Multiple Sclerosis', 'Patients with obesity', '2021-08-15', NULL, NULL, NULL),
  (1410, 'canagliflozin', NULL, 'Subcutaneous', 'DEU', 'Diabetes Mellitus Type 2; Systemic Lupus Erythematosus', 'Treatment-naive patients; Patients with obesity', '2014-01-04', NULL, 'Risk of anaphylaxis', '2017-01-19'),
  (1411, 'canagliflozin', NULL, 'Topical', 'AUS', 'Osteoporosis', 'Patients with hepatic impairment', '2001-12-05', NULL, 'Increased risk of serious infections', '2021-12-09'),
  (1412, 'canagliflozin', NULL, 'Subcutaneous', 'AUS', 'Asthma; Ankylosing Spondylitis', 'Pregnant women', '2008-08-16', NULL, NULL, NULL),
  (1413, 'canagliflozin', NULL, 'Subcutaneous', 'FRA', 'Asthma', 'Patients with prior treatment failure; Patients with diabetes', '1999-09-08', NULL, NULL, NULL),
  (1414, 'canagliflozin', NULL, 'Intravenous', 'FRA', 'Deep Vein Thrombosis; Multiple Sclerosis', 'Patients with comorbidities', '1999-05-14', NULL, NULL, NULL),
  (1415, 'canagliflozin', NULL, 'Topical', 'JPN', 'Crohn''s Disease; Ankylosing Spondylitis', 'Adults 65+ years; Adults with moderate to severe disease', '2015-05-10', NULL, NULL, NULL),
  (1416, 'canagliflozin', NULL, 'Intramuscular', 'CAN', 'Psoriatic Arthritis; Hepatitis C', 'Patients with prior treatment failure', '2018-04-24', NULL, NULL, NULL),
  (1417, 'canagliflozin', NULL, 'Sublingual', 'AUS', 'Multiple Sclerosis', 'Adults with mild disease', '1996-12-11', NULL, NULL, NULL),
  (1418, 'canagliflozin', NULL, 'Intramuscular', 'USA', 'Atrial Fibrillation', 'Adults 18-65 years; Pediatric patients 6 months-2 years', '1999-06-11', NULL, NULL, NULL),
  (1419, 'canagliflozin', NULL, 'Inhalation', 'BRA', 'Diabetes Mellitus Type 2', 'Patients with cardiovascular disease', '2014-02-13', NULL, NULL, NULL),
  (1420, 'canagliflozin', NULL, 'Transdermal', 'JPN', 'Diabetes Mellitus Type 2; Heart Failure', 'Patients with comorbidities; Treatment-naive patients', '2016-03-16', NULL, NULL, NULL),
  (1421, 'canagliflozin', NULL, 'Oral', 'USA', 'Hypertension', 'Adults with moderate to severe disease', '1998-12-03', NULL, 'Risk of central nervous system effects', '2016-02-12'),
  (1422, 'canagliflozin', NULL, 'Oral', 'FRA', 'Anxiety', 'Adults with mild disease', '1990-10-06', NULL, NULL, NULL),
  (1423, 'canagliflozin', NULL, 'Sublingual', 'JPN', 'Juvenile Idiopathic Arthritis', 'Adults with mild disease; Patients with comorbidities', '1996-12-12', NULL, 'Risk of central nervous system effects', '2020-03-19'),
  (1424, 'canagliflozin', NULL, 'Topical', 'DEU', 'Asthma; Migraine', 'Patients with hepatic impairment', '2005-09-12', '2022-04-02', NULL, NULL),
  (1425, 'canagliflozin', NULL, 'Intravenous', 'USA', 'Migraine', 'Patients with renal impairment', '2013-09-04', NULL, NULL, NULL),
  (1426, 'canagliflozin', NULL, 'Sublingual', 'UK', 'Diabetes Mellitus Type 2; Multiple Sclerosis', 'Adults 18-65 years', '1999-12-23', NULL, NULL, NULL),
  (1427, 'canagliflozin', NULL, 'Inhalation', 'AUS', 'Cancer', 'Patients with diabetes', '1994-08-02', NULL, 'Risk of hepatitis B reactivation', '2022-03-25'),
  (1428, 'dapagliflozin', NULL, 'Oral', 'DEU', 'Systemic Lupus Erythematosus', 'Patients with diabetes', '2024-08-01', '2020-10-18', 'Risk of peripheral neuropathy', '2015-04-12'),
  (1429, 'dapagliflozin', NULL, 'Rectal', 'JPN', 'Heart Failure', 'Pregnant women; Patients with diabetes', '1995-01-23', NULL, 'Risk of liver injury', '2022-10-13'),
  (1430, 'dapagliflozin', NULL, 'Sublingual', 'UK', 'Bacterial Infections; Bipolar Disorder; Systemic Lupus Erythematosus', 'Patients with hepatic impairment; Treatment-naive patients', '2018-03-21', NULL, NULL, NULL),
  (1431, 'dapagliflozin', NULL, 'Inhalation', 'FRA', 'Bacterial Infections; Juvenile Idiopathic Arthritis; Systemic Lupus Erythematosus', 'Immunocompromised patients', '2013-01-28', '2020-10-27', NULL, NULL),
  (1432, 'dapagliflozin', NULL, 'Nasal', 'CAN', 'Systemic Lupus Erythematosus; Psoriatic Arthritis; Hypertension', 'Patients with prior treatment failure', '2016-05-02', NULL, 'Risk of tuberculosis reactivation', '2016-09-07'),
  (1433, 'dapagliflozin', NULL, 'Sublingual', 'CAN', 'Hepatitis C; Bipolar Disorder', 'Patients with prior treatment failure', '1998-03-17', NULL, NULL, NULL),
  (1434, 'dapagliflozin', NULL, 'Transdermal', 'FRA', 'Juvenile Idiopathic Arthritis; Deep Vein Thrombosis', 'Patients with diabetes; Patients with cardiovascular disease', '2009-03-02', NULL, 'Risk of vision changes', '2016-04-26'),
  (1435, 'dapagliflozin', NULL, 'Rectal', 'CAN', 'Multiple Sclerosis; Fungal Infections', 'Pediatric patients 6 months-2 years; Patients with prior treatment failure', '2019-03-15', NULL, 'Risk of central nervous system effects', '2022-05-13'),
  (1436, 'dapagliflozin', NULL, 'Topical', 'UK', 'Viral Infections; Chronic Obstructive Pulmonary Disease; Deep Vein Thrombosis', 'Adults 18-65 years; Adults 65+ years', '1996-05-26', NULL, NULL, NULL),
  (1437, 'dapagliflozin', NULL, 'Nasal', 'BRA', 'Asthma', 'Adults 65+ years', '1991-12-08', NULL, 'Risk of serious cardiovascular events', '2017-06-10'),
  (1438, 'dapagliflozin', NULL, 'Nasal', 'FRA', 'Chronic Obstructive Pulmonary Disease; Pulmonary Embolism; Diabetes Mellitus Type 2', 'Pediatric patients 6 months-2 years', '1991-06-14', NULL, 'Risk of tuberculosis reactivation', '2024-08-04'),
  (1439, 'dapagliflozin', NULL, 'Intravenous', 'FRA', 'Depression', 'Adults 18-65 years', '2013-07-18', NULL, 'Risk of gastrointestinal perforation', '2022-05-14'),
  (1440, 'dapagliflozin', NULL, 'Sublingual', 'FRA', 'Psoriatic Arthritis', 'Adults with moderate to severe disease', '1994-08-21', '2023-05-11', NULL, NULL),
  (1441, 'dapagliflozin', NULL, 'Subcutaneous', 'ITA', 'Psoriatic Arthritis; Bipolar Disorder', 'Patients with hepatic impairment; Patients with cardiovascular disease', '2019-02-07', NULL, NULL, NULL),
  (1442, 'dapagliflozin', NULL, 'Oral', 'UK', 'Deep Vein Thrombosis', 'Adults 18-65 years', '2004-04-15', NULL, NULL, NULL),
  (1443, 'dapagliflozin', NULL, 'Inhalation', 'USA', 'Rheumatoid Arthritis; Juvenile Idiopathic Arthritis; Anxiety', 'Patients with hepatic impairment; Patients with prior treatment failure', '2015-02-12', NULL, NULL, NULL),
  (1444, 'dapagliflozin', NULL, 'Nasal', 'UK', 'Ankylosing Spondylitis; Pulmonary Embolism; Juvenile Idiopathic Arthritis', 'Patients with prior treatment failure; Pregnant women', '2012-09-03', NULL, NULL, NULL),
  (1445, 'dapagliflozin', NULL, 'Subcutaneous', 'ITA', 'Deep Vein Thrombosis; Viral Infections', 'Patients with renal impairment; Patients with obesity', '2010-12-07', NULL, NULL, NULL),
  (1446, 'dapagliflozin', NULL, 'Sublingual', 'CAN', 'Diabetes Mellitus Type 2; Migraine', 'Patients with hepatic impairment; Adults 18-65 years', '1992-02-21', NULL, NULL, NULL),
  (1447, 'dapagliflozin', NULL, 'Nasal', 'AUS', 'Rheumatoid Arthritis', 'Treatment-naive patients', '2004-01-28', NULL, 'Risk of blood disorders', '2019-06-18'),
  (1448, 'dapagliflozin', NULL, 'Sublingual', 'DEU', 'Osteoporosis; Hepatitis C; Systemic Lupus Erythematosus', 'Patients with prior treatment failure; Immunocompromised patients', '1990-02-03', NULL, NULL, NULL),
  (1449, 'dapagliflozin', NULL, 'Inhalation', 'USA', 'Osteoporosis; Migraine; Heart Failure', 'Patients with diabetes', '1996-02-25', NULL, 'Risk of progressive multifocal leukoencephalopathy', '2018-02-25'),
  (1450, 'dapagliflozin', NULL, 'Transdermal', 'UK', 'Osteoporosis; Diabetes Mellitus Type 2; Hepatitis C', 'Pediatric patients 2-17 years', '2015-10-20', NULL, NULL, NULL),
  (1451, 'dapagliflozin', NULL, 'Nasal', 'DEU', 'Crohn''s Disease; Bacterial Infections', 'Adults with mild disease', '2014-09-01', NULL, NULL, NULL),
  (1452, 'empagliflozin', NULL, 'Sublingual', 'JPN', 'Rheumatoid Arthritis', 'Adults 65+ years', '2006-07-19', NULL, 'Risk of hypersensitivity reactions', '2019-01-06'),
  (1453, 'empagliflozin', NULL, 'Transdermal', 'AUS', 'Rheumatoid Arthritis; Bacterial Infections', 'Adults 65+ years; Patients with prior treatment failure', '1995-11-03', NULL, NULL, NULL),
  (1454, 'empagliflozin', NULL, 'Topical', 'UK', 'Asthma', 'Patients with renal impairment; Pediatric patients 2-17 years', '1990-05-03', NULL, NULL, NULL),
  (1455, 'empagliflozin', NULL, 'Intramuscular', 'ITA', 'Hypertension; Crohn''s Disease', 'Pediatric patients 2-17 years', '2009-05-13', NULL, 'Risk of gastrointestinal perforation', '2024-08-01'),
  (1456, 'empagliflozin', NULL, 'Intravenous', 'ESP', 'Rheumatoid Arthritis; Schizophrenia', 'Adults with mild disease', '1993-08-15', NULL, NULL, NULL),
  (1457, 'empagliflozin', NULL, 'Intramuscular', 'BRA', 'HIV Infection', 'Adults with mild disease; Adults 18-65 years', '1997-07-05', NULL, NULL, NULL),
  (1458, 'liraglutide', NULL, 'Rectal', 'JPN', 'Ulcerative Colitis', 'Patients with prior treatment failure; Pediatric patients 2-17 years', '2005-07-19', NULL, NULL, NULL),
  (1459, 'liraglutide', NULL, 'Intravenous', 'AUS', 'Bipolar Disorder', 'Adults with mild disease', '2008-03-10', NULL, NULL, NULL),
  (1460, 'liraglutide', NULL, 'Topical', 'FRA', 'Multiple Sclerosis; Anxiety', 'Patients with diabetes; Patients with hepatic impairment', '2014-03-14', '2022-04-21', NULL, NULL),
  (1461, 'exenatide', NULL, 'Inhalation', 'DEU', 'Bipolar Disorder', 'Adults 18-65 years', '1991-03-11', NULL, NULL, NULL),
  (1462, 'exenatide', NULL, 'Intramuscular', 'BRA', 'Systemic Lupus Erythematosus; Bacterial Infections', 'Patients with prior treatment failure; Patients with cardiovascular disease', '1995-12-27', NULL, NULL, NULL),
  (1463, 'exenatide', NULL, 'Oral', 'UK', 'Atrial Fibrillation; Plaque Psoriasis', 'Treatment-naive patients; Adults with moderate to severe disease', '1996-11-08', NULL, NULL, NULL),
  (1464, 'exenatide', NULL, 'Intramuscular', 'UK', 'Anxiety', 'Adults with moderate to severe disease', '2001-09-25', NULL, NULL, NULL),
  (1465, 'exenatide', NULL, 'Transdermal', 'AUS', 'Osteoporosis; Viral Infections', 'Patients with obesity; Patients with prior treatment failure', '2016-05-21', NULL, 'Risk of peripheral neuropathy', '2023-02-27'),
  (1466, 'exenatide', NULL, 'Oral', 'JPN', 'Ankylosing Spondylitis; Bacterial Infections', 'Pediatric patients 2-17 years; Patients with comorbidities', '2015-01-20', NULL, NULL, NULL),
  (1467, 'exenatide', NULL, 'Nasal', 'FRA', 'Psoriatic Arthritis', 'Adults 65+ years', '2023-11-07', NULL, 'Risk of hepatitis B reactivation', '2016-08-21'),
  (1468, 'exenatide', NULL, 'Nasal', 'CAN', 'Pulmonary Embolism; Psoriatic Arthritis; Juvenile Idiopathic Arthritis', 'Patients with obesity; Immunocompromised patients', '1995-10-20', NULL, NULL, NULL),
  (1469, 'exenatide', NULL, 'Rectal', 'JPN', 'Osteoporosis; Schizophrenia; Multiple Sclerosis', 'Adults 65+ years; Pediatric patients 6 months-2 years', '2012-06-26', NULL, NULL, NULL),
  (1470, 'exenatide', NULL, 'Rectal', 'DEU', 'Psoriatic Arthritis; Viral Infections', 'Patients with comorbidities; Adults 18-65 years', '2016-08-18', NULL, 'Risk of tuberculosis reactivation', '2024-02-02'),
  (1471, 'exenatide', NULL, 'Inhalation', 'ITA', 'Migraine; Anxiety; Systemic Lupus Erythematosus', 'Patients with comorbidities', '1993-11-20', NULL, 'Risk of hearing loss', '2017-07-13'),
  (1472, 'exenatide', NULL, 'Intramuscular', 'CAN', 'Systemic Lupus Erythematosus; Atrial Fibrillation; Rheumatoid Arthritis', 'Adults 18-65 years', '2014-12-07', NULL, 'Risk of vision changes', '2022-05-13'),
  (1473, 'exenatide', NULL, 'Topical', 'JPN', 'Pulmonary Embolism; Ulcerative Colitis', 'Patients with prior treatment failure', '2013-09-23', NULL, NULL, NULL),
  (1474, 'exenatide', NULL, 'Nasal', 'FRA', 'Pulmonary Embolism; Cancer', 'Patients with obesity', '2006-09-27', NULL, NULL, NULL),
  (1475, 'exenatide', NULL, 'Intramuscular', 'DEU', 'Viral Infections', 'Immunocompromised patients; Patients with prior treatment failure', '2019-03-04', NULL, NULL, NULL),
  (1476, 'exenatide', NULL, 'Oral', 'DEU', 'Atrial Fibrillation', 'Patients with hepatic impairment', '2000-12-21', NULL, NULL, NULL),
  (1477, 'exenatide', NULL, 'Sublingual', 'ITA', 'Juvenile Idiopathic Arthritis', 'Adults with moderate to severe disease', '2015-11-26', NULL, NULL, NULL),
  (1478, 'semaglutide', NULL, 'Inhalation', 'BRA', 'Hypertension; Anxiety; Osteoporosis', 'Patients with obesity; Patients with hepatic impairment', '2000-12-16', NULL, 'Risk of anaphylaxis', '2019-05-08'),
  (1479, 'semaglutide', NULL, 'Transdermal', 'USA', 'Asthma; Hepatitis C; Ulcerative Colitis', 'Patients with hepatic impairment; Pediatric patients 2-17 years', '2008-02-17', NULL, NULL, NULL),
  (1480, 'semaglutide', NULL, 'Transdermal', 'AUS', 'Fungal Infections; Rheumatoid Arthritis; Psoriatic Arthritis', 'Immunocompromised patients', '2020-05-10', NULL, NULL, NULL),
  (1481, 'semaglutide', NULL, 'Intramuscular', 'FRA', 'Chronic Obstructive Pulmonary Disease', 'Patients with prior treatment failure; Treatment-naive patients', '2012-11-04', NULL, NULL, NULL),
  (1482, 'semaglutide', NULL, 'Sublingual', 'DEU', 'Ankylosing Spondylitis', 'Patients with cardiovascular disease', '2022-03-15', NULL, 'Risk of hepatitis B reactivation', '2023-05-24'),
  (1483, 'semaglutide', NULL, 'Rectal', 'DEU', 'Crohn''s Disease; Plaque Psoriasis', 'Patients with hepatic impairment', '2016-06-20', NULL, 'Increased risk of serious infections', '2024-11-26'),
  (1484, 'semaglutide', NULL, 'Topical', 'ITA', 'Osteoporosis; Heart Failure', 'Adults 65+ years', '2009-02-22', NULL, NULL, NULL),
  (1485, 'insulin-glargine', NULL, 'Subcutaneous', 'CAN', 'Multiple Sclerosis; Viral Infections; Heart Failure', 'Patients with diabetes', '2014-11-16', NULL, 'Risk of renal impairment', '2017-06-07'),
  (1486, 'insulin-glargine', NULL, 'Rectal', 'UK', 'Psoriatic Arthritis; Schizophrenia; Hepatitis C', 'Patients with diabetes; Patients with renal impairment', '2007-11-18', NULL, NULL, NULL),
  (1487, 'insulin-glargine', NULL, 'Intravenous', 'JPN', 'HIV Infection', 'Immunocompromised patients', '2004-11-23', NULL, NULL, NULL),
  (1488, 'insulin-glargine', NULL, 'Rectal', 'AUS', 'Juvenile Idiopathic Arthritis; Bipolar Disorder; Asthma', 'Immunocompromised patients; Patients with renal impairment', '2021-04-23', NULL, NULL, NULL),
  (1489, 'insulin-glargine', NULL, 'Inhalation', 'ITA', 'Cancer', 'Pregnant women', '2010-08-13', NULL, NULL, NULL),
  (1490, 'insulin-glargine', NULL, 'Inhalation', 'AUS', 'Atrial Fibrillation; Schizophrenia', 'Patients with prior treatment failure', '2006-10-22', NULL, NULL, NULL),
  (1491, 'insulin-glargine', NULL, 'Inhalation', 'USA', 'Hepatitis C; Ulcerative Colitis; Hypertension', 'Immunocompromised patients', '1996-02-16', NULL, 'Risk of gastrointestinal perforation', '2017-07-20'),
  (1492, 'insulin-glargine', NULL, 'Inhalation', 'JPN', 'Diabetes Mellitus Type 2; Psoriatic Arthritis; Depression', 'Patients with comorbidities; Pediatric patients 6 months-2 years', '2024-09-08', NULL, NULL, NULL),
  (1493, 'insulin-glargine', NULL, 'Sublingual', 'ITA', 'Pulmonary Embolism', 'Adults with moderate to severe disease; Adults 65+ years', '2007-12-25', NULL, NULL, NULL),
  (1494, 'insulin-glargine', NULL, 'Rectal', 'UK', 'Schizophrenia', 'Adults with moderate to severe disease', '1994-07-01', NULL, NULL, NULL),
  (1495, 'insulin-glargine', NULL, 'Rectal', 'UK', 'Plaque Psoriasis', 'Patients with comorbidities', '2022-01-19', '2020-10-10', NULL, NULL),
  (1496, 'insulin-glargine', NULL, 'Oral', 'UK', 'Bipolar Disorder; Psoriatic Arthritis; Cancer', 'Patients with prior treatment failure; Patients with comorbidities', '2017-12-16', NULL, NULL, NULL),
  (1497, 'insulin-glargine', NULL, 'Sublingual', 'BRA', 'Chronic Obstructive Pulmonary Disease; Asthma', 'Adults 18-65 years', '1990-04-17', NULL, 'Risk of peripheral neuropathy', '2023-03-27'),
  (1498, 'insulin-aspart', NULL, 'Rectal', 'FRA', 'Depression; Juvenile Idiopathic Arthritis; Fungal Infections', 'Treatment-naive patients', '1995-01-08', NULL, NULL, NULL),
  (1499, 'insulin-aspart', NULL, 'Topical', 'USA', 'Juvenile Idiopathic Arthritis; Crohn''s Disease; Atrial Fibrillation', 'Patients with comorbidities', '2023-03-16', NULL, 'Risk of peripheral neuropathy', '2021-05-01'),
  (1500, 'insulin-aspart', NULL, 'Nasal', 'JPN', 'Osteoporosis', 'Pediatric patients 2-17 years', '2004-01-13', '2020-08-20', 'Risk of anaphylaxis', '2021-11-28'),
  (1501, 'insulin-aspart', NULL, 'Transdermal', 'JPN', 'Ulcerative Colitis; Ankylosing Spondylitis; Atrial Fibrillation', 'Patients with cardiovascular disease; Patients with diabetes', '2011-12-05', NULL, NULL, NULL),
  (1502, 'insulin-aspart', NULL, 'Topical', 'DEU', 'Plaque Psoriasis', 'Patients with hepatic impairment', '2010-01-06', NULL, 'Risk of anaphylaxis', '2018-03-04'),
  (1503, 'insulin-aspart', NULL, 'Nasal', 'USA', 'Fungal Infections', 'Pediatric patients 2-17 years', '2024-09-06', NULL, NULL, NULL),
  (1504, 'insulin-aspart', NULL, 'Topical', 'ESP', 'Cancer', 'Adults with mild disease; Patients with renal impairment', '1996-09-18', NULL, NULL, NULL),
  (1505, 'insulin-aspart', NULL, 'Intramuscular', 'ITA', 'Multiple Sclerosis', 'Adults with mild disease', '2008-06-06', NULL, NULL, NULL),
  (1506, 'insulin-aspart', NULL, 'Transdermal', 'AUS', 'Systemic Lupus Erythematosus; Atrial Fibrillation; Psoriatic Arthritis', 'Pediatric patients 6 months-2 years; Adults 65+ years', '2019-04-02', NULL, NULL, NULL),
  (1507, 'insulin-aspart', NULL, 'Intramuscular', 'USA', 'Schizophrenia; Deep Vein Thrombosis', 'Immunocompromised patients; Adults 18-65 years', '2002-07-28', NULL, NULL, NULL),
  (1508, 'insulin-aspart', NULL, 'Oral', 'FRA', 'Juvenile Idiopathic Arthritis; Psoriatic Arthritis', 'Patients with prior treatment failure; Patients with cardiovascular disease', '2022-08-13', NULL, 'Risk of hearing loss', '2017-09-13'),
  (1509, 'insulin-aspart', NULL, 'Transdermal', 'UK', 'Systemic Lupus Erythematosus; Hypertension', 'Patients with renal impairment', '2024-07-09', NULL, NULL, NULL),
  (1510, 'insulin-aspart', NULL, 'Intramuscular', 'JPN', 'Hepatitis C', 'Patients with comorbidities', '2000-04-21', NULL, NULL, NULL),
  (1511, 'insulin-aspart', NULL, 'Rectal', 'ITA', 'Anxiety', 'Patients with comorbidities', '2004-12-09', NULL, 'Risk of progressive multifocal leukoencephalopathy', '2017-02-16'),
  (1512, 'insulin-aspart', NULL, 'Oral', 'USA', 'Bacterial Infections; Anxiety', 'Adults with mild disease', '2019-05-23', NULL, 'Risk of peripheral neuropathy', '2022-09-05'),
  (1513, 'insulin-aspart', NULL, 'Intramuscular', 'AUS', 'Viral Infections', 'Patients with comorbidities', '2007-08-28', NULL, NULL, NULL),
  (1514, 'insulin-aspart', NULL, 'Topical', 'BRA', 'Fungal Infections; Bipolar Disorder; Ulcerative Colitis', 'Patients with renal impairment; Pediatric patients 2-17 years', '1991-10-10', NULL, NULL, NULL),
  (1515, 'insulin-aspart', NULL, 'Oral', 'ITA', 'Osteoporosis; Migraine; Pulmonary Embolism', 'Immunocompromised patients; Adults 18-65 years', '2011-01-11', '2022-06-03', NULL, NULL),
  (1516, 'insulin-aspart', NULL, 'Nasal', 'DEU', 'Bipolar Disorder; Multiple Sclerosis', 'Adults 18-65 years', '2019-06-20', NULL, NULL, NULL),
  (1517, 'insulin-aspart', NULL, 'Inhalation', 'FRA', 'Migraine; Anxiety', 'Patients with cardiovascular disease', '2005-11-17', NULL, NULL, NULL),
  (1518, 'insulin-aspart', NULL, 'Inhalation', 'AUS', 'Ulcerative Colitis', 'Patients with hepatic impairment; Pregnant women', '2008-09-19', NULL, NULL, NULL),
  (1519, 'insulin-aspart', NULL, 'Oral', 'USA', 'Anxiety', 'Pediatric patients 2-17 years; Immunocompromised patients', '2024-04-06', NULL, NULL, NULL),
  (1520, 'insulin-aspart', NULL, 'Intravenous', 'JPN', 'Juvenile Idiopathic Arthritis', 'Patients with prior treatment failure', '2004-01-18', NULL, NULL, NULL),
  (1521, 'insulin-lispro', NULL, 'Rectal', 'JPN', 'Multiple Sclerosis; Diabetes Mellitus Type 2', 'Pediatric patients 6 months-2 years', '2017-08-27', NULL, NULL, NULL),
  (1522, 'insulin-lispro', NULL, 'Transdermal', 'UK', 'Juvenile Idiopathic Arthritis', 'Adults 65+ years; Adults 18-65 years', '2023-09-11', NULL, NULL, NULL),
  (1523, 'insulin-lispro', NULL, 'Sublingual', 'DEU', 'Bipolar Disorder', 'Pediatric patients 2-17 years', '1995-07-11', NULL, NULL, NULL),
  (1524, 'insulin-lispro', NULL, 'Intramuscular', 'BRA', 'Rheumatoid Arthritis; Atrial Fibrillation', 'Adults 65+ years; Patients with diabetes', '1994-03-14', NULL, NULL, NULL),
  (1525, 'insulin-lispro', NULL, 'Sublingual', 'ESP', 'Migraine', 'Patients with obesity; Adults with mild disease', '2008-02-20', NULL, NULL, NULL),
  (1526, 'insulin-lispro', NULL, 'Transdermal', 'CAN', 'Anxiety; Ulcerative Colitis; Psoriatic Arthritis', 'Patients with prior treatment failure', '1993-10-04', NULL, NULL, NULL),
  (1527, 'insulin-lispro', NULL, 'Sublingual', 'CAN', 'Psoriatic Arthritis; Chronic Obstructive Pulmonary Disease', 'Treatment-naive patients', '2010-03-13', NULL, 'Risk of central nervous system effects', '2023-07-22'),
  (1528, 'insulin-lispro', NULL, 'Inhalation', 'UK', 'Plaque Psoriasis', 'Adults with moderate to severe disease; Pregnant women', '2005-04-14', NULL, 'Risk of vision changes', '2019-09-26'),
  (1529, 'insulin-lispro', NULL, 'Intramuscular', 'AUS', 'Atrial Fibrillation', 'Patients with comorbidities', '2003-01-10', '2022-07-21', 'Risk of progressive multifocal leukoencephalopathy', '2021-12-13'),
  (1530, 'insulin-lispro', NULL, 'Subcutaneous', 'USA', 'Atrial Fibrillation', 'Patients with comorbidities; Patients with diabetes', '1999-10-05', NULL, 'Increased risk of serious infections', '2018-01-27'),
  (1531, 'insulin-lispro', NULL, 'Rectal', 'JPN', 'Chronic Obstructive Pulmonary Disease; Heart Failure; Deep Vein Thrombosis', 'Adults 18-65 years', '2007-06-12', NULL, 'Risk of central nervous system effects', '2016-12-25'),
  (1532, 'insulin-lispro', NULL, 'Intravenous', 'ESP', 'Heart Failure; Hypertension; Multiple Sclerosis', 'Adults with mild disease', '2003-12-13', NULL, 'Increased risk of serious infections', '2018-04-04'),
  (1533, 'insulin-lispro', NULL, 'Topical', 'JPN', 'Pulmonary Embolism; Hypertension; Diabetes Mellitus Type 2', 'Adults 18-65 years', '2018-01-05', '2022-03-14', NULL, NULL),
  (1534, 'insulin-lispro', NULL, 'Sublingual', 'DEU', 'Heart Failure; Multiple Sclerosis', 'Patients with cardiovascular disease', '2001-10-27', NULL, NULL, NULL),
  (1535, 'insulin-detemir', NULL, 'Nasal', 'ITA', 'Atrial Fibrillation', 'Patients with diabetes; Pediatric patients 6 months-2 years', '2007-01-20', NULL, NULL, NULL),
  (1536, 'insulin-detemir', NULL, 'Nasal', 'USA', 'Anxiety', 'Pregnant women; Pediatric patients 6 months-2 years', '2018-08-23', NULL, 'Risk of anaphylaxis', '2015-12-07'),
  (1537, 'insulin-detemir', NULL, 'Intramuscular', 'CAN', 'Crohn''s Disease', 'Pediatric patients 6 months-2 years; Patients with hepatic impairment', '2014-03-27', NULL, NULL, NULL),
  (1538, 'insulin-detemir', NULL, 'Sublingual', 'CAN', 'Deep Vein Thrombosis', 'Immunocompromised patients', '2000-01-03', NULL, 'Risk of hypersensitivity reactions', '2024-01-15'),
  (1539, 'insulin-detemir', NULL, 'Oral', 'BRA', 'Schizophrenia; Cancer; Pulmonary Embolism', 'Patients with diabetes; Treatment-naive patients', '2006-11-02', NULL, NULL, NULL),
  (1540, 'insulin-detemir', NULL, 'Nasal', 'ESP', 'Chronic Obstructive Pulmonary Disease', 'Patients with obesity; Treatment-naive patients', '2019-11-09', NULL, 'Risk of vision changes', '2018-08-22'),
  (1541, 'insulin-detemir', NULL, 'Oral', 'ESP', 'Crohn''s Disease', 'Patients with hepatic impairment; Patients with prior treatment failure', '2006-09-11', NULL, 'Increased risk of malignancy', '2023-02-14'),
  (1542, 'insulin-detemir', NULL, 'Intravenous', 'ITA', 'Hypertension; Pulmonary Embolism', 'Patients with hepatic impairment; Patients with prior treatment failure', '1998-10-14', NULL, NULL, NULL),
  (1543, 'insulin-detemir', NULL, 'Sublingual', 'JPN', 'Plaque Psoriasis', 'Patients with renal impairment', '2017-11-26', NULL, 'Risk of hypersensitivity reactions', '2019-08-15'),
  (1544, 'insulin-detemir', NULL, 'Intramuscular', 'JPN', 'Schizophrenia; Plaque Psoriasis; Anxiety', 'Patients with diabetes; Patients with prior treatment failure', '1992-05-25', NULL, 'Increased risk of malignancy', '2021-05-13'),
  (1545, 'insulin-detemir', NULL, 'Sublingual', 'ESP', 'Heart Failure; Ulcerative Colitis; Hepatitis C', 'Adults 18-65 years; Pediatric patients 2-17 years', '1990-05-14', '2020-07-10', NULL, NULL),
  (1546, 'insulin-detemir', NULL, 'Sublingual', 'CAN', 'Migraine; Fungal Infections; Psoriatic Arthritis', 'Immunocompromised patients; Adults with mild disease', '1997-03-09', NULL, NULL, NULL),
  (1547, 'insulin-detemir', NULL, 'Subcutaneous', 'UK', 'Juvenile Idiopathic Arthritis', 'Adults 65+ years', '1991-08-14', '2021-01-24', NULL, NULL),
  (1548, 'insulin-detemir', NULL, 'Rectal', 'ESP', 'Depression', 'Adults 18-65 years', '1996-12-03', NULL, NULL, NULL),
  (1549, 'insulin-detemir', NULL, 'Transdermal', 'BRA', 'Fungal Infections; Plaque Psoriasis', 'Patients with comorbidities', '1999-06-01', NULL, NULL, NULL),
  (1550, 'insulin-detemir', NULL, 'Topical', 'ESP', 'Psoriatic Arthritis; Deep Vein Thrombosis; Systemic Lupus Erythematosus', 'Patients with obesity; Adults 65+ years', '2019-07-15', '2024-02-23', 'Risk of vision changes', '2017-12-19'),
  (1551, 'insulin-detemir', NULL, 'Rectal', 'BRA', 'Anxiety; Viral Infections; Atrial Fibrillation', 'Patients with prior treatment failure', '2015-05-26', NULL, NULL, NULL),
  (1552, 'insulin-detemir', NULL, 'Transdermal', 'DEU', 'Ulcerative Colitis; Plaque Psoriasis', 'Adults with mild disease; Patients with cardiovascular disease', '1991-12-07', NULL, NULL, NULL),
  (1553, 'insulin-detemir', NULL, 'Intramuscular', 'UK', 'Pulmonary Embolism; Atrial Fibrillation', 'Patients with cardiovascular disease', '2020-03-24', NULL, 'Risk of hypersensitivity reactions', '2020-10-07'),
  (1554, 'warfarin', NULL, 'Topical', 'AUS', 'Bipolar Disorder', 'Patients with diabetes', '1991-12-14', NULL, NULL, NULL),
  (1555, 'warfarin', NULL, 'Rectal', 'USA', 'Osteoporosis; Crohn''s Disease; Atrial Fibrillation', 'Patients with comorbidities; Immunocompromised patients', '2015-09-25', '2021-05-02', 'Risk of vision changes', '2020-09-01'),
  (1556, 'warfarin', NULL, 'Subcutaneous', 'JPN', 'Systemic Lupus Erythematosus; Bacterial Infections; Fungal Infections', 'Treatment-naive patients', '2004-10-27', NULL, NULL, NULL),
  (1557, 'warfarin', NULL, 'Oral', 'FRA', 'Osteoporosis; HIV Infection', 'Adults with moderate to severe disease; Patients with hepatic impairment', '2002-09-03', NULL, NULL, NULL),
  (1558, 'warfarin', NULL, 'Subcutaneous', 'DEU', 'Plaque Psoriasis; Ulcerative Colitis', 'Pregnant women', '2022-05-18', NULL, NULL, NULL),
  (1559, 'warfarin', NULL, 'Oral', 'ESP', 'Deep Vein Thrombosis; Hepatitis C; Ulcerative Colitis', 'Patients with diabetes', '2013-06-13', NULL, NULL, NULL),
  (1560, 'warfarin', NULL, 'Intramuscular', 'JPN', 'Ankylosing Spondylitis; Rheumatoid Arthritis', 'Pregnant women; Adults with moderate to severe disease', '2002-09-02', NULL, 'Increased risk of serious infections', '2022-04-14'),
  (1561, 'warfarin', NULL, 'Nasal', 'CAN', 'Psoriatic Arthritis; Multiple Sclerosis; Ankylosing Spondylitis', 'Adults with mild disease; Adults 18-65 years', '1992-04-11', NULL, NULL, NULL),
  (1562, 'warfarin', NULL, 'Rectal', 'DEU', 'Anxiety; Rheumatoid Arthritis', 'Patients with comorbidities; Pregnant women', '2002-06-22', NULL, 'Risk of liver injury', '2020-11-08'),
  (1563, 'warfarin', NULL, 'Transdermal', 'BRA', 'Rheumatoid Arthritis; Diabetes Mellitus Type 2', 'Adults with moderate to severe disease; Patients with diabetes', '2020-08-06', NULL, NULL, NULL),
  (1564, 'warfarin', NULL, 'Transdermal', 'BRA', 'Bipolar Disorder', 'Pediatric patients 6 months-2 years; Patients with comorbidities', '2008-08-21', NULL, NULL, NULL),
  (1565, 'warfarin', NULL, 'Intramuscular', 'AUS', 'Heart Failure; Pulmonary Embolism', 'Treatment-naive patients; Pediatric patients 2-17 years', '2023-06-12', NULL, 'Risk of hypersensitivity reactions', '2020-05-23'),
  (1566, 'warfarin', NULL, 'Rectal', 'ESP', 'Bipolar Disorder', 'Immunocompromised patients; Pediatric patients 6 months-2 years', '1992-09-03', NULL, 'Risk of hypersensitivity reactions', '2015-07-17'),
  (1567, 'warfarin', NULL, 'Topical', 'ESP', 'Pulmonary Embolism; HIV Infection', 'Patients with prior treatment failure; Patients with comorbidities', '2023-01-16', '2023-09-15', NULL, NULL),
  (1568, 'warfarin', NULL, 'Intravenous', 'BRA', 'Cancer; Fungal Infections', 'Patients with diabetes', '2000-12-28', NULL, NULL, NULL),
  (1569, 'warfarin', NULL, 'Nasal', 'AUS', 'Fungal Infections; Chronic Obstructive Pulmonary Disease', 'Patients with cardiovascular disease', '2011-04-10', NULL, NULL, NULL),
  (1570, 'warfarin', NULL, 'Oral', 'CAN', 'Bacterial Infections', 'Adults with mild disease', '2007-01-23', NULL, 'Risk of anaphylaxis', '2018-11-13'),
  (1571, 'warfarin', NULL, 'Sublingual', 'ESP', 'Ankylosing Spondylitis', 'Adults 65+ years; Adults with mild disease', '2006-03-14', NULL, NULL, NULL),
  (1572, 'warfarin', NULL, 'Oral', 'ITA', 'Schizophrenia; Atrial Fibrillation', 'Patients with hepatic impairment', '2018-05-15', NULL, 'Risk of hypersensitivity reactions', '2015-10-28'),
  (1573, 'warfarin', NULL, 'Nasal', 'CAN', 'Psoriatic Arthritis; Viral Infections', 'Pregnant women; Patients with renal impairment', '1994-06-17', NULL, NULL, NULL),
  (1574, 'warfarin', NULL, 'Sublingual', 'UK', 'Chronic Obstructive Pulmonary Disease; Multiple Sclerosis; Fungal Infections', 'Pediatric patients 6 months-2 years; Patients with prior treatment failure', '1997-01-17', NULL, NULL, NULL),
  (1575, 'warfarin', NULL, 'Intravenous', 'CAN', 'Ulcerative Colitis', 'Patients with comorbidities', '2015-11-16', NULL, NULL, NULL),
  (1576, 'warfarin', NULL, 'Intravenous', 'USA', 'Bacterial Infections; Schizophrenia; Ulcerative Colitis', 'Patients with diabetes', '1996-03-17', NULL, 'Increased risk of malignancy', '2020-01-18'),
  (1577, 'apixaban', NULL, 'Rectal', 'DEU', 'Psoriatic Arthritis; Osteoporosis', 'Patients with obesity', '2004-12-12', NULL, 'Risk of central nervous system effects', '2016-04-14'),
  (1578, 'apixaban', NULL, 'Intramuscular', 'AUS', 'Heart Failure; Ankylosing Spondylitis', 'Adults with mild disease; Immunocompromised patients', '2023-03-10', NULL, NULL, NULL),
  (1579, 'apixaban', NULL, 'Inhalation', 'UK', 'Bipolar Disorder; Pulmonary Embolism', 'Adults with mild disease', '2016-04-08', NULL, 'Risk of hypersensitivity reactions', '2021-01-15'),
  (1580, 'apixaban', NULL, 'Transdermal', 'USA', 'Ulcerative Colitis; Pulmonary Embolism', 'Patients with diabetes; Treatment-naive patients', '2005-09-12', NULL, NULL, NULL),
  (1581, 'apixaban', NULL, 'Inhalation', 'JPN', 'Anxiety', 'Patients with diabetes', '2010-04-23', NULL, NULL, NULL),
  (1582, 'apixaban', NULL, 'Inhalation', 'AUS', 'Deep Vein Thrombosis; Anxiety; Ankylosing Spondylitis', 'Patients with obesity; Adults 65+ years', '2005-04-15', NULL, NULL, NULL),
  (1583, 'rivaroxaban', NULL, 'Subcutaneous', 'ITA', 'Psoriatic Arthritis; Bipolar Disorder', 'Pediatric patients 2-17 years', '2002-04-24', NULL, NULL, NULL),
  (1584, 'rivaroxaban', NULL, 'Intramuscular', 'AUS', 'Cancer', 'Pediatric patients 6 months-2 years; Patients with diabetes', '2009-05-10', NULL, NULL, NULL),
  (1585, 'rivaroxaban', NULL, 'Intravenous', 'FRA', 'Systemic Lupus Erythematosus; Bipolar Disorder', 'Adults 65+ years', '1992-01-19', '2021-02-08', NULL, NULL),
  (1586, 'rivaroxaban', NULL, 'Oral', 'UK', 'Hepatitis C', 'Adults with moderate to severe disease', '2000-01-16', NULL, 'Risk of central nervous system effects', '2023-04-05'),
  (1587, 'rivaroxaban', NULL, 'Transdermal', 'USA', 'Hypertension; Juvenile Idiopathic Arthritis', 'Patients with prior treatment failure; Immunocompromised patients', '2008-09-10', NULL, NULL, NULL),
  (1588, 'rivaroxaban', NULL, 'Sublingual', 'BRA', 'Heart Failure', 'Patients with obesity', '2009-09-01', NULL, NULL, NULL),
  (1589, 'rivaroxaban', NULL, 'Intravenous', 'UK', 'Pulmonary Embolism; Ankylosing Spondylitis; Ulcerative Colitis', 'Adults with moderate to severe disease; Pediatric patients 6 months-2 years', '2011-02-01', '2023-07-18', NULL, NULL),
  (1590, 'rivaroxaban', NULL, 'Sublingual', 'DEU', 'Psoriatic Arthritis', 'Patients with obesity; Immunocompromised patients', '2006-08-18', NULL, NULL, NULL),
  (1591, 'rivaroxaban', NULL, 'Intramuscular', 'USA', 'Plaque Psoriasis; Bacterial Infections', 'Patients with cardiovascular disease; Patients with comorbidities', '2022-04-22', NULL, 'Risk of renal impairment', '2015-06-22'),
  (1592, 'rivaroxaban', NULL, 'Intravenous', 'CAN', 'Psoriatic Arthritis', 'Pregnant women; Adults with moderate to severe disease', '1996-12-19', NULL, 'Risk of serious cardiovascular events', '2024-09-25'),
  (1593, 'rivaroxaban', NULL, 'Nasal', 'USA', 'Atrial Fibrillation; Multiple Sclerosis; Schizophrenia', 'Immunocompromised patients; Patients with obesity', '2010-09-28', NULL, 'Risk of hepatitis B reactivation', '2015-06-02'),
  (1594, 'rivaroxaban', NULL, 'Subcutaneous', 'DEU', 'Bacterial Infections', 'Immunocompromised patients', '2021-10-23', NULL, 'Risk of hearing loss', '2016-08-14'),
  (1595, 'rivaroxaban', NULL, 'Intravenous', 'JPN', 'Bipolar Disorder', 'Patients with comorbidities', '1994-02-13', NULL, NULL, NULL),
  (1596, 'rivaroxaban', NULL, 'Oral', 'USA', 'Deep Vein Thrombosis', 'Pediatric patients 6 months-2 years', '2019-05-27', NULL, NULL, NULL),
  (1597, 'rivaroxaban', NULL, 'Intramuscular', 'JPN', 'Heart Failure; Psoriatic Arthritis', 'Patients with cardiovascular disease', '2018-08-28', NULL, NULL, NULL),
  (1598, 'rivaroxaban', NULL, 'Subcutaneous', 'ITA', 'Systemic Lupus Erythematosus', 'Patients with renal impairment; Adults 65+ years', '2003-01-04', NULL, NULL, NULL),
  (1599, 'dabigatran', NULL, 'Inhalation', 'ITA', 'Diabetes Mellitus Type 2', 'Patients with diabetes; Pediatric patients 6 months-2 years', '2002-02-20', NULL, NULL, NULL),
  (1600, 'dabigatran', NULL, 'Inhalation', 'AUS', 'Anxiety', 'Pregnant women', '2023-07-28', NULL, NULL, NULL),
  (1601, 'dabigatran', NULL, 'Nasal', 'BRA', 'Anxiety', 'Adults with moderate to severe disease', '2007-06-17', NULL, NULL, NULL),
  (1602, 'dabigatran', NULL, 'Intravenous', 'FRA', 'Anxiety; Psoriatic Arthritis; Bipolar Disorder', 'Pregnant women; Adults 18-65 years', '1996-09-01', NULL, 'Risk of peripheral neuropathy', '2018-08-24'),
  (1603, 'dabigatran', NULL, 'Transdermal', 'USA', 'Heart Failure; Schizophrenia', 'Patients with comorbidities; Adults 65+ years', '1996-03-15', NULL, 'Risk of central nervous system effects', '2016-12-09'),
  (1604, 'dabigatran', NULL, 'Subcutaneous', 'UK', 'Asthma; Crohn''s Disease; Juvenile Idiopathic Arthritis', 'Patients with cardiovascular disease', '2013-09-10', NULL, NULL, NULL),
  (1605, 'dabigatran', NULL, 'Subcutaneous', 'CAN', 'Cancer', 'Patients with comorbidities; Pediatric patients 2-17 years', '2014-06-08', NULL, 'Risk of blood disorders', '2016-11-12'),
  (1606, 'dabigatran', NULL, 'Oral', 'FRA', 'HIV Infection; Chronic Obstructive Pulmonary Disease; Ankylosing Spondylitis', 'Patients with prior treatment failure; Patients with comorbidities', '1991-03-22', NULL, 'Risk of central nervous system effects', '2024-04-06'),
  (1607, 'dabigatran', NULL, 'Sublingual', 'BRA', 'Deep Vein Thrombosis; HIV Infection', 'Pregnant women; Patients with comorbidities', '1999-02-12', NULL, 'Risk of hepatitis B reactivation', '2021-02-10'),
  (1608, 'dabigatran', NULL, 'Transdermal', 'FRA', 'Hepatitis C', 'Patients with prior treatment failure; Treatment-naive patients', '2015-05-15', NULL, NULL, NULL),
  (1609, 'clopidogrel', NULL, 'Inhalation', 'ESP', 'Multiple Sclerosis; Anxiety', 'Patients with prior treatment failure', '2019-09-25', NULL, NULL, NULL),
  (1610, 'clopidogrel', NULL, 'Nasal', 'BRA', 'Schizophrenia', 'Patients with hepatic impairment; Adults 65+ years', '1997-03-19', '2020-10-24', 'Increased risk of serious infections', '2015-11-02'),
  (1611, 'clopidogrel', NULL, 'Transdermal', 'FRA', 'Systemic Lupus Erythematosus; Osteoporosis', 'Treatment-naive patients; Pediatric patients 6 months-2 years', '2012-11-21', NULL, NULL, NULL),
  (1612, 'clopidogrel', NULL, 'Oral', 'USA', 'Heart Failure', 'Patients with hepatic impairment', '2016-06-24', NULL, NULL, NULL),
  (1613, 'clopidogrel', NULL, 'Oral', 'DEU', 'Bipolar Disorder; Viral Infections', 'Pediatric patients 2-17 years; Treatment-naive patients', '1996-04-28', NULL, 'Risk of gastrointestinal perforation', '2018-12-02'),
  (1614, 'clopidogrel', NULL, 'Oral', 'FRA', 'Viral Infections; Bacterial Infections; Fungal Infections', 'Pediatric patients 6 months-2 years', '2013-01-04', NULL, NULL, NULL),
  (1615, 'clopidogrel', NULL, 'Rectal', 'DEU', 'Viral Infections; Depression', 'Pediatric patients 6 months-2 years', '2012-12-08', NULL, NULL, NULL),
  (1616, 'clopidogrel', NULL, 'Nasal', 'BRA', 'Bipolar Disorder', 'Adults with moderate to severe disease; Pregnant women', '2005-09-13', '2022-09-11', NULL, NULL),
  (1617, 'clopidogrel', NULL, 'Intramuscular', 'AUS', 'Asthma; Cancer; Hypertension', 'Adults with mild disease; Treatment-naive patients', '2013-09-01', NULL, 'Risk of hypersensitivity reactions', '2023-03-04'),
  (1618, 'clopidogrel', NULL, 'Rectal', 'USA', 'Systemic Lupus Erythematosus', 'Patients with renal impairment', '2013-10-19', NULL, 'Risk of blood disorders', '2016-04-03'),
  (1619, 'clopidogrel', NULL, 'Transdermal', 'CAN', 'Crohn''s Disease; Ulcerative Colitis; Osteoporosis', 'Patients with diabetes', '2021-07-18', NULL, NULL, NULL),
  (1620, 'clopidogrel', NULL, 'Topical', 'AUS', 'Asthma; Anxiety', 'Adults with mild disease', '2020-12-13', NULL, NULL, NULL),
  (1621, 'clopidogrel', NULL, 'Topical', 'JPN', 'HIV Infection; Ulcerative Colitis', 'Adults 18-65 years; Pediatric patients 6 months-2 years', '2009-04-08', NULL, 'Increased risk of serious infections', '2024-12-01'),
  (1622, 'clopidogrel', NULL, 'Rectal', 'ITA', 'HIV Infection', 'Adults 18-65 years; Adults 65+ years', '1993-05-22', NULL, NULL, NULL),
  (1623, 'clopidogrel', NULL, 'Subcutaneous', 'AUS', 'Fungal Infections', 'Pediatric patients 6 months-2 years', '1998-02-07', NULL, 'Risk of progressive multifocal leukoencephalopathy', '2021-12-20'),
  (1624, 'clopidogrel', NULL, 'Subcutaneous', 'DEU', 'Hypertension; Ankylosing Spondylitis; Chronic Obstructive Pulmonary Disease', 'Patients with comorbidities', '2008-01-08', NULL, 'Risk of renal impairment', '2024-07-06'),
  (1625, 'sarilumab', NULL, 'Subcutaneous', 'DEU', 'Bacterial Infections; Juvenile Idiopathic Arthritis', 'Patients with renal impairment', '2003-12-09', NULL, NULL, NULL),
  (1626, 'sarilumab', NULL, 'Sublingual', 'FRA', 'Diabetes Mellitus Type 2; Cancer', 'Patients with hepatic impairment; Pediatric patients 2-17 years', '1993-10-23', NULL, NULL, NULL),
  (1627, 'sarilumab', NULL, 'Sublingual', 'DEU', 'Bipolar Disorder; Ulcerative Colitis; Fungal Infections', 'Immunocompromised patients', '2015-09-17', NULL, NULL, NULL),
  (1628, 'sarilumab', NULL, 'Intravenous', 'DEU', 'Asthma; Hepatitis C; Deep Vein Thrombosis', 'Adults 18-65 years', '2004-03-11', '2024-06-18', 'Risk of blood disorders', '2019-10-26'),
  (1629, 'sarilumab', NULL, 'Oral', 'DEU', 'Hypertension', 'Patients with renal impairment', '2007-01-07', NULL, 'Risk of progressive multifocal leukoencephalopathy', '2024-03-21'),
  (1630, 'sarilumab', NULL, 'Intravenous', 'DEU', 'Ankylosing Spondylitis; Schizophrenia', 'Immunocompromised patients', '2016-05-19', NULL, NULL, NULL),
  (1631, 'sarilumab', NULL, 'Rectal', 'AUS', 'Osteoporosis', 'Pediatric patients 6 months-2 years; Patients with cardiovascular disease', '2023-09-16', NULL, NULL, NULL),
  (1632, 'sarilumab', NULL, 'Topical', 'FRA', 'Crohn''s Disease; Systemic Lupus Erythematosus', 'Patients with renal impairment; Adults 65+ years', '2021-03-21', NULL, 'Risk of anaphylaxis', '2022-12-07'),
  (1633, 'sarilumab', NULL, 'Nasal', 'AUS', 'Fungal Infections; Viral Infections', 'Patients with renal impairment', '2019-09-11', '2021-06-27', NULL, NULL),
  (1634, 'sarilumab', NULL, 'Topical', 'DEU', 'Plaque Psoriasis', 'Pediatric patients 6 months-2 years; Patients with obesity', '2016-10-13', NULL, NULL, NULL),
  (1635, 'sarilumab', NULL, 'Sublingual', 'UK', 'Schizophrenia; Bacterial Infections; Viral Infections', 'Immunocompromised patients', '1993-03-08', NULL, 'Risk of hepatitis B reactivation', '2020-12-23'),
  (1636, 'sarilumab', NULL, 'Rectal', 'ESP', 'HIV Infection; Viral Infections', 'Patients with prior treatment failure; Patients with hepatic impairment', '2012-04-14', NULL, 'Risk of liver injury', '2017-08-27'),
  (1637, 'sarilumab', NULL, 'Transdermal', 'UK', 'Heart Failure; Ulcerative Colitis; Bacterial Infections', 'Adults 65+ years; Patients with cardiovascular disease', '2024-07-13', NULL, 'Risk of peripheral neuropathy', '2022-03-10'),
  (1638, 'sarilumab', NULL, 'Intramuscular', 'UK', 'Multiple Sclerosis; Plaque Psoriasis', 'Patients with obesity; Pediatric patients 6 months-2 years', '2006-12-19', NULL, 'Risk of liver injury', '2016-10-09'),
  (1639, 'sarilumab', NULL, 'Rectal', 'CAN', 'Psoriatic Arthritis; Hepatitis C', 'Patients with diabetes; Adults with mild disease', '2007-12-09', NULL, NULL, NULL);
